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General Introduction 
Avontuur JAM, Bruining HA, Ince C 
Adv Exp Med BioI 1996;388:551-567 
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Chapler 1 
1.1 Sepsis and septic shock 
Sepsis and its sequelae are the leading cause of mortality in todays medical and surgical 
intensive care. 1-5 The incidence of sepsis continues to increase. Mortality of septic shock ranges 
from 30 to 80% depending on the severity of disease and the presence of organ failure. Despite 
recent progress in antibiotic therapy and intensive care support mortality from septic shock has 
remained high over the last years. 1.2 
Sepsis can be defmed as the systemic response to severe infection.'" When certain 
micro-organisms or their toxic products invade the bloodstream, this may result in a wide 
variety of symptoms that are characteristic of sepsis and its sequelae (Table 1). When 
hypotension develops unresponsive to fluid therapy and signs of inadequate organ perfusion 
are present, the condition is often referred to as septic shock.s Shock develops in 
approximately 40 % of septic patients. The initial cardiovascular changes during hyperdynamic 
sepsis are characterized by massive vasodilatation with a normal to high cardiac output, low 
peripheral vascular resistance and severe hypotension.'" In a large number of patients the 
initial hypotension is unresponsive to treatment with fluid substitution or vasopressors. 
Umesponsive hypotension is present in 50% of patients that die of septic shock. 10 In the first 
week unresponsive hypotension is the primary cause of mortality of septic patients. In the later 
stages of sepsis, the hyperdynamic circulatory state may turn into hypodynamic septic shock 
witl! failure to guarantee adequate oxygen supply to tissues and irreversible organ damage. In 
a retrospective study with one hundred intensive care patients with sepsis 80% of mortality in 
the first week was caused by severe hypotension. 11 
Although manifestations of sepsis can be seen with systemic infections with all classes 
of micro-organisms, septic shock is most often caused by gram negative bacteria (40 to 60 % 
of cases). Staphylococci, pneumococci, streptococci and other gram positive organisms are 
slightly less frequent causes (30 to 50% of cases), but their relative incidence has increased 
over the last few years'·12 Mixed pathogens are found in 10 to 20% of septic patients. Other 
micro-organisms are opportunistic fungi (2 to 5 %), and rarely mycobacteria, certain vimses 
and protozoa. Gram negative sepsis is seen primarily in hospitalised patients, most of whom 
have underlying diseases or procedures which render their blood stream susceptible to invasion 
10 
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by micro-organisms. Gram positive sepsis may be community acquired, with the exception of 
staphylococcal sepsis that mostly arises from indwelling intravenous catheters. Other 
predisposing factors include the use of corticosteroid or innuunosuppressive therapy for organ 
transplantation or inflammatory diseases, cytotoxic chemotherapy causing neutropenia, diabetes 
Table 1. Characteristics of sepsis and septic shock 
fever or hypothermia 
chills 
tachycardia 
tachypnea 
altered mental state 
skin lesions 
leucocytosis or leucopenia 
thrombocytopenia 
hypotension 
low systemic vascular resistance 
high cardiac output 
left and right ventricular dilatation 
myocardial depression 
oliguria and renal failure (A TN) 
hypoxemia, respiratory failure and ARDS 
elevated lactate and acidosis 
organ failure (single or multiple) 
From references 1.1.s-.1l.1J.21 
release of pro~inflammatory mediators: 
TNP-a,IL-Ip, IL-2, IL-6, IL-8, IL-
15, IPN-y, MDP, thromboxane, PAP, 
prostacyclin, prostaglandins, 
phospholipase A" free radicals, NO 
release of anti~inflammatory mediators: 
IL-lra, IL-4, IL-lO, IL-13, 
transforming growth factor~p, soluble 
TNP~a receptors, LPS binding protein, 
NO (7) 
coagulation abnormalities 
complement system activation 
endothelial dysfunction 
increased microvascular permeability 
bacterial translocation 
maldistribution of blood flow 
microcirculatory oxygen deficit 
mellitus, a wide variety of surgical and invasive medical procedures, mechanical ventilation 
and prolonged antibiotic therapy. Blood cultures are only positive in approximately 40 to 50% 
of patients with manifestations of sepsis. 
Most important in the pathophysiology of sepsis are macro- and microvascular 
disturbances in combination WitIl myocardial depression resulting from the complex interaction 
between bacterial cell products like lipopolysaccharides (LPS) andlor toxins and host defense 
mechanisms leading to the release of several pro-inflammatory mediators such as cytokines 
[e.g., tumor necrosis factor-alpha (TNF-Ct), interleukines (IL-IP, IL-2, IL-6, IL-8 and IL-15), 
interferon-gamma (IFN-y)]. myocardial depressant factor (MDF), platelet activating factor 
11 
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(PAP), kitlins, arachidonic acid metabolites and several others (Figure 1).,.6.9.13." High levels 
of pro-inflammatory cytokines are found in septic patients and these levels correlate with organ 
failure and survival.'6-" More recently it has been found that quite rapidly after the first pro-
inflammatory mediators are released, the body mounts a compensatory anti-inflannnatory 
response.20 The goal of this anti-inflannnatory reaction is to downregulate synthesis of pro-
inflanunatory mediators and to modulate their effects, thereby restoring homeostasis. However, 
during sepsis, the balance between pro- and anti-inflammatory mediators is upset by a variety 
of forces, resulting in disturbed homeostasis. At macro-circulatory level the disturbance of 
homeostasis leads to increased cardiac output, reduced vascular resistance and hypotension.6-9 
At microcirculatory level the disturbances lead to increased permeability of capillaries and 
maldistribution of blood flow causing inadequate tissue perfusion and tissue damage. 21-23 The 
maldistribution of blood flow during sepsis may result from defective vascular 
autoregulation. 24•25 In addition to these changes myocardial depression is present in septic 
patients. 26 The combination of cardiovascular derangements will eventually lead to inadequate 
oxygen transport to tissue, causing multiple organ failure and death. 
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Figure 1. Sequelae of sepsis. 
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1.2 Nitric oxide, mechanism of action 
In 1987 it was demonstrated that the NO radical was the same molecule as the earlier 
discovered but never isolated Endothelium Derived Relaxing Factor (EDRF).27.28 We can say 
that this was the beginning of a whole new area of cardiovascular research. Nitric Oxide (NO) 
released from the endothelium is an important endogenous vasodilator and plays an important 
role in the regulation of tissue perfusion."·30 Other biological roles of NO include a role as 
neurotransmitter in the brain and peripheral nerves," a role in host defense by being cytotoxic 
to bacteria,3l-3I and tumour cells," and a role in preventing platelet aggregation." Nitric oxide 
is released from the amino acid L-arginine, but not D-arginine, by the enzyme NO synthase, 
that is located in a number of different cell types. The NO radical is synthesized from the 
terminal guanidino nitrogen atom of L-arginine and forms L-citrulline as a co-product. 
Evidence from studies using 1'0, and mass spectrometry indicates that in this reaction 
molecular oxygen is incorporated into both NO and citrulline by NO synthase which shows 
that the enzyme is a dioxygenase.37 Endothelial cells react to physical and chemical stimuli like 
shear stress, hypoxia or endothelial dependent vasodilators such as bradykinine, acetylcholine, 
serotonin and adenosinediphosphate (ADP) which can elicit Ca2+ release from intracellular 
stores, with the release of NO in small amounts and for short periods."40 The enzyme 
responsible for NO production in endothelial cells and neural tissue is called constitutive NO 
synthase (c-NOS). NO synthase is a heme containing enzyme which belongs to the P-4S0 class 
of enzymes. 41 The constitutive NO synthase is activated by Ca'+, which binds to caimodulin, 
fonning a complex that is a crucial cofactor for enzyme activity." Furthermore nicotinamide 
adenine dinucleotide phosphate (NADPH), flavine mononucleotide (FMN), flavin adenine 
dinucleotide (FAD), and tetrahydrobiopterin (BH,) are required as cofactorsY·43 NO is a small 
lipophilic molecule that travels freely through cell membranes and can, therefore, act on 
neighbouring target cells. NO released from endothelial cells diffuses readily to the vascular 
smooth muscle cells where, by binding to iron in the heme at the active site of soluble guanyla-
te-cyclase, the enzyme is activated to convert guanyl-tri-phosphate (GTP) to cyclic-3'S'guanyl-
mono-phosphate (c-GMP). The intracellular rise of c-GMP will lead to relaxation of the 
vascular smooth muscle cell which causes vasodilation." NO can be considered as an endoge-
13 
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naus nitrovasodilator since the same mechanism is responsible for vasodilation upon infusion 
of nitrovasodilator drugs as glyceryltrinitrate or nitroprusside that act as exogenous donors of 
NO." Organic nitrovasodilators. such as glyceryltrinitrate, undergo intermediate metabolism, 
an enzymatic step requiring thiol groups whereas the inorganic nitrovasodilators, such as 
sodiumnitroprusside, release NO readily when exposed to vascular tissue by a mechanism that 
is not fully understood. 
Since NO is soluble in water and lipid, it is freely diffusible in the enviromnent of the 
cell. The half-life of the NO radical is only a couple of seconds because following production 
the NO radical reacts easily with sulphydryl groups in amino acids or proteins, metal ions in 
redox reactions, hemoglobin in the blood, oxygen and radicals like superoxide. Nitrate and 
Analogues of 
L-Arginine 
L-NMMA 
L-NAME 
L-NA 
L-Arginine I 
NADPH 
BH, 
FMN 
FAD NOS 
Scavengers of Inhibitors of 
Nitric Oxide Guanyl Cyclase 
Hemoglobin Methylene Blue 
Superoxide 
GTP 
§J --- ---- --(B~ '-+_G_C----' 
c-GMP t t 
1 
L-Citrulline vasodilation 
Figure 2. Schematic representation of the chemical reaction leading to formation of NO and c-GMP and 
the different pharmacological agents thai intervene with the arginine/NO/c-GMP pathway at 
their specific sites. L-NMMA = NO-monoruethyl-L-arginine, L-NAME = N°-nitro-L-arginine 
methylester. L-NA = NG-nitro-L-arginine, NO = nitric oxide, GC = guanylate-cyclase, GTP 
= guanyltriphosphate. c-GMP = cyclic-guanylmonophosphate. BH~ = tetrahydrobiopterin. 
NADPH = nicotinamide adenine dinucleotide phosphate. FMN = flavine mononucleotide. FAD 
= flavin adenine dinucleotide. 
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nitrite are the inactive and stable endproducts of NO production which are further eliminated 
in urine."·" Although cultured endothelial cells depend on the p,esence of L-arginine in their 
medium for production of NO for longer periods, intracellular concentrations of L-arginine ill 
vitro and ill vivo are under normal conditions not rate limiting in the production of NO so that 
administration of L-arginine will not lead to vasodilation through increased NO release. 39•48 
1.3 Inhibitors of nitric oxide synthesis 
There are several ways to intervene with the L-arginine/NO/c-GMP pathway (Figure 
2). Nitro-substituted or methylated analogues of L-arginine are able to competitively and 
stereospecific inhibit the production of NO by the constitutive and inducible NO synthase. 
Analogues that are frequently used are NG-monometllyl-L-arginine (L-NMMA)," NG-nitro-L-
arginine (L-NA or NNLA)SO and NG-nitro-L-arginine methylesteT (L-NAME).51 The structural 
formulas of these analogues are displayed in Figure 3. These analogues all inhibit NO 
Figure 3. 
L-Arg 
NH 
L-NA 
A CO,H 
02N.N N~ 
H NH , 
L-NAME 
NH 
L-NMMA 
U ~CO,H 
MaN/"'-..N· . j 
H H NH , 
Structural formulas of L-arginine and analogues that inhibit NO formation. L-arg = L*arginine, 
L-NA = NG·nitro-L-arginine, L-NAME = NG~nilro-L-argininemethylester, L-NMMA = Nl! 
monomethyl-L-arginine. 
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synthesis by competition with L-arginine. but differ in their specific actions. The order of 
potency in inhibiting endothelial derived NO synthesis seems to be L-NA> L-NAME> L-
NMMA whereas in macrophages their order of potency is L-NMMA> L-NAME> L-NA.51•S2 
The pharmacokinetics of these NO inhibitors are largely unknown. although some differences 
have been shown in uptake and degradation. L-NMMA is converted to L-citrulline by 
endothelial cells whereas L-NA is not. 53 In dogs and rabbits L-NAME is rapidly converted to 
Figure 4. 
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Effect of L-NAME on mean arterial blood pressure (±SEM) in anaesthetized male Wistar rats 
without (A) and with endotoxemia (B). Following anaesthesia blood pressure was measured by 
inserting a canula in the carotid artery. In the non·endotoxemic group, rats were injected with 
a bolus injection (0.3 mI) of either saline (n=3), L-NAME 10 mg/kg (n=4) or L·NAME 20 
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injection of lipopolysaccharide (LPS 10 rug/kg) at T=-20 min. Note that following injection 
of a single bolus L-NAME mean arterial blood pressure remains elevated for at least 30 min. 
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L-NA which seems to be the final degradation product."·» L-NAME however easily enters 
the intracellular compartment whereas L-NA does not. These three analogues of L-arginine 
are orally active. III vivo these analogues of L-arginine can raise blood pressure by inhibition 
of NO synthesis. Figure 4 shows the dose-dependent rise of blood pressure during inhibition 
of NO synthesis with a bolus injection of L-NAME in the anaesthetized rat. In patients with 
chronical renal failure endogenous inhibitors of NO synthase are present in the serum. 56 It is 
not clear whether these endogenous inhibitors of NO synthesis playa role in the hypertension 
seen in these patients. 
Scavengers of NO production can be used to inactivate the NO radical itself preventing 
interaction of NO with the ferrous heme-containing receptor site on soluble guanylate 
cyclase." Two potent scavengers of NO are the superoxide anion (02) and free hemoglobin." 
The superoxide anion can inactivate NO/EDRF in the vascular endothelium thus causing local 
vasoconstriction and selective loss of endothelium dependent vasodilation." The chemical 
reaction that could be involved is that the superoxide anion reacts with NO to form 
peroxynitrite (ONOO'), ".61 Peroxynitrite is a powerful and very toxic oxidant that can react 
with biological molecules such as structural proteins and may result in DNA strand breakage 
and tyrosine nitration. Nitrotyrosine measurements can be used to demonstrate peroxynitrite 
free radical-mediated cellular and organ danlage.61 Nitrotyrosine residues are found in human 
lung biopsy and autopsy samples with sepsis or ARDS,6'·63 Control lung samples show 
relatively little nitration. Other cytotoxic effects of nitric oxide that are possibly mediated by 
peroxynitrite fonnation include inhibition of cellular DNA synthesis, complex fomlation with 
iron-containing compounds and enzymes, and inactivation of complexes I and II of the 
mitochondrial electron-transport chain.29 The enzyme superoxide dismutase (SOD) specifically 
catalyses the reaction 20,' + 2H+ ~ H,O, + 0" and thus decreases the local concentration 
of the superoxide anion. Since with SOD less O2' is present to form toxic peroxynitrite and 
inactivate NO, the half-life of NO is increased by SOD. This may explain the vasodilating 
effect of superoxide dismutase in the microcirculation. 
Hemoglobin is a scavenger that directly binds NO."'" However, the interaction of NO 
with hemoglobin is complex. Depending on the degree of oxidation of hemoglobin, the 
oxidation state of the heme and other factors, NO reacts differently with hemoglobin. 65 
17 
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Deoxyhemoglobin (Hb) reacts with NO producing nitrosyl-hemoglobin (HbNO). 
Oxyhemoglobin (HbO,) and NO react quantitatively forming oxidized or methemoglobin 
(MetHb) and nitrate. MetHb binds NO and is slowly reduced to Hb, which, in the presence 
of more NO can form HbNO. Since hemoglobin is a large protein that does not enter the 
intracellular space, the binding of NO is confIned to the extracellular space. However, because 
NO readily crosses cell membranes, binding by hemoglobin in the extracellular space may 
increase the concentration gradient across the cell membranes, increase the net rate of 
diffusion out of the cells and thereby reduce the magnitude of vascular smooth muscle 
relaxation. Hemoglobin from lysed erythrocytes has been implicated in the profound cerebral 
vasospasm which often follows cerebral hemorrhage,66 and macrophage cytotoxicity can be 
inhibited by the presence of free hemoglobin or erythrocytes.67 The NO scavenging properties 
of hemoglobin could playa role in this. 
Another way to interfere with NO metabolism is to inhibit the effector enzyme of NO 
synthesis with methylene blue (MB) which inhibits the enzyme soluble guanylate cyclase (Ge) 
in the vascular smooth muscle cell." Methylene blue easily enters cells and inhibits soluble 
guanylate cyclase probably by oxidizing the ferrous form of the hemoprotein component of 
the enzyme to the ferric form. However, other mechanisms of action by MB, independent of 
guanylate cyclase inhibition, have also been suggested. MB can act as a direct inhibitor of 
NOS and by generation of a superoxide anion which directly inactivates NO."·69 
1.4 Nitric oxide in experimental sepsis 
Recently much interest has been focused on the role of nitric oxide in septic shock. 
Following discovery of the NO radical it was clear that NO could playa role in the vascular 
relaxation and hypotension during sepsis and endotoxemia. III vitro studies showed that isola-
ted macrophages produced increased amounts of nitrate and nitrite upon stimulation with 
lipopolysaccharides (LPS=endotoxin)."·" This was shown to be caused by the increased 
production of NO that depended on the presence of L-arginine and could be inhibited by 
analogues of L-arginine. 70 
The enzyme responsible for production of NO in macrophages differs from the c-NOS 
18 
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in endothelial cells and neural tissue (Table 2). The c-NOS is calcium and calmodulin 
dependent and releases small amounts of NO whereas the enzyme in activated macrophages 
is calcium and ca~nodulin independent and releases high amounts of NO for a prolonged 
Table 2. Comparison of the constitutive and inducible NO synthase 
c·NOS i·NOS 
L-arginine Substrate 
Cofactors 
Heme group 
Inhibitors 
NADPR, FAD, FMN, BR, 
Protoporphyrin IX 
Analogues of L-arginine 
Expression 
Activation/induction 
always present 
activators: 
thrombin, serotonin, 
histamine, ADP, 
acetylcholine, calcium 
ionophores, pressure, 
shear stress 
Rate limiting calcium/calmodulin 
binding 
NO formation rate smail (picomoles) 
intermittent 
Cellular sources endothelial cells 
certain brain cells 
peripheral neurons 
myocardial cells 
Human chromosomal location ecNOS: 7, ncNOS: 12 
Pathophysiologic role down-regulated in 
hypertension and 
atherosclerosis 
From references !9·l2A(l.H.7(1.75.ro-9J 
must be induced 
inducers: 
LPS, IFN·y, TNF-c<, 
IL-16 
inhibition by corticosteroids 
substrate/cofactor availability 
large (nanomoles) 
continuous 
macrophages 
Kupffer cells 
vascular smooth muscle 
myocardial cells 
17 
up-regulated in inflanmlation, 
sepsis, hemorrhagic shock, 
dilated cardiomyopathy, Iype I 
diabetes, 
inunune-mediated arthritis, 
inflammatory bowel disease, 
allograft rejection 
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period of time and independent of any stimuli. The same enzyme shown in macrophages could 
also be found in neutrophils, hepatocytes, myocardial cells and vascular smooth muscle after 
stimulation with LPS or cytokines and is called inducible NO synthase (i_NOS).,,·,o.7l.72 In 
humans, each enzyme is a product of a unique gene, and they share approximately 50% 
aminoacid homology.7l·" The constitutive enzyme is located on chromosome 7 (endothelial 
type) and chromosome 12 (neural type), and the inducible enzyme is located on chromosome 
17. The i-NOS is expressed under influence of LPS and several cytokines like TNF-a, inter-
leukin-l (lL-l) and interferon-y."·7(;'79 The expression of i-NOS takes a lag-phase of several 
hours and can be inhibited by pretreatment with glucocorticoids and inhibitors of protein 
synthesis."'·8l Once the i-NOS is expressed glucocorticoids are without effect. Both c-NOS and 
i-NOS depend on the presence of NADPH and tetrahydrobiopterin as a cofactor." There is 
some evidence that when i-NOS is present the availability of the substrate L-arginine can be 
a linliting factor of NO production.8l 
A schematic representation of the different types of NO synthase and their role in the 
circulation are displayed in Figure 5. In general the constitutive NO synthase plays a physio-
logical role in maintaining organ perfusion, whereas the expression of the inducible form, as 
in sepsis and endotoxemia, plays a more pathological role leading to the production of exces-
sive amounts of NO resulting in vascular relaxation and tissue damage.84 The expression of i-
NOS has been implicated in several other disease processes such as type I diabetes mellitus,"·86 
immune-mediated arthritis," inflammatory bowel disease," and allograft rejection." Further-
more downregulation of the constitutive NO synthase has been implicated in 
atherosclerosis,90·91 and hypertension.91,93 
Studies with isolated vessels of septic rats show that the contractile response to 
noradrenaline is reduced.94 The same is seen in vessels of endotoxemic animals and in vessels 
of healthy animals incubated with LPS.95 .% The reduced response to noradrenaline is 
accompanied by a rise in c-GMP content of the vessel wall.91 Inhibitors of NO synthesis such 
as L-NMMA, L-NAME or L-NA and methylene blue, an inhibitor of soluble guanyl cyclase, 
can normalise the vasodilatation and the reduced response to noradrenaline. 95~98 Furthermore 
it was found that following endotoxin injection the i-NOS is present primarily in the vascular 
smooth muscle cells and not in the vascular endothelium. %,99 These ill vitro studies are 
20 
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A,h 
normal situation sepsis and endotoxemia 
Schematic representation of blood vessels with the different types of NO synthase in the normal 
situation (left) and during sepsis and endotoxcntia (right). In the normal situation only 
constitutive NO synthase is present in endothelial cells (ET) that can be stimulated by specific 
agonists such as acetylcholine (Ach), adenosinediphosphate (ADP). or bradykinine (BK) and/or 
flow induced shear stress. During sepsis and endotoxemia a second type of NO synthase is 
induced in macrophages (M~) and vascular smooth muscle cells (VSM) by stimulation with 
cytokines e.g., interleukin-l (IL-l) and twnor necrosis factor (TNF), and endotoxin (LPS) with 
a lag-phase of 4·8 hours, This non·regulated inducible NO synthase produces large amounts of 
NO for long periods of time resulting in massive vasodilation and tissue damage, 
underscored by ill vivo experiments. Rats injected with LPS have reduced blood pressure and 
a diminished response to noradrenaline together with increased serum levels of nitrate and ni-
trite. Inhibition of NO synthesis in these endotoxemic rats increases blood pressure and resto-
res the response to noradrenaline. H)(>!03 Similar findings were done in dogs where the NO 
inhibitor L-NMMA could prevent the fall in blood pressure during LPS and cytokine induced 
shock.n-79 In i-NOS knockout mice, that lack the inducible NO synthase, some protection has 
been reported against bacterial infection and endotoxin shock. IO'·I05 Furthermore inhibition of 
NO synthesis may improve survival in animal models of sepsis although much depends on the 
specific model used.I06.107 Figure 4 shows the dose-dependent rise of blood pressure during 
inhibition of NO synthesis with a bolus injection of L-NAME in the anaesthetized endotoxemic 
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rat. However, this model and many other models of endotoxemia,71-79,l00-10J result in an instant 
reduction in blood pressure which is not likely related to induction of i-NOS. !Os Continuous 
infusion of endotoxin for 24 hours in conscious sheep resulted in a hyperdynamic circulation 
with systemic vasodilatation, hypotension and increased cardiac outpUt. I09 This model 
resembles the cardiovascular flndings of human sepsis. Infusion of the NO inhibitor L-NAME 
normalised the hemodynamic changes despite continuation of endotoxin infusion. Although 
oxygen delivery was reduced following L-NAME by reduction of cardiac output, total oxygen 
consumption was unaffected. It was concluded that L-NAME caused reduced perfusion of 
tissues with low metabolic demand. In the same model the effect of L-NAME on blood 
perfusion of the separate organs was studied. llo Twenty-four hours following endotoxin infusi-
on increased blood flow to brain, heart, intestines, liver and kidneys was seen. L-NAME 
reduced all regional flows. No detrimental effects of inhibition of NO synthesis were seen in 
this model of endotoxemia. However, a direct negative inotropic effect on the myocardium 
causing the reduction in cardiac output could not be excluded. 
The flndings from these animal studies suggest that NO may play an important role in 
the pathophysiology of sepsis and inhibition of NO synthesis may offer a novel therapeutic 
target for treatment of hypotension in patients with septic shock. 
1.5 Nitric Oxide in the myocardium 
In the coronary vessels NO plays an important role in the regulation of myocardial 
blood flow. In the isolated perfused rabbit heart there is a basal release of NO and increased 
release of NO accounts for the vasodilatation induced by acetylcholine and bradykinine. III •1l2 
In the same heart preparation inhibition of NO synthesis with L-NMMA increases coronary 
resistance and prevents the vasodilator response to acetylcholine. 1I3 In the awake dog L-
NMMA causes a dose-dependent reduction in epicardial coronary diameter ,114 In humans 
intracoronary infusion of L-NMMA causes a reduction in epicardial calibre and coronary blood 
flow, lIS 
ConmlOn features of sepsis are myocardial depression with ventricular dilatation, 
decreased stroke work and reduced left ventricular and right ventricular ejection 
22 
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fractions. 6,9,10,116 Similar changes are seen in healthy volunteers when given endotoxin, 117 and 
in animal models of sepsis and endotoxemia."8."0 Some have related these changes to the 
depressant action of circulating factors such as myocardial depressant factor (MDF) and 
cytokines, especially TNF-ct and IL-lP, on cardiomyocytes.'·10·116 More recently myocardial 
depression has been suggested to result directly from increased NO production within cardiac 
myocytes. The myocardial depression probably does not depend on the presence of myocardial 
ischemia.12l The human coronary circulation during sepsis is often characterized by inappropri-
ately high coronary flow with decreased oxygen extraction, closely mimicking the peripheral 
circulatory anomalies of vascular relaxation.m.m Although defects in coronary autoregulation 
have been suggested, this has never been shown directly. The pattern of disordered coronary 
flow regulation could also be seen in models of hyperdynamic sepsis in the rat both ill vivo and 
ill vitro and was suggested to result from the release of a putative vasodilator substance.""!" 
In the isolated rabbit heart preparation the coronary vasodilation induced by endotoxin was 
found to be nitric oxide dependent and could be inhibited by dexamethasone suggesting that 
i-NOS plays a role."6 In the isolated rat heart endotoxin rapidly stimulates endothelium 
dependent vasodilatation which suggests that c-NOS can also playa role. 127 Both isoforms of 
NO synthase may therefore contribute to the coronary vasodilatation during sepsis. Not only 
the coronary vessels express NO synthase, but also the endocardium and myocardium itself 
have the capacity to express the constitutive and inducible NO synthase in both animal and 
human. The constitutive form of NO synthase has been shown to be present in cultured 
endocardial cells of the pig and in normal rat myocardium. '28.!29 The inducible NO synthase 
is expressed following endotoxemia and isolated rat myocytes express the inducible NO 
synthase after stimulation with cytokines which can be inhibited with dexamethasone. '29 The 
increased release of NO by i-NOS within cardiomyocytes itself could playa role in myocardial 
depression during sepsis. In the isolated papillary muscle of pig and ferret, endocardial NO 
release reduces the duration of contraction and accelerates relaxation, an effect that is mediated 
by c-GMP.!"·13! Decreased influx of calcium from the sacroplasmatic reticulum through 
specific calcium channels and decreased myofilament response to calcium induced by c-GMP 
results in loss of cardiac myocyte contractility. Isolated ventricular myocytes of the guinea pig 
heart following endotoxemia show reduced contractility to electrical stimulation.71 The depres-
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sion in myocyte contraction can be corrected with L-NAME, L-NMMA, MB or 
dexamethasone pretreatment which suggests a causative role for i-NOS. Myocytes exposed to 
MB show signs characteristic of calcium overload with hypercontractility and fibrillation. This 
suggests that MB has direct toxic effects on cardiomyocytes. 132 Human ventricular tissue of 
patients with dilated cardiomyopathy shows a significant activity of the inducible NO synthase 
and increased levels of c-GMP with low activity of the constitutive enzyme.133 This could 
suggest that the inducible enzyme plays a pathological role in the human myocardium, whereas 
the constitutive enzyme has a more physiological role. Increased production of nitric oxide in 
the myocardium may be directly responsible for myocardial depression during sepsis. 
In theory inhibition of NO synthesis during sepsis or endotoxemia can normalise the 
pattern of disordered coronary flow regulation and correct the contractile dysfunction caused 
by overproduction of NO. However, in contrast to this, many investigators have reported 
reductions in heart frequency and cardiac output following inhibition of NO production during 
sepsis and endotoxernia ill ViVD. 84 .l09,llO,134.135 Combined with the increased vascular resistance 
seen after inhibition of NO formation such reductions in cardiac output may compromise 
myocardial and tissue perfusion. It is not clear whether the fall in cardiac output seen after 
administration of inhibitors of NO synthesis during sepsis and endotoxemia is only secondary 
to increased blood pressure and increased afterload or a direct effect of NO synthase inhibition 
in the heart. A direct negative effect on isolated cardiomyocytes was shown not to be present 
using the NO inhibitor L-NMMA and L_NAME. 71 .136 Decreased coronary flow causing 
myocardial ischemia has been hypothesized. In the isolated perfused rat heart L-NMMA caused 
a dose dependent reduction in coronary flow together with a reduction in cardiac performance 
and increased release of lactate in the effluent which could be suggestive for anaerobic 
metabolism and myocardial ischemia. I" Administration of L-NMMA ill vivo has been reported 
to exacerbate global myocardial ischemia in a rabbit model of endotoxemia as indicated by 
changes on the electrocardiogram,84 However J in this model of endotoxernia, ischemic changes 
were already present before administration of L-NMMA which suggest that a hypodynamic 
circulation was present with reduced cardiac output and reduced coronary flow rates, In 
Chapter 2 and 3 of this thesis we studied the pathophysiological role of nitric oxide in coronary 
flow regulation and myocardial metabolism in a rat model of hyperdynamic endotoxemia. 
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1.6 Nitric Oxide in human sepsis 
Plasma levels of nitrate (NO,-) and nitrite (NO,) represent the stable endproducts of NO 
synthesis and can be used as a marker of NO synthase activity.27.m In a study by Ochoa et 
al. 138 in 39 intensive care patients it was found that septic patients had increased levels of 
nitrate and nitrite whereas trauma patients had not. Systemic vascular resistance showed an 
inverse correlation to the levels of nitrate and nitrite in the plasma. High plasma levels of c-
GMP during sepsis correlate with low systemic vascular resistance. l39 In pediatric sepsis 
increased plasma nitrite and nitrate concentrations are associated with the development of 
multiple organ failure. 140 In another clinical study plasma levels of nitrate were evaluated in 
12 patients treated with IL-2 as antitumour therapy.141 An important complication of this the-
rapy is the presence of a hyperdynamic circulation with hypotension and low systemic vascular 
resistance. Patients under treatment showed an eight-fold raise in plasma nitrate levels and 
urine nitrate excretion. This increased production of nitrate was derived from the guanidino 
nitrogen atom of L-arginine. There was a significant negative correlation between mean arterial 
pressure and maximum increase in plasma nitrate levels. These results suggest that sepsis and 
cytokine-induced hypotension in humans result from increased NO release. 
Another way to indirectly estimate NO production is to determine consumption of L-
arginine that delivers the nitrogen atom in the NO radical. l".I43 Freund et al. showed that 
arginine levels in tile plasma of septic patients were reduced 24 % as compared to normal. Non-
survivors had lower serum levels of arginine than survivors although a causative relation is 
difficult to establish. 
NO plays a physiological role in human microcirculation.'" Intra-arterial infusion of L-
NMMA to healthy volunteers resulted in a rise in vascular resistance in the forearm and a 
reduced response to acetylcholine. I" Local intracoronary infusion of L-NMMA showed a 
reduction in coronary diameter without the presence of myocardial ischemia and prevented the 
response to acetylcholine. liS This shows that in humans NO has a physiological role in both 
the coronary vasculature and the peripheral arterial system. However I under normal conditions 
endothelial derived NO is not necessarily vital for adequate tissue perfusion. Possibly NO gives 
the vasculature some reserve in conditions of increased demand as during exercise. 
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In addition, NO has a role as a physiologic mediator in the lung. '45•l46 NO synthase is 
present in lung epithelium and other puhnonary cells and has been suggested to be a mediator 
of nerve-dependent bronchodilatation. 147 Furthermore hypoxic pulmonary vasoconstriction may 
result from reduced NO release."'·'" Inspired NO gas acts locally without systemic 
vasodilatation or hypotension in experimental models and healthy volunteers. '49•'50 NO is 
absorbed from ventilated alveoli, induces local vasodilatation, and is rapidly inactivated in the 
blood by binding to hemoglobin. Since NO exerts its effects selectively in aerated lung regions, 
the matching of lung perfusion with ventilation is enhanced, thereby reducing the right to left 
shunt and improving gas exchange. Inhalation of NO improves oxygenation in patients with 
acute respiratory distress syndrome (ARDS), 151 and reduces pulmonary artery pressure in 
pulmonary hypertension.
'
''·I53 Unfortunately, in ARDS patients NO inhalation may only be 
effective in a subgroup of responders,154 and in recent clinical trials NO inhalation during 
ARDS failed to improve outcome despite the improvement of oxygenation. 15'.156 
1.7 Inhibitors of NO synthesis ill human sepsis 
Inhibitors of NO synthesis have been used in the treatment of hypotension in patients 
with septic shock or to investigate the pathophysiological role of NO in human sepsis. Most 
studies were pilot studies and had only a limited amount of patients included. 
Several studies have used methylene blue (MB), an inhibitor of soluble guanylate-
cyclase, the effector enzyme of nitric oxide, in patients with septic shock. 157·1'" MB has been 
used for years in the treatment of patients with nitrous oxide and nitrate poisoning. 161 
Furthermore the oxidizing properties of MB have been used clinically to induce 
methemoglobinemia in the treatment of cyanide poisoning. 162 Infusion of MB in a dose range 
of 1-3 mg/kg causes an eady rise in blood pressure and systemic vascular resistance without 
reduction in cardiac output. Although ill vitro studies have shown that MB has direct toxic 
effects on cardiomyocytes,71.132 MB seems to improve cardiac function in human sepsis. Except 
for a blue coloration of the urine and skin, no negative side effects were noted in these studies. 
Despite the hemodynamic improvements most patients died because of shock and multiple 
organ failure. 
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Petros et al. 163 was Ole flrst to describe the use of Ole NO synthase inhibitors L-NMMA 
and L-NAME in two patients with unresponsive septic shock. In the flrst patient L-NMMA 
(0.3-1.0 mg/kg) increased blood pressure and systemic vascular resistance. In the second 
patient L-NAME was given in a bolus of 0.15 mg/kg and continued with continuous infusion 
of 5 I'g/kg/min. Bolus injection increased mean arterial pressure from 84 to 102 nunHg. This 
effect was present for 10-15 min and was caused by increased systemic vascular resistance 
since cardiac output and puhnonary wedge pressure were unchanged. During continuous L-
NAME administration the noradrenaline infusion could be reduced from 0.6 to 0.2 ltg/kg/min. 
Within 48 hours the infusion of noradrenaline and L-NAME could be stopped and blood 
pressure and systemic vascular resistance returned to normal. The first patient eventually 
became independent of intensive care support. The second patient died two days later because 
of the combination of repeated intra-abdominal sepsis, adult respiratory distress syndrome 
(ARDS), and disseminated intravascular coagulation (DlC). 
Schilling et al. "" used L-NMMA in the treatment of unresponsive hypotension in a 
septic patient that had two episodes of severe hypotension within a period of four weeks. 
Treatment with this inhibitor of NO synthesis resulted in an increase in mean arterial blood 
pressure, a reduction in cardiac output and an increase in arterial oxygen pressure. During 
infusion of L-NMMA catecholamines were reduced. The initial response to a bolus of L-
NMMA lasted only 5-10 min so that bolus injection had to be repeated several times. In a 
similar case report by Lin et al. l65 a single gift of L-NMMA 50 mg increased blood pressure 
and systemic vascular resistance in a patient with severe septic shock. 
In a double blind, placebo controlled study of Petros et al. l66 the effects of L-NMMA 
were investigated in I1 patients with severe sepsis. L-NMMA (0.3 and 1.0 mg/kg) resulted 
in a dose-dependent increase in mean arterial pressure, systemic vascular resistance, pulmonary 
vascular resistance, central venous pressure, and pulmonary artery occlusion pressure, and a 
decrease in cardiac output and heart rate. Continuous infusion of L-NMMA (1 mg/kg/h) 
produced sustained hemodynamic changes. No negative side effects were noted. In the L-
NMMA group 2/5 patients survived the 28 day study period whereas in the control group 1/6 
patients survived which was not signiflcantly different. 
In a prospective intervention study in septic patients by Lorente et al. 167 the effect of 
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a bolus injection of L-NA was evaluated followed by a bolus injection of L-arginine. Injection 
of L-NA in a dose of 20 mg/kg resulted in a generalised vasoconstriction of the systemic and 
pulmonary circulation with hypertension and a strong reduction of cardiac output. These effects 
could be reversed by administration of L-arginine. Administration of L-arginine in a separate 
group of septic patients resulted in transient hypotension and an increase in cardiac index 
together with an increase in oxygen consumption. This could be due to increased formation of 
NO, however, both L-arginine and D-arginine can cause vasodilation when administered into 
the brachial artery of healthy volunteers which suggests that this effect is not mediated by 
NO. I68 Compared to the studies mentioned above the dose of L-NA used was very high. 
Furthermore in vitro studies have shown that L-NA is a more potent inhibitor of constitutive 
NO synthase than L-NMMA and L-NAME. This could explain the generalised 
vasoconstriction seen in this study. 
Recently the scavenging properties of cell-free hemoglobin that has been cross-linked 
to avoid renal toxicity. have been used to control NO biosynthesis.56 The administration of 
hemoglobin to vasopressor dependent patients resulted in a reduction of the catecholamine 
requirements and an improvement in hemodynamics. similar to that observed with NO synthase 
inhibitors.169.170 
From these previous studies one can conclude that inhibition of NO synthesis in human 
sepsis leads to increased blood pressure and systemic vascular resistance. Furthermore, a 
reduction in the vasopressor requirements was observed, suggesting that catecholamine 
sensitivity was restored. Inhibition of NO synthesis could therefore be of help in patients with 
hyperdynamic septic shock where hypotension does not respond to conventional therapy. 
However, the exact role of nitric oxide in human septic shock remains to be detennined. Most 
previous reports on inhibition of NO synthesis only describe initial changes and not much is 
known about prolonged NO synthase inhibition. The effects NO synthase inhibitors on organ 
function, myocardial performance, pulmonary gas exchange and metabolism in human sepsis 
are not totally clear. Furthermore inhibition of NO synthesis may have immunological 
consequences,32-34 and NO may interact with other vasoactive mediators as has been described 
in recent animal studies. l7I.m In this thesis we investigated some of the unanswered questions 
regarding NO and inhibition of NO synthesis in experimental and human septic shock. 
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1.8 Aims of the studies 
Sepsis is the systemic response to infection and characterised by macro- and 
microcirculatory changes resulting from the release of several mediators. Nitric oxide, 
probably the smallest of these mediators in diameter but certainly not in action, has been 
suggested to be largely responsible for the cardiovascular derangements of sepsis and septic 
shock. We investigated the pathophysiological role of nitric oxide and the effect of nitric oxide 
inhibitors in experimental and clinical sepsis. 
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Experimental design of the set-up used for measurements in the isolated perfused rat heart. 
Hearts are perfused according to Langendorff with controlled perfusion pressure and two 
reservoirs of perfusate. Coronary flow rales are measured with an electromagnetic flow probe 
and Clark-type oxygen electrodes are used for measurement of influent and effluent p02' 
Mitochondrial energy state is evaluated using NADH autofluorescence. NADH is a key 
intermediate in the transfer of reducing equivalents from metabolic substrates in the cytosol to 
oxygen in the mitochondria. During hypoxia less NAOH is oxidized to NAO+ leading to 
accumulation of NADH. When excited with light at 360 nm the NADH, unlike NAD+, emits 
fluorescence light at wavelengths centred around 460 nm. Hypoxic regions therefore will appear 
as areas of high fluorescence on the surface of the heart. A Hg arc lamp provides the 360 run 
light needed for NAOH excitation and a CCD video camera detects 460 nm NADH 
fluorescence. TIle dichroic mirror (OM) separates excitation and emission light at appropriate 
wavelengths. 
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In chapter 2 we studied the role of nitric oxide in during endotoxemia in the rat. 
Intraperitoneal injection of lipopolysaccharides (LPS) was used as a model for hyperdynamic 
sepsis. 173•I" The isolated perfused rat heart was studied during retrograde perfusion in a 
Langendorff set-up (Figure 6). This set-up was used because it enabled us to control coronary 
perfusion pressure, flow and oxygen supply. Furthermore the effect of nitric oxide synthase 
inhibition on redox state of the myocardium was studied by using the fluorescent properties 
of reduced nicotinamide adenine dinucleotide (NADH). This technique is able to detect local 
areas of myocardial ischemia. 175 
The pattern of massive vasodilatation together with maldistribution of blood flow, as 
has been reported in human sepsis, could reflect disturbances of vascular autoregulation. In 
chapter 3 the isolated rat heart model was used to study coronary autoregulation following 
endotoxemia. Autoregulation was studied by analyzing flow-pressure relations and the pattern 
of reactive hyperemia after coronary occlusion. Furthermore the role of nitric oxide in 
autoregulatory disturbances was evaluated by studying the effects of NO inhibitors and the 
effect of NO donors. 
Previous studies have suggested nitric oxide may playa central role in human sepsis 
and that inhibition of NO synthesis might be beneficial in patients with septic shock. However, 
most clinical studies only describe initial effects on hemodynamics and not much is known 
about effects of NO synthase inhibitors on organ function, myocardial performance, pulmonary 
gas exchange and metabolism in human sepsis. In the next chapters we present the results of 
a clinical study that evaluated the effects of prolonged inhibition of NO synthesis with the NO 
inhibitor L-NAME in patients with septic shock. The 'L-NAME trial' was conducted in the 
intensive care units of the department of Surgery and the department of Internal Medicine of 
the University Hospital Rotterdam Dijkzigt. Patients were included in the period between 
January 1995 and FeblUary 1996. In chapter 4 the effects of continuous L-NAME infusion 
on hemodynamic, biochemical and metabolic parameters are presented. 
Several studies in animals and humans have mentioned reductions in cardiac output 
during inhibition of NO synthesis. So far the precise mechanism underlying this reduction in 
cardiac output remains unclear. Furthermore, NO plays a role in the puhnonary vasculature 
and NO inhalation can improve oxygenation in patients with ARDS.I'I TIllS could suggest that 
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inhibition of NO synthase in septic shock may have negative side effects on puhnonary 
function. In chapter 5 we present the effects of continuous L-NAME infusion on cardiac 
performance and pulmonary gas exchange. 
In chapter 6 the dose related side effects of NO synthase inhibition are described in a 
postoperative patient with severe septic shock who was given a high dose continuous infusion 
ofL-NAME. 
Besides the impact on vascular tone, NO has important immunological functions. 32-34 
In septic rats NO may have a negative feedback on cytokine release and inhibition of NO 
synthesis may result in detrimental increases in pro-inflammatOly cytokine levels ofTNF-u and 
IL_6. 176•177 The immunologic effects of NOS inhibition in human sepsis remain to be 
determined. In chapter 7 we describe the effect of L-NAME on plasma levels of IL-6, IL-8, 
TNF-u and nitrite/nitrate in human septic shock. 
The relation of NO with other vasoactive mediators in humans have not been fully 
identified. For instance, NO release may directly inhibit the release of endothelin-l (ET-l), 
a powerful vasoconstrictor produced by endothelial cells in animals and humans. I78•l79 In rats 
part of the hypertensive response after inhibition of NO synthesis results from increased 
production of ET_l.l7l·J7l Since ET-l levels have been shown to be increased during human 
sepsis, lEO we speculated that part of the vasoconstriction seen with L-NAME may result from 
increased levels ofET-l. In chapter 8 we describe the relation between ET-llevels and the 
increase in blood pressure with L-NAME in human sepsis. 
Although several others have used L-NAME as an inhibitor of nitric oxide synthesis, 
no phannacokinetic information exists on clearance, biodistribution or excretion in humans and 
the rationale for the dosage regimen in septic patients have been largely empirical. In chapter 
9 we describe distribution and metabolism of L-NAME in the patients with severe sepsis. 
Furthelmore we studied in vitro metabolism of L-NAME in buffer, plasma and whole blood. 
Measurements of L-NAME and its metabolite L-NA were done using high performance liquid 
chromatography (HPLC). 
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Abstract 
Increased production of nitric oxide (NO) may playa central role in the cardiovascular 
derangements of septic and endotoxin shock. We have investigated the pathophysiological role 
of NO and the effect of inhibition of NO synthesis following endotoxemia in the isolated 
perfused rat heart. 
In hearts from endotoxin-treated animals coronary flow was raised 64 % and oxygen 
consumption 20% compared to control hearts. NADH fluorescence imaging was used as 
indicator of regional hypoperfusion. A homogeneous low surface NADH fluorescence, 
indicative of adequate tissue perfusion, was observed in both control and endotoxin-treated 
hearts. The increase in coronary flow and oxygen consumption could only pal1ially be preven-
ted by pre-treatment of the animals with dexamethasone. Addition of NG-Nitro-L-Arginine 
(NNLA) , an inhibitor of NO synthesis, to the perfusion medium eliminated differences in 
coronary flow and oxygen consumption between normal and endotoxin-treated hearts. Howe-
ver, NADH surface fluorescence inlages of endotoxin-treated hearts following NNLA revealed 
areas of high fluorescence indicating local ischemia, whereas the control hearts remained wit-
hout signs of ischemia. The ischemic areas were present at various perfusion pressures and di-
sappeared after infusion of L-arginine, the natural precursor of NO, or the exogenous NO 
donor sodium-nitroprusside. Methylene blue (MB), an inhibitor of soluble guanylate cyclase 
(GC), also eliminated differences in coronary flow and produced similar areas of local myocar-
dial ischemia in endotoxin-treated hearts but not in control hearts. Reducing coronary flow by 
direct vasoconstriction with vasopressin resulted in similar patterns of myocardial ischemia as 
with NNLA and MB. 
Our results suggest that the coronary vasodilation in the isolated rat heart following 
endotoxemia is caused by an increased release of NO. Coronary flow reduction with NNLA, 
MB or vasopressin causes local areas of myocardial ischemia in endotoxin-treated hearts but 
not in untreated hearts. These data suggest that endotoxemia promotes myocardial ischemia 
in vulnerable areas of the heart following inhibition of the NO pathway or direct vasocon-
striction. 
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Introduction 
Sepsis remains an important cause of mortality, especially when accompanied by shock 
or Multiple Organ Failure (MOF), despite advances in antibiotic and vasopressant therapy. I 
The initial cardiovascular changes observed during the hyperdynamic septic state are often 
characterized by profound vasodilation with normal to high cardiac output, low systemic 
vascular resistance, and severe hypotension.2 Persistent hypotension with low vascular 
resistance refractory to vasopressor therapy is present in approximately 50% of patients who 
die of septic shock.'" By promoting the release of cytokines and other mediators, bacterial 
lipopolysaccharides (LPS = endotoxin) initiate many of the cardiovascular changes seen 
during sepsis both in animals and in the human. 4•s 
Recent evidence suggests that a massive release of nitric oxide (NO), a very potent 
endogenous vasodilator, causes much of the vascular relaxation and hypotension of sepsis and 
endotoxemia." NO is fonned from L-arginine by the constitutive NO synthase present in the 
vascular endothelium and stimulates the enzyme soluble guanyl-cyclase (GC) in the smooth 
muscle cell which converts GTP to c-GMP resulting in vascular relaxation. Under physiologic 
conditions NO plays an important role in the regulation of blood pressure and tissue perfusion. 
In sepsis and endotoxemia an inducible fonn of NO synthase, located in vascular smooth 
muscle, is fonned leading to a massive release of NO resulting in profound vasodilation.6 The 
induction of tltis inducible type of NO synthase can be prevented by pre-treatment with 
glucocorticoids such as dexamethasone.7,8 
In the coronary vessels NO plays a role in the regulation of myocardial blood flOW.'·13 
In human septic shock inappropriately high coronary flow with decreased oxygen extraction 
has been reported closely mimicking the peripheral circulatory anomalies of vascular 
relaxation.I'.ls This pattern of disordered coronary flow regulation may be due to the release 
of a putative vasodilator substance such as NO.'·16 
Methylated or nitro-substituted analogues of L-arginine competitively inhibit the forma-
tion of NO from L-arginine by NO synthase. 17.I' Furthermore, at the end of the NO pathway 
the effect of NO can be inhibited by methylene blue (MB) which inhibits the enzyme soluble 
guanylate cyclase (GC) in the vascular smooth muscle cell. I' It has been suggested that such 
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inhibitors have therapeutic value in the treatment of septic shock since hypotension is corrected 
following administration of these L-arginine analogues and MB.'O-23 However, complete 
inhibition of NO formation can increase mortality in endotoxemic animals.24-26 Also, many 
investigators have reported reductions in cardiac output following inhibition of NO 
production.21-25 ,27 Combined with the increased vascular resistance seen after inhibition of NO 
formation such reductions in cardiac output may compromise myocardial and tissue perfusion 
even further. Decreased coronary flow causing myocardial ischemia has been hypothesised to 
contribute to the fall in cardiac output seen after administration of inhibitors of NO synthesis 
during sepsis and endotoxemia; however, this has never been shown directly.25.28 
In this study we investigated the effect of N°-Nitro-L-Arginine (NNLA)18 and MR'9 on 
myocardial metabolism and coronary flow in hearts of normal and endotoxin-treated rats using 
a Langendorff heart preparation. To identify any inadequacies in oxygen supply causing 
myocardial ischemia in the perfused hearts, we used the fluorescence properties of reduced 
pyridine nucleotide (NADH), an indicator of mitochondrial respiration."'" We used this 
technique recently to visualise the existence of microcirculatory units vulnerable to ischemia 
in the isolated rat heart." In the present study we hypothesize that such units might be 
susceptible for ischemia during endotoxemia when the NO pathway is inhibited. Preliminary 
results have been presented elsewhere.31 
Materials and Methods 
Experimental set-up. The protocol was approved by the animal ethics board. Male 
Wistar rats (300-360 g) received either 0.7 mg/kg of body weight (BW) E. Coli endotoxin 
(LPS, 0127:B8, Sigma St. Louis, MO) or saline by intraperitoneal (Lp.) injection 12 hours 
before the initiation of the experiments. Control and endotoxin-treated animals were used for 
ill vivo measurement of blood pressure and heart rate. Following anesthesia with pentobarbi-
tone (50 mg/kg BW, Lp.) the right carotid artery was cannulated and blood pressure was 
measured on a pressure transducer (Hewlett Packard 8B05B Corner Amplifier, MA) in control 
and endotoxemic rats. 
Animals to be used for isolated perfusion of the heart were anesthetized with ether and 
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rectal temperature was measured. These animals were heparinized (0.5 ml, 100 IV) and 1 mI 
of blood was withdrawn from the descending aorta. To assess the adequacy of endotoxin admi-
nistration, collected blood samples were analyzed for lactate using an enzymatic and 
colorimetric procedure.32 For indirect determination of global NO release, measurement of 
plasma nitrite and nitrate, the stable end products of NO oxidation, were done using an 
automated procedure based on the Griess reaction." The hearts were removed, immediately 
cooled in ice-cold perfusion medium and rapidly arranged for constant pressure perfusion at 
37"C according to the Langendorff teclmique. The perfusion medium consisted of (rnM) 128 
NaC!, 4.7 KCl, 1 MgCl" 0.4 NaH,PO" 20.2 NaHCO" 1.3 CaCI" 5.0 glucose, 2.0 pyruvic 
acid, and was oxygenated with 95% 0, and 5% CO,. All hearts were continuously paced at 
5 Hz. To minimize metabolic demand, the left ventricle was drained by a cannula in the apex 
so that no external work was performed. Flow rates (expressed as m1lmin1g of ventricle wet 
weight) were measured by an electromagnetic flow probe (Skalar-Medical, Delft, The Nether-
lands) in the aortic perfusion line. For the determination of effluent oxygen pressure the right 
puhnonary artery was cannulated and a constant fraction of the coronary effluent was led along 
a Clark-type electrode (ySI Biological Oxygen Monitor, model 5300, Yellow Springs Instru-
ments, OR). The coronary influent was sinillarly monitored for oxygen pressure via a side ann 
of the aortic cannula. Oxygen consumption (J<mollminlg of ventricle wet weight) was calcula-
ted from the product of the influent-effluent concentration difference and coronary flow using 
the Bunsen solubility coefficient of oxygen in Krebs-Henseleit buffer (22.7 1'1 O,/mI per 
atmosphere at 37°C). 
NADH videofluol'irnetry. NADH is a key intermediate in the transfer of reducing 
equivalents from metabolic substrates in the cytosol to oxygen in the mitochondria in the 
myocardial cells. During hypoxia less NADH is oxidized to NAD+ leading to accumulation 
of NADH. When excited with light at 360 nm the NADH, unlike NAD+, emits fluorescence 
light at wavelengths centered around 460 nm. Hypoxic regions therefore will appear as areas 
of high fluorescence on the surface of the heart. NADH surface fluorescence provides a 
sensitive method to visualise any regional inadequacies in oxygen supply and beginning myo-
cardial ischemia. NADH video-fluoroscopy allows on-line evaluation of spatial heterogeneity 
in hypoxia, not detected by global parameters of flow, pressure and metabolites. NADH 
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surface fluorescence imaging was done by excitation of about 1 cm' of the left ventricle of the 
Langendorf[ rat heart with light of 360 nm and measurement of the emitted fluorescence (460-
490 nm) using an image intensified CCD videocamera as described elsewhere." Fluorescence 
images were recorded on a video~recorder and computer-analyzed off-line. A substraction 
routine was used in all pictures to enhance contrast. 
Table 1. Effects of endotoxin administration. 
Control (n) Endotoxin (n) 
Temperature (OC) 36.9±O.3 (S) 3S.1 ±O.6*(S) 
MABP (rrunHg) 112.2±4.2 (5) 95.2±4.S*(5) 
Heart rate (BPM) 3S4± IS (5) 408± 19*(5) 
Plasma lactate (mM) I.5±O.3 (S) 4.3±O.6*(S) 
Serum NO,. + NO,· (I,M) 23±S (S) 214±36*(S) 
All values represent means ± SD. Numbers of rats are presented in parenthesis. MABP=mean arterial blood 
pressure, BPM=beats per minute. For all parameters the endotoxin·treated group differed significantly from the 
control group. ·p<O.OS. 
Experimental protocol Perfusion pressure is an important determinant of both oxygen 
delivery and oxygen consumption in the isolated Langendorff rat heart." Therefore, we 
investigated myocardial metabolism over a range of perfusion pressures in eight control and 
eight endotoxin-treated hearts. Hearts were perfused for a total of 130 min. Following a period 
of 30 min allowing coronary flow to stabilize at 60 mmHg, perfusion pressure was first 
lowered to 20 rrumHg and subsequently increased by stepwise changes in perfusion pressure 
of 10 rrumHg at 3 min intervals to a maximum of 100 mmHg. At the end of this series of 
pressure changes, perfusion pressure was set at the initial value of 60 mmHg. When the flow 
was stable, perfusion medium was switched to one containing NNLA in a concentration of 100 
I'M. After a 30 min interval, when a new steady state was achieved, the stepwise changes in 
perfusion pressure were repeated once again. In three hearts the effects of either L-arginine 
(100 I'M), the precursor of NO production,' or nitroprusside (10 I'M), a nitrovasodilator that 
acts as an exogenous NO donor," were studied following 30 min of NNLA. To study the 
effect of inhibition of soluble guanylate-cyclase (GC), the effector enzyme of NO, we used 
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methylene blue (MB) in four control and four endotoxin-treated hearts. MB was used in a 
concentration of 5 I'M since higher concentrations (> 20 I'M) caused a paradoxal increase in 
coronary flow in control hearts, probably by nonspecific toxic ~ffects.36 To see whether the 
effect of direct vasoconstriction was different from the effect of inhibition of NO metabolism, 
in three separate hearts we switched to vasopressin, a direct smooth muscle vasoconstrictor, 
in a concentration of -1 nM in order to reach approximately the same reduction in flow as did 
NNLA. 
The LPS-stimulated induction of NO synthase can be prevented by pre-treatment with 
dexamethasone without affecting NO release of the constitutive enzyme.7•8 To investigate the 
effect of dexamethasone pre-treatment, five rats were injected with dexamethasone 4 mg/kg 
intravenously 90 min prior to LPS infusion as compared to three rats of a control group that 
received only dexamethasone in combination with saline. 
Histologic examination by light microscopy was done following fixation with 10% 
formaldehyde and hematoxylin-eosine staining to assess if histo-pathologic differences were 
present between control and endotoxin-treated hearts. 
Chemicals NNLA, MB, arginine-vasopressin and dexamethasone were obtained from 
Sigma (St. Louis, MO). All the other chemicals were obtained from Merck (Darmstadt, 
Germany). 
Statistics All values are expressed as mean ± S.D. Student's t-test for group compari-
sons or paired t-test where appropriate were used to statistically compare values. To test 
whether drug effects were perfusion pressure dependent, we used analysis of covariance. 
p < 0.05 was taken as statistically significant. NS is used to denote not significant. 
Results 
Effects of endotoxin administration. Although most altimals of the endotoxin-treated 
group showed signs of lethargy, all animals survived. As shown in Table I endotoxin-treated 
animals showed raised rectal temperature, decreased mean arterial blood pressure, increased 
heart rate and increased plasma levels of lactate. Serum nitrite + nitrate (NO,' + NO,') were 
elevated in endotoxin-treated animals as a sign of increased systemic release of NP (Table I). 
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Histologic examination of the hearts following perfusion revealed no signs of capillary 
thrombosis, leukocyte infiltration, intracellular edema or signs of tissue damage in control 
(n=3) or endotoxin-treated (n=3) hearts. 
Effect of endotoxin and dexamethasone pre-treatmelll on coronary flo IV, eff/uelll pO, 
and mygen consumptioll. In steady state conditions at a perfusion pressure of 60 mlnHg, the 
coronary flow was raised 64% in endotoxin-treated hearts (n=8) (from 9.2±O.6 to IS.O± 1.6 
ml/minlg wet weight; Figure la) and oxygen consumption was raised 20% (from 4.0±0.2 to 
4.8±0.3 I'mol/minlg wet weight; Figure Ie) as compared to control hearts (n=8). Since the 
relative rise in coronary flow was greater than in oxygen consumption, this was accompanied 
by a rise in coronary effluent pO, (from 374±20 to 463±37 mmHg; Figure lb). To see 
whether increased coronary flow could he prevented with glucocorticoids, we pre-treated rats 
(n = S) with dexamethasone 90 min before the injection of endotoxin. Dexamethasone pre-
treatment could only partially prevent the increase in coronary flow and oxygen consumption 
in the endotoxin-treated hearts (11.3±1.9 ml/minlg and 4.3±0.3I'mol/minlg, respectively; 
Figure 1). Dexamethasone pre-treatment was without effect on coronary flow and oxygen con-
sumption in control hearts (n=3) (8.9±0.7 mlIminlg and 4.0±0.3 I'mol/minlg, respectively, 
NS). 
Effect of perfusion pressure 011 coronaty flolV, eff/uellt pO, , o:o.ygell cOllsumptioll alld 
meall NADH fluorescellce. During perfusion at different perfusion pressures, ranging from 20 
to 100 mmHg, coronary flow (Figure 2a) and oxygen consumption (Figure 2c) were signifi-
cantly raised in hearts from endotoxic animals at perfusion pressures above 20 mmHg. 
Decreased oxygen extraction resulted in a rise of coronary effluent pO, (Figure 2b). Mean 
NADH surface fluorescence was not significantly different between the control and endotoxin-
treated hearts for all perfusion pressures. Signs of local ischemia, detected as small areas of 
high fluorescence and a rise of mean NADH surface fluorescence, were only present at 20 
mmHg perfusion pressure. At higher perfusion pressures a homogeneous image with low 
NADH fluorescence intensity was seen in both groups (Figures Sa and Sc ). 
Effect of inhibitillg NO synthesis with NNLA 011 coronaty flow, eff/uem pO, and mygen 
consumption. Figure 3 shows two representative tracings of the response in time of coronary 
flow following inhibition of NO synthesis with 100 I'M NNLA in an endotoxin-treated and 
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Effect of endotoxin (LPS) and dexamethasone pre-treatment (LPS + DEXA) on coronary flow, 
effluent p02' and oxygen consumption (MVOJ as compared to untreated control hearts (C), at 
steady state perfusion pressure of 60 mmHg. Each column represents the mean, vertical bars 
indicate S.D. of control (n=8), endotoxin (n=8) or LPS+DEXA (n=5) hearts. >I< Statistically 
significant difference of LPS against C (p<O.05). # Statistically significant difference of 
LPS+DEXA against LPS (p<0.05). 
control heart. In the endotoxin-treated heart there is an initial steep reduction of 4.0 mllminlg 
in coronary flow the first 3 min with a more sustained decrease in flow the following 20 min. 
In the control heart a gradual decline in coronary flow of only 0.5 mlImin1g is seen during the 
first 3 min following NNLA. As early as 5 min after starting NNLA administration the endo-
toxin-treated heart had reached approximately the same coronary flow as the control heart. 
Figure 4 shows the steady state situation 30 min after inhibition of NO synthesis. NNLA 
decreased coronary flow by 8.5 m1lmin1g (57%) in the endotoxin group (p<O.05) and by 3 
m1lmin1g (34%) in the control group (p<O.05). Thirty min following NNLA, coronary flow 
in endotoxin-treated hearts (6.5±0.6 mllmin/g) was not significantly different from control 
hearts (6.1 ±O.6 mllmin/g). Effluent pO, was reduced 35 % to 299 ±50 mmHg in endotoxin-
treated hearts and 26% to 276±27 mmHg in control hearts. Oxygen consumption was signifi-
cantly reduced in both endotoxin-treated and control hearts (endotoxin 32% reduction to 
3.3±O.3 /imollmin/g and control 18% reduction to 3.3±O.3 I'mollmin/g wet weight). In 
hearts of dexamethasone pre-treated endotoxemic animals NNLA reduced coronary flow to 
6.6±O.5 m1lmin1g and oxygen consumption to 3.4±0.4/imollmin/g wet weight (p<O.05). 
No significant differences in coronary flow, effluent pO" and oxygen consumption were 
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Figure 2. Effect of perfusion pressures on coronary flow (a), effluent pOl (b), oxygen consumption (c) 
in control (-0-) and endotoxin-treated (-e-) rat hearts. Control (-D-) and endotoxin-treated (-
.-) hearts after inhibition of NO synthesis with 100 11M NG-Nitro-L-arginine (NNLA). Each 
point is the mean ± S.D. of 8 hearts at a given perfusion pressure. * Statistically significant 
difference of LPS against C (p <0.05). 
present between the three groups receiving NNLA (Figure 4). 
Effect of perfusioll pressure followillg NNLA. Figure 2 shows the effect of different 
perfusion pressures on coronary flow (Figure 2a), effluent pO, (Figure 2b) and oxygen 
consumption (Figure 2c) following inhibition of NO synthesis with NNLA (100 I'M) in 
endotoxin-treated and control hearts. Relative changes in coronary flow induced by NNLA 
depended on perfusion pressure: they were larger at higher perfusion pressures in both control 
and endotoxin-treated hearts (analysis of covariance, p <0.05). After NNLA administration 
no significant differences were present between endotoxic and control hearts at all perfusion 
pressures. 
Effect of NNLA 011 sUrface NADH fluorescellce of rat hearts. Switching to perfusate 
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Two representative tracings of coronary flow in a control (C) and an endotoxin-treated (LPS) 
rat heart after inhibition of NO synthesis with NG-Nitro-V-arginine (100 pM) at t=O, and a 
constant perfusion pressure of 60 mmHg. 
containing NNLA at 60 mmHg perfusion pressure resulted in the development of small areas 
of high fluorescence in the endotoxin-treated hearts (Figure 5d) which is indicative of local 
ischemia. The control hearts (Figure 5b) remained without any sign of ischemia. The ischemic 
areas in the endotoxic hearts were present at all perfusion pressures. They disappeared after 
addition of L-arginine, the natural precursor of NO, or sodium-nitroprusside, an exogenous 
NO donor, indicating that the areas of ischemia are indeed caused by the action of NO. In 
normal hearts, areas of ischemia appeared only when perfusion pressure was lowered to 20 
and 30 mmHg. The mean NADH fluorescence was not significantly different between groups 
and was raised only at 20 mmHg perfusion pressure in both endotoxin and control group. 
NNLA did not significantly affect mean NADH fluorescence in either group. 
Effect of methylelle blue (MB) 011 corollmy flolV alld slIIface NADH fluorescellce. To 
study the effect of inhibiting soluble guanylate-cyclase (GC), the effector enzyme of NO, we 
used MB (5 I'M) in control hearts (n=4) and endotoxin-treated hearts (n=4). MB reduced 
coronary flow from 8.7 ±0.6 to 7.6±0.9 m1lmin1g wet weight (NS) in control hearts and from 
J6.0± 1.3 to 8.9± 1.4 m1lmin1g (p<0.05) in endotoxin-treated hearts at 60 mmHg perfusion 
pressure. There was no significant difference in coronary flow between control and endotoxin-
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Effect of NG~Nitro-L-arginine on coronary flow, effluent pOl and oxygen consumption (MVOJ 
in control (C), endotoxic (LPS) and dexamethasone pre-treated (LPS+DEXA) rat hearts at 60 
mmHg perfusion pressure. Each column represents the mean of control (n=8), endotoxin (n=8) 
or LPS+DEXA (n=5) hearts, vertical bars indicate S.D. Differences between groups were not 
significant (NS). 
treated hearts following MB. However, MB produced areas of local ischemia in endotoxin 
hearts (Figure 6d) but not in the control group (Figure 6b). The areas of ischemia remained 
present in endotoxin-treated hearts at all perfusion pressures, whereas control hearts showed 
signs of ischemia only at 20 and 30 mmHg perfusion pressure. MB in a dose of 10 I'M did not 
further reduce flow in control or endotoxin-treated hearts. Higher doses of MB (20 I'M) 
caused a paradoxal vasodilatation with sustained increase in coronary flow, probably by non-
specific toxic effects on cardiomyocytes. 36 
Effect of direct smooth muscle vasoconstriction with vasopressill 011 sUiface NADH 
fluoresceflce. It has been suggested that prevention of excess vasodilatation might less likely 
cause ischemia and poor tissue perfusion than the use of powerful vasoconstrictors." We 
investigated whether the effect of reduction of coronary flow by a vasoconstrictor on local 
tissue oxygenation was different from the reduction of flow by inhibition of the NO pathway 
with NNLA or MB in control and endotoxin-treated hearts. We used vasopressin, a direct 
smooth muscle vasoconstrictor, in a concentration (~1 nM) that achieved a similar reduction 
in coronary flow to that of 100 I'M NNLA at 60 mmHg perfusion pressure. At 60 mmHg 
perfusion pressure, vasopressin produced areas of local ischemia in endotoxin hearts (Figure 
7d) but not in the control group (Figure 7b). With vasopressin the areas of ischemia remained 
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present in endotoxin-treated hearts at all perfusion pressures, whereas control hearts showed 
signs of ischemia only at 20 and 30 nunHg perfusion pressure. 
Discussion 
The myocardial circulation during septic shock is often characterised by an inapprop-
riately high coronary flow."·" Nitric oxide (NO) plays an important role in the regulation of 
myocardialflow.9-13 Therefore, we investigated the role of NO in the hyperdynamic changes 
of coronary flow in hearts of endotoxin-treated rats. The data presented in this study indicate 
that these vascular changes are predominantly due to the vasodilatory action of NO. However, 
inhibition of the NO pathway can result in focal areas of ischemia in endotoxin-treated hearts, 
suggesting an inabalance of local oxygen supply to demand. 
A model of endotoxemia, using a sublethal low dose of endotoxin in the rat, was 
selected that produced a hyperdynamic coronary circulation," which is also seen in human 
sepsis."'" Comparable to human sepsis the model resulted in raised temperature;' reduced 
blood pressure and increased levels of plasma lactate," and nitrate+nitrite. The 12 hours 
needed to establish tllis model provides sufficient time for the inducible type of NO synthase 
to form, estinaated to take a lag-phase of approxinaately 4 to 6 hours." Pre-treatment with 
Figure 5. 
Effect of inhibiting NO synthesis 
with NG.Nitro.L.arginine (NNLA) 
on NAOH fluorescence images in a 
control and endotoxin·treated rat 
heart. Before administration of 
NNLA both the control (A) and the 
endoloxic (C) heart show a 
homogeneous low fluorescence. 
Following NNLA (100 ~M) the 
control heart (B) shows no changes 
in NADH fluorescence, wbereas in 
the endotoxic heart (0) local areas 
of high fluorescence are visible, 
indicative of myocardial ischemia. 
55 
Chapler 2 
dexamethasone, an inhibitor of only the inducible type of NO synthase without affecting the 
constitutive enzyme,"s inhibited the increase in coronary flow in this model of endotoxemia. 
This suggests that the inducible type of NO-synthase is to a large extent responsible for the 
increase in coronary flow. Dexamethasone, however, could not totally prevent the increase in 
coronary flow suggesting the effect of dexamethasone to be either temporary, or that part of 
increased NO release is produced by the increased activity of the constitutive NO synthase."'·41 
Since dexamethasone inhibits the LPS-induced synthesis and release of interleukin-l and tumor 
necrosis factor alpha" -both cytokines stimulate the production of inducible NO synthase"- the 
inhibitory effect could also be the result of diminished release of these mediators in addition 
to direct inllibition of expression of the enzyme. 43 
Not only the coronary vessels but also the myocardium itself has the capacity to express 
the constitutive and inducible NO synthase."·«·" The constitutive form of NO synthase has 
been shown to be present in normal rat myocardium and the inducible NO synthase is expres-
sed following endotoxemia." Isolated myocytes of the rat express the inducible NO synthase 
only after stimulation with cytokines which could be inhibited with dexamethasone." Increased 
release of NO by the inducible NO synthase within the cardiac myocytes themselves has been 
suggested to contribute to the reduced contractility of isolated guinea pig cardiac ventricular 
myocytes following endotoxemia.44 Human ventricular tissue of patients with dilated cardio-
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Effect of methylene blue (MB), an 
inhibitor of soluble guanylate-
cyclase, on NADH fluorescence 
images in a control and endotoxin-
treated rat heart. Before administ-
ration of MB both the control (A) 
and the endotoxic (C) heart show a 
homogeneous low fluorescence. 
Following MB (5 ItM) the control 
heart (8) shows no change in 
NADH fluorescence, whereas in 
the endotoxic heart (D) local areas 
of high fluorescence are visible, 
indicative of myocardial ischemia. 
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myopathy shows a significant activity of the inducible enzyme accompanied by a low activity 
of the constitutive NO synthase. 45 This suggests that the inducible enzyme plays a pathological 
role in the myocardium, whereas the constitutive enzyme plays a more physiological role. To 
what extent the direct expression of NO synthase within cardiac myocytes itself contributed 
to the vascular relaxation in our model of endotoxemia remains to be established. 
Our data indicate that reduction of excess coronary flow in endotoxemia, due to 
inhibition of the NO pathway with NNLA or MD, can cause local myocardial ischemia. In a 
recent study by Duncker et al. 46 using radioactive microspheres, NNLA was shown to exacer-
bate myocardial hypoperfusion during exercise in the presence of a coronary stenosis in awake 
dogs. Administration of L-N°-Monomethyl-Arginine (L-NMMA), another inhibitor of NO 
synthesis, has been reported to exacerbate global myocardial ischemia ill vivo in a rabbit model 
of endotoxemia as indicated by changes on the electrocardiogram.24 In our study, foci of ische-
mia are indicated by areas of enhanced NADH fluorescence. This inhomogeneity of NADH 
fluorescence may be explained by a heterogeneously distributed blood flow throughout the 
heart,"'" leading to an uneven distribution of ischemic areas in the myocardium during low 
coronary perfusion pressure or coronary flow restriction.49 Tllis study shows that heterogene-
ollsly distributed ischemia also exists following flow restriction by inhibition of the NO 
pathway in endotoxin-treated rat hearts but not in normal hearts. Since histologic examination 
Figure 7. 
Effect of direct smooth muscle 
vasoconstriction with vasopressin 
on NADH fluorescence images in a 
control and endotoxin-treated rat 
heart. Before vasopressin both the 
control (A) and the endotoxic (C) 
heart show a homogeneous low 
fluorescence. Following smooth 
muscle vasoconstriction with 
vasopressin (-10M), the control 
heart (B) shows no changes in 
NADH fluorescence, whereas in 
the endotoxin heart (D) local areas 
of high fluorescence exist, 
indicative of myocardial ischemia. 
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revealed no differences between groups and since overall parameters of coronary flow, effluent 
pO, and oxygen consumption in endotoxin-treated hearts were not significantly different from 
control hearts following NNLA, the mismatch in local oxygen balance may reflect changes in 
local myocardial blood flow. The size of the ischemic areas, as revealed by NADH 
videofluorimetry, are approximately the same size as those seen during near hypoxia in normal 
hearts. We have recently shown, using NADH videofluorimetry, that such areas represent 
microcirculatory units at capillary level that are consistently vulnerable to ischemia in the 
isolated rat heart. 30 Our results suggest that endotoxemia promotes ischemia in these vulnerable 
areas, 
Maldistribution of heterogeneous coronary blood flow has been demonstrated during 
endotoxin shock ill vivo and may playa role in the development of depressed cardiac functi-
on. SO.SI This idea is supported by the results of the present study. There could be several 
explanations for the appearance of ischemic foci during inhibition of the NO pathway. Regio-
nal maldistribution of coronary flow leading to under-perfusion of myocardial tissue could 
have caused a local decrease in oxygen supply in endotoxin-treated hearts. No signs of 
ischemia, either local or global, were present in the isolated endotoxin-treated rat hearts when 
the NO pathway was not irdtibited. This might indicate that maldistribution of coronary blood 
flow did not exist prior to flow limitation, or that maldistribution of blood flow was compensa-
ted by increased overall coronary flow. Reducing coronary flow by Inhibiting NO metabolism 
or direct smooth muscle vasoconstriction could have unmasked relatively under-perfused (low-
flow) areas in the endotoxin-treated hearts by causing myocardial ischemia. These ischemic 
areas probably represent the vulnerable units in the capillary network of the rat myocardium 
which are the first to be compromised when oxygen supply becomes limited." An alternative 
explanation may be that oxygen demand is higher whilst distribution of flow remains the same. 
However, our results showed equal oxygen consumption for both groups following inhibition 
of NO synthesis. Increasing coronary flow by restoring NO synthesis with L-arginine or 
providing exogenous NO with the NO-donor nitroprusside restored perfusion in the ischemic 
areas in both cases. These findings support the idea that NO plays a role in maintaining organ 
perfusion,24,26 
In general it is thought that the constitutive NO synthase plays a role in maintaining 
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organ perfusion, whereas the expression of the inducible form (as in sepsis and endotoxemia) 
leads to the production of excessive amounts of NO resulting in vascular relaxation and tissue 
damage. 24 The therapeutic use of NO inhibitors during sepsis should, therefore, be directed 
to inhibition of the inducible NO synthase. In this study we used inhibitors that affect both the 
constitutive and the inducible NO synthase. The inhibition of only the inducible NO synthase 
might have prevented myocardial ischemia in endotoxin-treated hearts. However, to our 
knowledge, no selective inhibitors of only the inducible NO synthase are currently available. 
To prevent tissue hypoperfusion, total inhibition of NO synthesis combined with an exogenous 
NO donor could be helpful." In our study the exogenous NO donor sodium nitroprusside 
restored myocardial hypoperfusion when endogenous NO synthesis was totally inhibited with 
NNLA. Development of selective inhibitors of inducible NO synthase must be awaited; such 
selective inhibitors may be of special value in the future management of septic patients. For 
now, we suggest that the therapeutic use of non-selective NO inhibitors during sepsis must be 
done with caution and under careful cardiac monitoring. 
The present study supports the notion that the massive coronary vasodilation seen in 
the isolated endotoxin-treated rat heart is caused by an increased release of NO. Inhibition of 
NO metabolism Ivitll'NNLA or MB following endotoxemia reduced the coronary flow and 
caused areas of myocardial ischemia. Reducing coronary flow by direct vasoconstriction 
resulted in similar areas of myocardial ischemia, as did inhibition of the NO pathway. This 
finding suggests that the local balance between oxygen supply and oxygen demand in endo-
toxin-treated hearts is disturbed following flow restriction. Inhibition of NO synthesis during 
sepsis and endotoxemia has been reported to be accompanied by reductions in cardiac output2l· 
25.27 and increased mortality.24-26 It could be that localized myocardial ischemia reported in this 
study may have contributed to these deleterious effects. Conversely, it could be that the 
induction of NO synthase in tile myocardium during endotoxemia may be a protective mecha-
nism that prevents the development of local ischemia of malperfused cardiac tissue and that 
inhibition of NO synthesis could act counter-productive. 
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Abstract 
This study tested the hypothesis that overproduction of endogenous nitric oxide (NO) 
during endotoxemia may modulate coronary autoregulation and myocardial reactive hyperemia. 
Hearts of endotoxin-pretreated rats and controls were isolated and arranged for perfusion in 
a Langendoiff preparation. Autoregnlation was studied by examining flow-pressure relations 
during stepwise changes in perfusion pressure. The contribution of nitric oxide was examined 
by pefusion with N°-nitro-L-arginine (NNLA), an inhibitor of nitric oxide synthesis and 
methylene blue (MB), an inhibitor of soluble gnanylate-cyclase. 
Endotoxin-treated hearts showed massive coronary vasodilatation and autoregnlatory 
function was impaired at perfusion pressures from 20 to 60 mmHg. Both NNLA and MB 
reduced coronary flow, improved autoregulation and eliminated differences in coronary flow 
and autoregnlation between the control and endotoxin-treated group. Vasoconstriction with 
vasopressin, a direct smooth muscle constrictor. could not eliminate differences in auto-
regulation between groups. Reactive hyperemia following coronary occlusion in endotoxin-
treated hearts showed decreased duration, flow repayment and repayment ratio. In the presence 
of NNLA or MB, however, no significant differences in reactive hyperemic flow patterns were 
present. 
These observations suggest that massive coronary vasodilatation due to increased 
myocardial NO synthesis can result in autoregulatory dysfunction and altered myocardial reac-
tive hyperemia during endotoxemia. 
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Introduction 
Coronary autoregulation is the ability of the coronary vasculature to maintain blood 
flow relatively constant during changes in perfusion pressure,'" Among the physiological 
mechanisms that are known to influence autoregulation are metabolic factors (Le., oxygen 
tension andlor tissue metabolites) and the so-called myogenic response, which mediates 
constriction in response to increased transmural pressure.3 By increasing vascular tone in 
response to increasing perfusion pressure, the myogenic autoregulatory response may be an 
important' mechanism in keeping capillary hydrostatic pressure relatively constant and 
preventing excess flow to the microcirculation.4,5 
Nitric oxide is a major endothelium derived relaxing factor (EDRF), formed from the 
precursor mnino acid L-arginine and stimulates the enzyme soluble guanylate-cyclase (GC) in 
the smooth muscle cell which converts GTP to cGMP resulting in vascular relaxation,6 In the 
coronary vessels NO plays an important role in the regulation of vascular tone and myocardial 
blood flow both ill vivo and in the isolated heart preparation,7,8 The increased release of NO 
is suggested to be responsible for the vascular relaxation and hypotension seen in states of 
sepsis and endotoxemia,6 Recently it was found that endothelium derived NO can counteract 
coronary autoregulation by opposing myogenic tone and that inhibition of NO synthesis results 
in improved coronary autoregulation in the isolated guinea pig heart and rabbit heart. 9,10 
Furthermore NO plays a role in myocardial reactive hyperemia, 11,12 i.e, the increase in flow 
following a period of coronary arterial occlusion, 
During sepsis and endotoxemia the coronary circulation is often characterized by 
inappropriately high coronary flow rates secondary to coronary vasodilatation with uncoupling 
of flow from metabolic demand,13,14 This massive coronary dilatation may depend on 
accelerated cardiac production of NO,,,,16 We recently showed that inhibition of this increased 
NO synthesis can result in focal myocardial ischemia,l7 Since the basal release of NO can 
attenuate coronary autoregulation,',10 it is feasible to hypothesize that increased synthesis of 
NO, as in sepsis and endotoxelnia, can interfere with the physiological process of flow 
regulation leading to dysfunction of coronary autoregulation and altered reactive hyperemic 
response. 
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In this study, we investigated coronary myogenic autoregulatory function in response 
to step-wise changes in perfusion pressure and myocardial reactive hyperemia after a stop of 
coronary flow in isolated hearts of normal and endotoxin-treated rats. To investigate the role 
of NO, we used the L-arginine analogue NG-nitro-L-arginine (NNLA)!' to inhibit NO 
synthesis and methylene blue (MB),19 to inhibit soluble guanylate-cyclase. To see if the effect 
of direct vasoconstriction was different from the effect of inhibition of NO synthesis, we used 
vasopressin, a direct smooth muscle constrictor that acts independent of the L-
arginine/NO/cGMP pathway." 
Materials and methods 
Experimental set-up This investigation conforms with the Guide for the Care and Use 
of Laboratory Animals published by the US National Institutes of Health. The protocol was 
approved by the animal ethics board of our university. Male Wistar rats (300-360 g) received 
either a sublethal dose of 0.7 mg/kg of body wt Escileria Coli endotoxin (LPS, 0127:B8, 
Sigma Chemical Co) or saline by intraperitoneal injection 12 hours before U,e initiation of the 
experiments. III vivo measurements of hemodynamic parameters and plasma metabolites have 
been previously presented. 17 Endotoxin-treated animals showed elevated rectal temperature, 
decreased mean arterial blood pressure, increased heart rate, and increased plasma levels of 
lactate. Serum nitrite+nitrate (NO,-+ NO,), the stable end products of NO production, were 
elevated in endotoxin-treated animals as a sign of increased systemic release of NO. Rats were 
anesthetized with ether, heparinized (0.5 mL, 100 IU), the hearts were removed, immediately 
cooled in ice-cold perfusion medium and rapidly arranged for constant pressure perfusion at 
37'C according to Langendorff. The perfusion medium consisted of (mmol/L) NaCI 128, KCl 
4.7, MgCl,l, NaH,PO, 0.4, NaHCO, 20.3, CaCl, 1.3, glucose 5.0, pyruvate 2.0, and was 
oxygenated with 95 %0,15 %CO,. All hearts were continuously paced at 5 Hz. To minimize 
the metabolic component of coronary autoregulation, the left ventricle was drained by a 
cannula in the apex so that no external work was performed. Flow rates (expressed as 
milliliters per minute per gram of ventricular wet weight) were measured by an 
electromagnetic flow probe (Skalar-Medical) in the aortic perfusion line. For the determination 
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of effluent oxygen pressure the right puhuonary artery was cannulated and a corntant fraction 
of the coronary effluent was led along a Clark-type electrode (YSI Biological Oxygen Monitor, 
model 5300, Yellow Springs Instruments). The coronary influent was similarly monitored for 
oxygen pressure via a side arm of the aortic cannula. Oxygen consumption (in micromoles per 
minute per gram of ventricular wet weight) was calculated from the product of influent-effluent 
oxygen concentration difference and coronary flow. 
Autoregulatory function protocol Autoregulatory function was investigated by 
studying adjustments in coronary flow in resporne to step-wise changes in perfusion pressure." 
Following stabilization at 60 mmHg perfusion pressure, perfusion pressure was flrst lowered 
to 20 mmHg and subsequently increased by step-wise changes in perfusion pressure of 10 
mmHg at 3-minute intervals to a maximum of 100 mmHg. At the end of this series of pressure 
changes, perfusion pressure was set at the initial value of 60 mmHg. When the flow was 
stable, the perfusion medium was switched to one containing 100 I'mollL NNLA or 5 I'mol/L 
ME. After a 30-minute interval to reach a new steady state, the step-wise changes in perfusion 
pressure were repeated. Hearts were perfused for a total of 130 minutes. MB was used in a 
concentration of 51'mollL since higher concentrations (>20 I'mollL) caused a paradoxical 
increase in coronary flow in control hearts, probably by non-speciflc toxic effects." 
In flve hearts of the control and endotoxin-treated group, a supramaxinlUm dose of 
nitroprusside (10 I'moIlL), a nitrovasodilator that acts as an exogenous NO donor, was tested 
to obtain maximum vasodilatation. To see if the effect of direct vasoconstriction was different 
from the effect of inhibiting the release of the endogenous vasodilator NO, we repeated the 
protocol of pressure steps switching to vasopressin, a direct smooth muscle constrictor that 
acts independent of the L-arginine/NO/cGMP pathway,20 in a concentration of ImnollL that 
caused approximately the same reduction in flow as NNLA did in four hearts of the control 
and endotoxin-treated group. In four separate hearts of the control group the effect of 
increasing flow similar to endotoxin-treated hearts with nitroprusside (O.ll'mollL) was tested. 
NNLA, MB, vasopressin and nitroprusside were diluted in the perfusate in their fmal 
concentration. 
Hyperemic flow response Myocardial reactive hyperemia is the increase in coronary 
flow following a period of coronary artery occlusion."·" Reactive hyperemic flow response 
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Figure 1. 
Control 
~t-...t-r-r-'l 
Control + NNLA 
Control + MB 
Control + VP 
LPS + NNLA 
LPS + MB 
LPS + VP 
Representative tracings of coronary flow (four lower tracings) in response to step-wise changes 
in perfusion pressure (upper tracings) of an isolated control heart and endotoxin-treated (LPS) 
heart before and after inhibition of the L-arginineINO/cGMP pathway with 100 ~mollL NG_ 
nitro-L-arginine (NNLA) or 5 I-/ffioUL methylene blue (MB) and direct vasoconstriction with 
1 nmollL vasopressin (VP). Note that endotoxin-treated hearts showed increased pressure 
induced flow changes as compared to control which could be prevented by treatment with 
NNLA or MB, whereas vasopressin was less effective. 
was investigated after a stop of coronary flow for 90 seconds in hearts of control and 
endotoxin-treated animals (n=8 in both groups). To study the contribution of NO in reactive 
hyperemic response, the flow stop was repeated after the perfusion medium was switched to 
one containing 100 I'moi/L NNLA or 5 I'mol/L MB in four hearts each. In four separate 
hearts of the control group the effect of increasing flow similar to endotoxin-treated hearts on 
reactive hyperemic flow response was tested with nitroprusside (O.ll'moI/L). In four separate 
hearts of the endotoxin-treated group the effect of reducing flow similar to NNLA with 
vasopressin was tested. 
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Defmitions and calculations Autoregulatory function was quantified by an index (ArI) 
ftrst described by Norris et al. 21 which compares the observed change in vascular conductance 
for a given change in pressure in relation to the calculated change in conductance assuming 
that flow remained constant: ArI = 1 - (aFIF;) I (aplP;), where F is flow at pressure P, F land 
Pi are initial flow and pressure, respectively, aF=F,-F and ap=p;-p. If conductance is 
unchanged or increases when pressure is increased (passive vascular bed), then ArI s;0 and 
there is no autoregulation. If conductance decreases when pressure increases, then ArI > 0 with 
a maxinulIll value for ArI of 1.0, where coronary flow remains constant irrespective of 
pressure changes indicating perfect autoregulation. I Quantitative analyses of features 
characterizing the myocardial reactive hyperemic flow response were performed according to 
the criteria described by Coffman and Gregg" where flow debt (roL) = control flow rate 
(mLls) x occlusion time (s); Flow repayment (roL) = total flow volume during reactive 
hyperemia (roL) - control flow rate (roLls) x duration of reactive hyperemia (s); Flow 
repayment ratio = flow repayment I flow debt. 
Statistics All values are expressed as mean ± SEM. Student's t-test for group 
comparisons or paired t-test where appropriate were used to statistically compare values. 
Linear regression analysis was performed to determine the relation between myocardial oxygen 
consumption and coronary flow. p<0.05 was taken as statistically signiftcant. NS is used to 
denote not signiftcant. 
Chemicals NNLA, MB, vasopressin and nitroprusside were obtained from Sigma. All 
the other chemicals were obtained from Merck. 
Results 
Effect oj endotoxemia on coronaJY flow, oxygen consumption and autoregulatOlY 
junction at varying per/usion pressure. Figure 1 shows representative tracings of coronary 
flow responses to step-wise changes in perfusion pressure. During the different perfusion 
pressures ranging from 20 to 100 mmHg, coronary flow (Figure 2a) and oxygen consumption 
were significantly raised in hearts from endotoxin-treated animals at all perfusion pressures 
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studied. At 60 mmHg perfiIsion pressure coronary flow was raised 58±3% (from 1O.5±0.2 
to 16.6±0.5 mL/min per gram wet weight) and oxygen consumption 23±3% (from 4.0±0.1 
to 4.9±0.ll'mollmin per gram wet weight) in hearts from endotoxin-treated animals (n= 16) 
as compared to control (n= 15). As shown in Figure 3 there was a linear relation between 
oxygen consumption and coronary flow ill control (y =0.130X +2.58, R'=0.76, p <0.001) 
and endotoxin-treated hearts (Y =0.125X +2. 74, R'=0.78, P < 0.001). The endotoxin-treated 
hearts showed significantly reduced autoregulatory function at perfusion pressures ranging 
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Line graphs showing effect of perfusion pressure on coronary flow in control and endotoxin-
treated hearts with and without inhibition of the L-arginine/NO/cGMP pathway. (a) Coronary 
flow-pressure relations in (n = 15) control (CrR) (-8-) and (n = 16) endotoxin-treated (LPS) (-
0-) hearts. Coronary flow following inhibition of NO-synthesis with 100 J.tmol/L N°-nitro-L-
arginine (NNLA) in (n=8) control (---) and (n=8) endotoxin-treated (-0-) hearts. (b) 
Coronary flow following 5 ,umollL methylene blue (MB), an inhibitor of soluble guanylate-
cyclase, in (n=4) control (-... -) and (n=4) endotoxin-treated (-v-) hearts and coronary flow in 
(n=4) untreated hearts witb 0.1 ,umollL nitroprusside (NP) (-+-). (c) Coronary flow in a 
"passive" vascular bed following maximum vasodilatation with 10 ,umollL nitroprusside (NP) 
in (n=5) control (_.1.._) and (n=5) endotoxin-treated (-A-) hearts and with the direct smooth 
muscle constrictor vasopressin (VP) 1 nmollL in (n=4) control (-+-) and (n=4) endotoxin-
treated (-0-) hearts. Values are mean±SEM. *p<O.05 for LPS v. control. 
Figure 3. 
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Scatlerplot showing the relation of coronary flow and oxygen consumption in control hearts 
(CTR, +.~), endotoxin-treated hearts (LPS, -0-), and normal hearts with O.l.umoIlL nitrop-
russide (CTR+NP, -+-). Each point represents a single measurement at a given perfusion 
pressure ranging from 20 to 100 mmHg (nine measuments per separate heart). In all three 
groups there was a linear relation between coronary flow and oxygen consumption (all 
p<O.OOl). Regression lines were not significantly different between groups with regard to slope 
or intercept. 
from 20 to 60 nunHg (Figure 4a). At perfusion pressures of 70 nunHg and higher autoregu-
latory function was not significantly different from control hearts. Attaining maximum 
coronary flow with a supra-maximum dose of nitroprusside (10 i'moIlL) caused a rise of 
coronary flow of 9.4±0.5 mL/min per gram (89%) in control hearts (n=5) and 3.5±0.7 
mLimin per gram (21 %) in endotoxin-treated hearts (n=5), which resulted in similar flow 
rates (Figure 2c) and absence of autoregulation (Ad < 0 at all perfusion pressures studied) in 
control and endotoxin-treated hearts. 
Effect oj nitroprusside (0.1 i'mo/IL) on coronary flo IV, oxygen consumplion alld 
auloregu/atOlY jUllclioll oj conlro/ hearts. The effect of increasing flow in normal hearts 
similar to the flow level of endotoxin-treated hearts at 60 nunHg was tested using nitroprusside 
(0.1 i'ffioIlL) (n=4). Normal hearts with 0.1 i'mollL nitroprusside had increased coronary 
flows (Figure 2b). Oxygen consumption increased parallel to the increase in flow (4.8±0.1 
71 
Chapter 3 
I'mol/min per gram wet weight at 60 mmHg) with a linear relation between oxygen 
consumption and coronary flow (Y=0.127X+2.71, R'=0.74, p<O.OOI) (Figure 3). 
Regression lines were not significantly different between goups with regard to slope and 
intercept (Figure 3). Normal hearts with nitroprusside (O.ll'moI/L) showed decreased ArI at 
perfusion pressures from 20 to 60 mmHg (p < 0.05 compared to control) similar to endotoxin-
treated hearts (Figure 4b). 
Effect of NNLA, MB and vasopressin all corollOlY f/01V alld autoregulatioll. Switching 
to perfusion medium containing 100 I'mollL NNLA reduced coronary flow at all perfusion 
pressures to similar levels in control and endotoxin-treated hearts (Figure 1 and 2a). Parallel 
to the reduction in flow there was a reduction in oxygen consumption (per gram wet weight) 
to 3.1 ±O.ll'mol/min in control hearts and 3.2±0.ll'mollmin in endotoxin-treated hearts at 
60 mmHg perfusion pressure, which is not significantly different between groups. With NNLA 
autoregulation index was increased at all perfusion pressures in both control and endotoxin-
treated hearts (p<0.05) to similar levels in both groups (Figure 4c) resulting in a plateau of 
considerable autoregulation at perfusion pressures above 40 mmHg 
Inhibition of soluble guanylate-cyclase with 5 1'1ll01lL MB reduced coronary flow at 
all perfusion pressures to a sunilar level in both groups (Figure 1 and 2b). Autoregulation 
index with MB (Figure 4d) was ulcreased at perfusion pressures from 20 to 40 nnuHg and 
above 70 mmHg in control hearts (p < 0.05) and at all perfusion pressures in endotoxin-treated 
hearts (p < 0.05) to similar levels at all perfusion pressures. ArI following MB compared to 
before MB was not increased at 50 and 60 nnnHg perfusion pressure (p = NS). 
Direct smooth muscle constriction with vasopressin in a concentration of 1 nmoUL that 
reduced flow to a similar level as NNLA at 60 mmHg perfusion pressure (figure 1 and 2c) 
increased ArI at 20 nuuHg perfusion pressure and decreased ArI at perfusion pressures above 
40 mmHg in control and endotoxin-treated hearts. Vasopressin could not elUninate differences 
in ArI between control and endotoxin-treated hearts in the pressure range between 30 and 70 
llunHg (p <0.05 of LPS versus control) (Figure 4e). In all hearts coronary flow returned to 
the baseline value, when at the end of the series of pressure step changes, perfusion pressure 
was set at the initial value of 60 mmHg. 
Effect of elldotoxemia all reactive hyperemicf/ow respollse. Endotoxernia resulted in 
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Line graphs showing the effect of perfusion pressure on coronary autoregulation. 
~ Autoregulation indexn was calculated from the data in the pressure-flow relations of control 
and endotoxin-treated hearts before and after inhibition of the L-arginine/NO/cGMP pathway. 
(a) Autoregulation index in control (CTR) (-e-) and endotoxin-treated (LPS) (-0-) hearts. (b) 
Autoregulation index in untreated hearts with 0.1 .umoUL nitroprusside (NP) (-+ -). (c) Auto-
regulation index with 100 .umoUL NO-nitro-L-arginine (NNLA) in control (-.-) and endotoxin-
treated (-D-) hearts. (d) Autoregulation index with 5 .umollL methylene blue (MB) in control 
(_T_) and endotoxin-treated (-v-) hearts. (e) Autoregulation index with 1 nmollL vasopressin 
(VP) in control (-+-) and endotoxin-treated (-0-) hearts. Values are mean±SEM. *p <0.05 for 
LPS v. control. 
a changed pattern of reactive hyperemia (Figure 5a). As displayed in Table I, endotoxemia 
resulted in 59± 7% increased basal flow and flow debt, 66± 7% decreased duration of reactive 
hyperemia, 65 ± 7% decreased flow repayment and 80±6% decreased repayment ratio (all 
p < 0.01 compared to control). Maximum hyperemic flow was not significantly different from 
control hearts (Table I). The changed pattern of reactive hyperemia could be mimicked in 
untreated hearts by increasing flow equally to endotoxin-treated hearts with 0.1 !'moUL 
nitroprusside (Figure 5d). Quantitative analyses of reactive hyperemic response showed no 
significant differences of untreated hearts with 0.1 !,mol/L nitroprusside versus endotoxin 
treated hearts (p=NS, Table I). 
73 
Chapter 3 
a 
20 
~ 
Cl 
-c 
E 
-
10 ... 
.§. 
LI. 
0 
0 
C 
20 
~ 
'" 
-c 
'f] 
:J 10 
E 
~ 
IL 
0 
0 
Figure 5. 
eTR 
2 mIn 
eTA 
+ 
MB 
LPS 
LPS 
+ 
MB 
b 
Ci 
-c 
'f] 
-..J 
.§. 
IL 
0 
d 
:§ 
c 
'f] 
:J 
E 
~ 
IL 
0 
20 
10 
0 
20 
10 
0 
eTA 
+ 
NNLA 
eTA 
+ 
NP 
LPS 
+ 
NNLA 
LPS 
+ 
VP 
Representative tracings of myocardial reactive hyperemic response in control and endotoxin-
treated hearts following a 90 seconds occlusion period and effect of inhibition of the L-
argininelNOIcGMP pathway. (a) Reactive hyperemic response in control (CTR) and endotoxin-
treated (LPS) heart. (b) Reactive hyperemic response in control and endotoxin-treated heart with 
100 J.lllioUL NG-nitro-L-arginine (NNLA). (c) Reactive hyperemic response in control and 
endotoxin-treated heart with 5 J.lmoUL methylene blue (MB). (d) Reactive hyperemic response 
in nonna! heart with 0.1 J.lmollL nitroprusside (CTR + NP) and endotoxin-treated heart with 1 
nmoUL vasopressin (LPS + VP). For quantitative analyses of hyperemic responses see Table 1. 
Effect of NNLA. MB alld vasopressill all reactive hyperemic respollse. Perfusion of the 
hearts with 100 I'mollL NNLA or 5 I'mollL MB resulted in similar reactive hyperemic flow 
patterns of control and endotoxin-treated hearts (Figure 5b and 5c). In the presence of NNLA 
or MB reductions in basal flows, flow debt and maximum hyperemic flow were seen in control 
and endotoxin treated animals (p<0.05, Table 1). NNLA reduced the duration of reactive 
hyperemia and flow repayment in control hearts and increased flow repayment in control and 
endotoxin-treated hearts (p<0.05, Table 1). NNLA did not change the duration of reactive 
hyperemia in endotoxin-treated hearts (p=NS, Table 1). MB reduced the duration of reactive 
hyperemia in control hearts but increased the duration of reactive hyperemia in endotoxin-
treated hearts (p<0.05, Table 1). MB increased flow repayment in endotoxin-treated hearts 
(p <0.05) but did not change flow repayment in control hearts (p=NS, Table 1). MB resulted 
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in increased flow repayment ratio in both control and endotoxin hearts (p < 0.05, Table 1). 
In the presence of NNLA or MB no significant differences in basal flow, flow debt, 
maximal reactive flow, duration of hyperemia, flow repayment and repayment ratio were 
present between control and endotoxin-treated hearts (p=NS, Table 1). Ineodotoxin-treated 
hearts, the presence of 1 nmollL vasopressin caused a similar reduction in basal flow, flow 
debt and maximal reactive flow as was seen with NNLA (p = NS of NNLA versus vasopressin, 
Table 1) and increased duration of reactive hyperemic flow, flow repayment and repayment 
ratio (p<0.05 ofNNLA versus vasopressin, Table 1). 
Discussion 
The main finding of tilis study is that the excessive myocardial production of NO in 
isolated hearts from endotoxemic rats leads to massive coronary vasodilatation that results in 
dysfunction of coronary autoregulation and attenuation of myocardial reactive hyperemia. 
Reduction of coronary flow by inhibition of the L-arginineiNOlcGMP pathway with NNLA 
or MB could restore this autoregulatory dysfunction, whereas direct smooth muscle con-
striction with vasopressin could not. These findings may bring some new insights into the 
pathophysiological processes leading to cardiovascular dysfunction in sepsis and septic shock. 
Coronary flow autoregulation has been extensively studied both ill vivo and ill vitro in 
the isolated vessel preparation and isolated perfused heart preparation.'" The present study 
used an isolated perfused heart preparation. In this preparation, which does no external work, 
oxygen demand is low so that perfusion at low pressures is tolerated without causing severe 
ischemia. Furthermore oxygen consumption is kept as constant as possible minimizing 
variations in flow through metabolic coronary vasodilatation. Compared to the isolated vessel 
preparation tilis whole organ preparation has the advantage that it contains all consecutive 
vascular segments including larger coronary arteries and small arterioles, since autoregulation 
of blood flow can be spatially organized."·26 However, some reservations must be made to 
extrapolate the fmdings of the present study to the ill vivo situation. The isolated non-working 
heart preparation that was used misses the neurohumoral and metabolic input which are known 
to influence autoregulation ill vivo.' Furthermore, changes in NO production may directly in-
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Table1. Basal flow and parameters for reactive hyperemia following 90 seconds of coronary occlusion in control and endotoxin-treated (LPS) 
hearts before and after NG-nitro-L-arginine (NNLA), methylene blue (ME), nitroprusside (NP) and vasopressin (VP). 
before +NNLA +MB +NP +VP 
control LPS control LPS control LPS control LPS 
(n=S) (n=S) (n=4) (n=4) (n=4) (n=4) (n=4) (n=4) 
Basal flow (mL/minlg) 1I.S±O.2 lS.3±O.4* 4.S±O.2 S.O±O.4 6.0±O.3 6.S±O.S lS.5±O.l 5.3±O.3 
Flow debt (mL/g) 17.2±O.3 27.S±O.5* 7.2±O.2 7.5±O.5 S.9±O.5 lO.2±O.S 27.S±O.2 7.9±O.6 
Maximal flow (mL/minlg) 20.7±O.4 20.1±O.4 17.5±O.6 17.3±O.4 lS.S±O.2 19.1±O.3 20.5±O.7 17.6±O.4 
Duration (s) 119±lO 40±4* 46±3 50±3 77±4 7S±lO 29±4 117±12 
Flow repayment (mL/g) 11.0±O.S 3.S±O.7* 7.4±O.4 S.4±O.6 lO.3±O.9 11.1±2.0 3.3±l.O lO.3±O.6 
Repayment ratiot O.6HO.OS O.14±O.O3* l.O4±O.04 1.13±O.OS 1.14±O.O7 l.07±O.lS O.l2±O.04 l.32±O.O6 
Values are means ± SEM. *p<O.05 ofLPS v. control. tRepayment ratio = flow repayment/flow debt. 
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fluence myocardial contractility,27 which was not measured in the preparation used. Therefore 
we cannot rule out that any changes in autoregulation that have been found during isolated 
perfusion may have been compensated for in the ill vivo situation. 
A hyperdynamic model of endotoxemia was used that showed increased coronary flow 
together with increased myocardial oxygen consumption. Although the origin of this high 
oxygen consumption in hearts of endotoxin-treated animals is still speculative, the increases 
in oxygen consumption could have directly resulted from increases in coronary flow, the so-
called Gregg phenomena. 28•19 This is supported by the finding that isolated hearts showed a 
linear increase in oxygen consumption with increases in coronary flow and increased oxygen 
consumption following addition of the vasodilator nitroprusside (Figure 3). Parallel with these 
observations, reduction of coronary flow by NNLA resulted in decreased oxygen consumption. 
Similar rmdings were done by PoW et al. 9 in the isolated rabbit heart where NNLA reduced 
oxygen consumption during constant pressure perfusion but was without effect during constant 
flow perfusion excluding a direct inhibitory effect of NNLA on myocardial metabolism. 
Coronary autoregulation depends on the balance between competing constricting and 
dilating influences.' Autoregulatory dysfunction in endotoxin-treated hearts could therefore 
have resulted from defective vasoconstrictive mechanisms or an overshoot of vasodilator 
mechanisms. The myogenic response mediates vasoconstriction in response to increased 
transmural pressure and is considered a major constricting force in the coronary vessels. 3 
Myogenic dilation following a period of occlusion and myogenic constriction after restoration 
of flow is one of the mechanisms contributing to reactive hyperemia in the coronary vessels.24 
The mechanism responsible for the myogenic response is still incompletely understood but is 
probably located in the vascular smooth muscle cells itself, and mediated by an increase in 
intracellular calcium through influx via either stretch-activated or voltage gated ion-
channels.30·" Endotoxin could have induced defects in the myogenic response that may have 
resulled in a loss of vascular tone, autoregulatory dysfunction and altered reactive hyperemia. 
However, inhibition of the L-arginine/NO/cGMP pathway with NNLA or MB reduced basal 
coronary flow and prevented pressure induced increases in coronary flow of endotoxin-treated 
hearts reSUlting in similar levels of autoregulation as in control hearts with NNLA or MB 
whereas with vasopressin, a direct smooth muscle constrictor, differences in autoregulation 
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between control and endotoxin-treated hearts remained. Furthermore in endotoxin-treated 
hearts in the presence of NNLA or MB there was only a brief reactive hyperemic response 
following occlusion after which coronary flow returned to baseline levels. These results 
suggest that myogenic tone was well preserved following inllibition of the L-
arginine/NO/cGMP pathway. An overshoot in NO mediated vasodilating influences thus 
counteracting myogenic vascular tone is more likely to have caused the autoregulatory 
dysfunction and altered reactive hyperemic response in endotoxin-treated hearts. This view is 
further supported by the present finding that vasodilation with the exogenous NO donor 
nitroprusside in control hearts resulted in similar autoregulatory dysfunction and altered 
reactive hyperemic response as in endotoxin-treated hearts. 
Earlier studies have shown that under normal (i.e., non-septic or non-endotoxemic) 
conditions the endogenous production of NO can attenuate autoregulation by opposing 
myogenic tone in the isolated perfused rabbit ear," guinea pig heartlO and rabbit heart; and 
in the canine heart ill vivo. 33 The present study is the first that shows that autoregulatory 
dysfunction may exist in endotoxemia resulting from excessive production of NO. However, 
NO is not the only regulator of vascular tone. Other vasoactive factors, such as adenosine, 
prostaglandins, pOl and peol , are known to influence vascular tone. 1.34 To what extent one 
or more of these metabolites may have contributed to vasodilatation and derangements in 
autoregulation and reactive hyperemia in the endotoxin-treated hearts is unknown. 
Under physiological conditions NO plays an important role in myocardial reactive 
hyperemia. II." In the present study inhibition of the L-arginine/NO/cGMP pathway in normal 
hearts resulted in decreased peak reactive flow, decreased duration of the hyperemic response 
and decreased total reactive hyperemic blood flow which demonstrates the contribution of NO 
to myocardial reactive hyperemia. Although endotoxin-treated hearts showed a pattern of 
reactive hyperemia (Figure 5), flow repayment was only one third of that of control hearts. 
Vasoconstriction through inhibition of the L-arginine/NO/cGMP pathway with NNLA or MB 
could improve flow repayment in endotoxin-treated hearts and resulted in similar reactive 
hyperemic flow patterns as in control hearts with NNLA or MB. However, also vasopressin, 
a direct smooth muscle vasoconstrictor, could improve flow repayment and resulted in a 
'normal' reactive hyperemia pattern. These results suggest that an excessive coronary flow 
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secondary to endogenous NO production minimized flow reserve and blunted the reactive 
hyperemic response in endotoxin-treated hearts. 
In conclusion, the massive coronary vasodilatation due to increased myocardial 
production of NO during sepsis and endotoxemia may result in dysfunction of coronary 
autoregulation. Increasing vascular tone by inhibition of the L-arginine/NO/cGMP pathway 
with NNLA or ME can restore these changes, unlike direct smooth muscle constriction with 
vasopressin. These rmdings may help us understand some of the pathophysiological processes 
that lead to cardiovascular dysfunction during sepsis and endotoxemia. Improvement of 
vascular autoregulation may be one of the mechanisms by which inhibitors of the L-
arginine/NO/cGMP pathway contribute to correction of the cardiovascular derangements 
during human septic shock.35 
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Abstract 
Inhibitors of nitric oxide synthesis have suggested to be of value in the treatment of 
hypotension during sepsis. However, earlier clinical reports only describe initial effects of 
these nitric oxide inhibitors. This non-randomised clinical study was designed to examine the 
effects of prolonged inhibition of nitric oxide synthesis with NG-nitro-L-arginine methyl ester 
(L-NAME) in patients with severe septic shock. Eleven consecutive patients with ongoing 
hyperdynamic septic shock, unresponsive to fluid resuscitation and vasopressor therapy were 
included. Measurements of hemodynamic, hematological, and biochemical variables were 
made before, during and after a continuous intravenous infusion of 1 mglkglh of NG-nitro-L-
arginine methyl ester (L-NAME), an inhibitor of nitric oxide synthesis, for 12 hours. 
Continuous infusion of L-NAME resulted in a direct increase in mean arterial blood 
pressure from 65±3 (SEM) to 93±4 mmHg and systemic vascular resistance from 426±54 
to 700± 75 dyne's/cm' reaching a maximum in 0.5 h. Puhnonary artery pressure was increased 
from 31 ±2 to a maximum of36±2 mmHg at 1 h and pulmonary vascular resistance increased 
from 146±13 to a maximum of21O±23 dyne's/cm' at 3 h. Parallel to these changes, cardiac 
output decreased from 1O.8±0.8 to 8.7±0.7 IImin and oxygen delivery decreased from 
1600± 160 to 1370± 130 mL/min (for all changes p<0.05 as compared to the baseline value). 
Heart rate, cardiac filling pressures, oxygen consumption, urine production, arteriallactate 
and other biochemical parameters were not significantly changed by L-NAME (aU p > 0.05). 
During L-NAME infusion the dosage of catecholamines could be reduced (p < 0.05). Although 
sustained hemodynamic effects were seen, L-NAME was most effective during the early stages 
of adlninistration and the effect of L-NAME on blood pressure and vascular resistance tended 
to diminish during continued infusion. Seven of eleven patients ultimately died with survival 
time ranging from 2 to 34 days. 
We conclude that nitric oxide appears to playa role in the cardiovascular derangements 
during human sepsis. The increase blood pressure and vascular resistance are sustained during 
prolonged inhibition of nitric oxide synthesis with L-NAME in patients with severe septic 
shock, although the hemodynamic changes are most significant in the early stages of L-NAME 
infilsion. The high mortality rate suggests that L-NAME has only limited effects on outcome. 
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Introduction 
Human septic shock is characterised by massive systemic vasodilatation with low 
vascular resistance, increased cardiac output, hypotension and high mortality rate. 1 Increased 
synthesis of the potent vasodilator nitric oxide (NO) has been incriminated in the hypotension 
and vasodilatation during sepsis and endotoxemia.2 Under normal conditions small amounts 
of NO are formed from L-arginine by the constitutive NO synthase (eNOS) present in the 
vascular endothelium and stimulate the enzyme soluble guanylate cyclase (GC) in the smooth 
muscle cell which converts guanosine triphosphate (GTP) to cyclic guanosine monophosphate 
(c-GMP) resulting in vascular relaxation.' This endothelium derived NO (EDNO) plays a role 
in the regulation of blood pressure and tissue perfusion by maintaining vasodilatory tone. Upon 
stimulation by endotoxins (LPS) and cytokines such as TNF and IL-l, an inducible form of 
NO synthase (iNOS) is formed in macrophages and vascular smooth muscle cells.2 This 
inducible enzyme differs from the constitutive isoform in that it releases massive amounts of 
NO resulting in profound vasodilatation with hypotension, dysfunction of vascular 
autoregulation, resistance to catecholamines and tissue damage. 2 .4 
L-arginine analogues, like N°-monomethyl-arginine (L-NMMA), NG-nitro-L-arginine 
(L-NA) and N°-nitro-L-arginine methyl ester (L-NAME), competitively inhibit the production 
of nitric oxide from L-arginine by both isoforms of nitric oxide synthase.5•6 Animal studies 
have shown that these inhibitors of nitric oxide synthesis can prevent or reverse endotoxin or 
cytokine induced hypotension.'" Short-term administration of these analogues of L-arginine 
in patients with sepsis, can increase blood pressure and systemic vascular resistance.9,10 
Furthermore methylene blue, an inhibitor of soluble guanylate cyclase, has been shown to 
temporarily raise blood pressure in patients with septic shock. 11 Therefore inhibitors of NO 
synthesis have been suggested to be of value in the treatment of hypotension during human 
septic shock. However, no data are present about the effect of continued inhibition of nitric 
oxide synthesis in human sepsis and effects on mortality and organ function remain unclear, 12,13 
The goal of the present study was to asses the effects of prolonged inhibition of nitric 
oxide synthesis during continuous infusion of L-NAME for 12 hours in patients with severe 
septic shock. 
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Materials and Methods 
Subjects. The study was approved by the hospital's Medical and Ethics Connnittee. A 
total of 11 adult critically ill patients of the intensive care unit of our hospital were eruolled 
into the study (Table I). Because infonned consent could not be obtained personally from these 
severely ill patients, direct family members were informed of the nature of the study and gave 
informed consent. All patients met the criteria of sepsis as described by Bone et al.I< These 
criteria include evidence of infection, tachycardia (> 90 beats/min in the absence of p-
adrenergic receptor blockade), tachypnea (respiratory rate> 20 breaths/min or the requirement 
of mechanical ventilation), fever or hypothermia (temperature> 38.3°C or < 35.6°C), plus 
at least one of the following signs of inadequate organ perfusion: Pao,lFio, <280 (without 
other pulmonary or cardiovascular disease as the cause), increased blood lactate levels (> 2 
nnnol/L), and oliguria «0.5 mL/kg/h) for at least I hr. All patients were in shock (systolic 
BP <90 mmHg or a decrease >40 mmHg from baseline uruesponsive to a fluid challenge) 
on admission requiring therapy with pressor agents. At the time of the study all patients were 
receiving dopamine> 15I'g/kg/min, noradrenaline> O.ll'g/kg/min or a combination of both. 
All patients had respiratory failure and required mechanical ventilation. Patients received 
standard antibiotic therapy adjusted to bacterial cultures. Patients received total parenteral 
feeding in six patients and enteral feeding in five patients. Both enteral and parenteral feeding 
contained standard concentrations of L-arginine and administration was continued during L-
NAME infusion. Four patients required continuous hemodialysis because of renal failure. Only 
patients with cardiac index> 3.0 Llminlm' were included in the study since earlier reports 
have shown reductions of cardiac output during inhibition of NO synthesis.9•10 We hypothe-
sized that a further reduction in cardiac output would be undesirable and even dangerous in 
a state where cardiac output is reduced. Exclusion criteria for the study were severe coronary 
artery stenosis (angina pectoris grade III according to NYHA classification), pregnancy and 
cardiac index < 3.0 Llminlm'. 
Sflldy Protocol. All patients undenvent continuous electrocardiographic monitoring and 
had indwelling radial artery and pulmonary artery catheter. Mean systemic arterial blood 
pressure (MAP), central venous pressure (CVP) and mean pulmonary artery pressure (MPAP) 
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Table1. Patient characteristics and bacteriological data. 
Pt Gender Age Underlying disease APACHE II Sepsis Predominant Organism Outcome 
(yr) Score Severity (Survival 2&1) 
Seorea 
1 M 30 Peritonitis from bowel perforation after 27 26 Proteus vulgaris (B), Ente- Died 
severe trauma rococCUS 
2 M 59 Acute necrotising pancreatitis 21 20 Pseudomonas aeruginosa (B). Survived 
Enterococcus 
3 M 45 Pseudomembranous colitis and ARDS 23 21 Clostridium difficile, Strop- Died 
after severe trauma tococcus pneumoniae. 
4 M 69 Ischemic colitis after vascular graft for 19 18 Staphylococcus aureus (B) Survived 
ruptured abdominal aneurysm 
5 M 60 Bronchopneumonia following liver trans- 24 24 Enterococcus Died 
plantation for cryptogenic cirrhosis 
6 M 47 Acute necrotising pancreatitis 18 22 Klebsiella pneumoniae (B), Died 
Enterococcus 
7 M 49 ARDS and thoracal empyema following 20 24 Klebsiella pneumoniae, Stap- Died 
aspiration pneumonia hylococcus epidennidis 
8 F 40 Peritonitis from bowel perforation foll<>- 17 16 Enterococcus (B). Bacteroides Survived 
wing abdominal hysterectomy species 
9 M 57 Pelvic abscess following ileocolectomy 16 17 Escherichia coli, Staphyl<>- Survived 
for Non-Hodgekin's lymphoma coccus epidermidis 
10 M 38 Peritonitis from bowel perforation after 23 22 Enterococcus, Staphylococcus Survived 
severe trauma epidennidis 
11 M 75 Mediastinitis after esophageal resection 20 19 Enterococcus Died 
for carcinoma 
00 Pt = patient, APACHE IT = Acute Physiology and Chronic Health Evaluation, Knaus et al. [16], ARDS = adult respiratory distress syndrome, B = blood 
..., 
culture, ... Sepsis Severity Score as described by Elebute and StoDer [17]. 
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were continuously measured. Triplicate measurements of cardiac output (CO) were made 
according to the thermodilution method, and the mean value reported. Data were recorded on 
a computerised data system (Mennen Medical Systems, USA). Cardiac output and puhnonary 
artery occlusion pressure (PAOP) were measured three an six hours before L-NAME infusion 
(T= -6 and -3 h), at baseline (T= 0), during L-NAME infusion (T= 0.5, I, 3, 6, and 12 h) 
and three and six hours following L-NAME infusion (T= IS and 18 h). L-NAME was 
purchased from Sigma Chemicals (St. Louis, MO, USA). The pharmacy of our hospital 
prepared a sterile and pyrogen-free solution ofL-NAME 10 mg/mL, ready for infusion. Fol-
lowing baseline measurements L-NAME I mg/kg/h was infused for 12 hours. If mean arterial 
blood pressure increased above 100 Il1tllHg, the administration of vasopressors was gradually 
reduced and the dosage noted. Concomitant therapy was at the discretion of the clinician 
managing the patient. Continuous infusion of L-NAME was chosen since the effect of a bolus 
injection of 0.15 mg/kg L-NAME lasted only 5-10 minutes. Before and after administration 
ofL-NAME, blood was withdrawn for routine measurement of selUm electrolytes, urea and 
creatinine, liver function tests, lactate, hemoglobin, platelets and leukocytes. In eight patients 
arterial and central venous blood was withdrawn at T= 0, I, 3, 6, 12 and 15 h and blood 
gases and hemoglobin content analyzed for determination of oxygen delivery and oxygen 
consumption. For pharmacokinetic analysis, in three patients blood samples were hrnnediately 
centrifuged, plasma was separated and stored at -80 'C. Before analysis plasma was 
deproteinized with percbloric acid (HCIO" 4.4 M) and levels of L-NAME and L-NA, were 
measured by means of high performance liquid chromatography using a nucleosil 5SA column 
(200x4mm, Machery-Nagel, Germany), a NaH,PO, mobile phase with 10% methanol 
(200mM, pH 2.3, 1.5 mlfmin) and UV detection at a wavelength of 268 nm." The method 
was specific for L-NAME and L-NA as proved by monitoring the UV spectlUm of the 
substance during its determination in plasma samples. 
Calculations. Systemic vascular resistance (SVR) and pulmonary vascular resistance 
(PVR) were calculated according to standard formulae: SVR (dyne's/cm') = 80 x (MAP-
CVP)/CO and PVR (dyne's/cm') = 80 x (MPAF-PAOP)/CO. Arterial (CaO,) and venous 
(CvO,) oxygen content were calculated using a standard equation (oxygen content = hemoglo-
bin x 1.34 x oxygen saturation + PO, x 0.0031). Oxygen delivery (DO,) was calculated as 
88 
Figure 1. 
L-NAME ill septic shock 
L-NAME Infusion 
0; 100 
:r: 
E 80 MAP E 
~ 
... 
-----i 
« 60 
... 
... 
c: PAP : * * CO 40 
... ~! ! , 
« • 
:;; 20 
-6 0 6 12 18 
.. 
E 800 " 
" -
" " 
" 600 .. 
c: SVR 
... 
:!?. 400 
a: 
> : IOIO 
... 
... 200 ~ ~ 
" 
! 
CO PVR a: 
> 0 
Vl 
-6 0 6 12 18 
12 
11 I--E 
E 10 ::r 
~ V 0 1\- V 0 9 -
8 
-6 0 6 12 18 
Time (h) 
Effects of continuous infusion of 1 mglkglh of NO-nitro-L-arginine methyl ester (L-NAME) for 
twelve hours on hemodynamics in eleven patients with severe septic shock. Time of L-NAME 
infusion is from t=O to t=12 hours. L-NAME caused an increase in mean arterial pressure 
(MAP) and pulmonary artery pressure (PAP) (top figure), systemic vascular resistance (SVR) 
and pulmonary vascular resistance (PVR) (middle figure) and a reduction of cardiac output (CO) 
(haltom figure). Values are displayed as mean±SEM, *p<O.05 for comparison with the 
baseline value. 
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the product of cardiac output and CaO, (DO, = 10 x CaO, x CO) and oxygen consumption 
(VO,) was calculated as the product of cardiac output and arterio-venous oxygen content 
difference: VO, = (CaO,. CvO,) x CO x 10. All of the recorded variables (mean±SEM) were 
compared with baseline values using Student's paired I-test with Bonferroni correction and a 
p-value < 0.05 was considered statistically significant. 
Figure 2. 
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Effect of continuous infusion of 1 mglkglh of NG-nitro-L-arginine methyl ester (L-NAME) for 
twelve hours on oxygen delivery (DOJ.l (solid columns) and oxygen consumption (VOJ (hatched 
columllS) in eight patients with severe septic shock. Time of L-NAME infusion is from (=0 to 
t= 12 hours. Values are displayed as mean±SEM, *p<0.05 for comparison with the baseline 
value. 
Patient characteristics are shown in Table I. The majority of patients had an intra-
abdominal infection as the cause for sepsis. The Acute Physiology and Chronic Health 
Evaluation (APACHE) II score" was 21 ± 1 (mean±SEM) and the Sepsis Severity Score l'was 
21 ±2. Cultures revealed both gram negative and gram positive bacteria with positive blood 
cultures in 45 % of patients. Mortality at 28 days was 55 % and one patient died at day 34 when 
treatment was discontinued because of inoperable surgical problems. Two patients died 2 days 
following I.-NAME infusion, the others at 3, 5, 8 and 22 days respectively, because of a 
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combination of persistent septic shock and multiple organ failure. These deaths were not likely 
related to drug infusion but probably represent the severity of illness. 
Continuous infusion of L-NAME resulted in a direct increase (within 5 min) in blood 
pressure, systemic vascular resistance and pulmonary artery pressure reaching a maximum 
within one hour (Figure I and Table 2). Parallel to these changes cardiac output and oxygen 
delivery decreased whereas pulmonary vascular resistance increased with a maximum change 
at t=3 h (Figure I and 2, Table 2). Heart rate, central venous pressure, pulmonary artery 
occlusion pressure and oxygen consumption, were not significantly changed (Figure 2 and 
Table 2). Vasopressors could be significantly reduced during L-NAME administration (Figure 
3). Arterial oxygenation was significantly improved in the first six hours of L-NAME infusion 
(Figure 4) without significant changes in FiO, or PEEP (data not shown). In seven patients 
Table 2. Effects of L-NAME on hemodynamic parameters in severe sepsis. 
baseline maximum change time of max. end of 
[t=O] withL-NAME change infusion 
[t= 12 hl 
MAP (nmlHg) 65±3 9314' 0.5 h 7H3' 
PAP (nunHg) 3H2 36±2' Ih 3H2 
CO (L/min) JO.8±0.8 8.7±0.7' 3h 9.1±0.9' 
SVR (dyne·s/em') 426±54 700±75' 0.5 h 577±70' 
PVR (dyne·s/em') 146±13 2JO±23' 3h 18H21 
HR (beats/min) 112±4 J08H 1 h 110H 
CVD (nllllHg) 12.9± 1.0 14.1±1.3 3h 11.7± 1.3 
PAOP (nmlHg) 12.7± 1.1 14.4± 1.2 3h 12.31 1.1 
PaO, (torr) 81±5 107±15' 3h 85±6 
DO, (mLimin) (n=8) 1604±160 1372±131' 3h 1492±173 
VO, (mLimin) (n=8) 360±26 344±30 1 h 348±36 
L-NAME = continuous infusion of 1 mglkgih of N°-nitro-L-arginine methyl ester. MAP = mean arterial 
pressure, PAP = pulmonary artery pressure, CO = cardiac output, SVR = systemic vascular resistance, PVR 
= pulmonary vascular resistance, HR = heart rate, CVD = central venous pressure, PAOP = pulmonary artery 
occlusion pressure, Pa02 = arterial oxygenation, 002 = oxygen delivery, VOl = oxygen consumption. Values 
are displayed as mean±SEM of eleven patients, ap <O.05 for comparison with the baseline value. 
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with severe septic shock during continuous infusion of 1 mg/kglh of NG-nitro-L-arginine methyl 
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Values are displayed as mean±SEM, * and # p<O.05 for comparison with the baseline value. 
who did not require continuous hemodialysis J urine output showed a tendency to increase 
during L-NAME infusion although the difference was not significant (p=O.09 att=6 h, Figure 
5). During continuous infusion of L-NAME the hemodynamic effects persisted, although the 
effects on blood pressure and systemic vascular resistance were most pronounced in the early 
stages ofL-NAME administration and effects diminished after the first hour ofL-NAME. Car-
diac output remained depressed throughout the whole 12 hour infusion period. During admi-
nistration of L-NAME no changes were seen in the electrocardiogram. SelUm urea and 
creatinine, liver function tests, lactate, arterial pH, platelets and leukocytes were not signifi-
cantly changed (Table 3). No side effects were seen during administration of L-NAME. 
Pharmacokinetic analysis in three patients revealed a mean plasma level of 1.1 ±O.2 I'g/mL 
L-NAME and 7.3±0.4l'g/mL L-NA at the end of the infusion period. 24 H after L-NAME 
infusion had been stopped, mean plasma level of L-NA was 3.1 ±0.4 I'g/nlL, whereas L-
NAME was below the detection linlit of 0.05 I'g/mL. 
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Discussion 
Sepsis or the septic syndrome is the number one cause of mortality in today's intensive 
care. Overall mortality of sepsis is estimated to be 40 to 60% and when shock or organ failure 
is present mortality rate is even higher despite progress in antibiotic and vasopressor 
therapy.'·14 New modalities of sepsis treatment offering new therapeutic tools would therefore 
be desirable for the management of patients with sepsis. Increased production of nitric oxide 
by the inducible nitric oxide synthase has been implicated as a major factor in the arterial 
hypotension, low systemic vascular resistance and hyporeactivity to catecholamines associated 
with endotoxin and cytokirte induced shock in animals.'·7 The present study that used the nitric 
oxide synthase inhibitor L-NAME, shows that nitric oxide is at least in part responsible for 
the hemodynamic derangements in patients with severe sepsis and that inhibition of nitric oxide 
Table 3. Effect of L-NAME on biochemical and hematological parameters in 
severe sepsis. 
baseline after L-NAME P-value 
Urea (nlllOlIL) 25±4 27±5 NS 
Creatinine (umollL) 283±56 312±63 NS 
Bilirubin (umollL) 230±51 228±46 NS 
Alk. Phospho (U/L) 236±106 232±103 NS 
y·OT (U/L) 103±38 106±39 NS 
ASAT (UIL) 167±91 141±76 NS 
ALAT (UIL) 91±43 71±32 NS 
Lactate (nlllOI/L) 3.7±1.2 3.0±O.7 NS 
Arterial pH 7.36±O.O2 7.36±O.O2 NS 
Hemoglobin (mmollL) 6.8±O.6 6.9±O.6 NS 
Platelets (xlO'IL) 139±25 129±23 NS 
Leucocytes (xlO'/L) 17.0±2.3 19.1±2.6 NS 
L-NAME = continuous infusion of 1 mglkglh of NG-nitro-L-arginine methyl ester for 12 hours; Alk. 
Phosp. = alkaline phosphatase, y-GT = Y glutamyl transferase, ASAT = aspartate aminotransferase, 
ALAT = alanine aminotransferase. Values are displayed as mean±SEM of eleven patients, NS = not 
significant. 
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synthesis may provide a new therapeutic tool in the management of hypotension and 
vasodilatation in sepsis. 
Sepsis is a complicated multifactorial process resulting from the complex interaction 
between bacterial cell products like lipopolysaccharides (LPS) and host defense mechanisms 
Figure 4. 
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Arterial oxygenation in eleven patients with severe septic shock during continuous infusion of 
1 mglkg/h of NO-nitro-L-arginine methyl ester (L-NAME) for twelve hours. Time of L-NAME 
infusion is from t=O to t=12 hours. Values are displayed as mean±SEM, *p<O.05 for 
comparison with the baseline value. 
leading to the release of several cytokines [e.g .• tumour necrosis factor (TNF). interleukines 
(IL-l. IL-2 and IL-6)1. myocardial depressant factor (MDF). platelet activating factor (PAP). 
kinins, arachidonic acid metabolites, endothelin-l and several other vasoactive mediators. 1,14 
Increased synthesis of nitric oxide is only one of many factors contributing to the 
derangements in the pathophysiological processes of septic shock. Inhibition of nitric oxide 
synthesis alone will most likely not be sufficient in stopping the cascade of events leading to 
overactivation of the inunune system. Tltis concept may explain the fact that there was no 
sustained clinical improvement and mortality rate of these severely ill patients remained high. 
over 60% which is in line of expectation considering APACHE II and Sepsis Severity sco-
res. 16•17 Although our study was not designed to deterntine the impact on survival. this high 
mortality rate could suggest that L-NAME had only lintited effect on outcome in these 
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patients. Possibly these patients were already in such a bad clinical condition that either 
therapy would have failed. Also, the 12 hour infusion period may have been too short to see 
any clinical improvement and a regimen with repeated infusions might be more effective. 
However, inhibition of nitric oxide synthesis may be considered as a potent therapeutic tool 
to gain time for therapy directed at the cause of septic shock e.g. adequate management of the 
infective site through antibiotics and surgery. New treatment modalities such as the use of 
selective inhibitors of the inducible type of NO synthase,18 or the combination of these 
selective inhibitors with anticytokine drugs, with the aim of blocking the causative inflam-
matory mediators, may proof effective therapy in the future. 19 
The present study shows that the continuous infusion of NG-nitro-L-arginine methyl 
ester (L-NAME), a specific inhibitor of nitric oxide synthesis, raised systemic blood pressure, 
systemic vascular resistance and pulmonary vascular resistance in patients with severe septic 
shock. Furthermore vasopressors could be reduced during L-NAME infusion. Our findings 
that L-NAME can raise blood pressure through preventing excess vasodilatation are consistent 
with the data from animal studies using L-NAME and other inhibitors of nitric oxide synthesis 
in endotoxin-induced shock.' and from studies using analogues of L-arginine in human 
sepsis ,9.10 but these reports only describe initial effects. The hemodynamic effects of L-NAME 
were direct in onset (within 5 min.) and persisted during the 12 hours of infusion, although 
the effect on blood pressure was most pronounced in the first hour of infusion. The fact that 
blood pressure gradually declined after the first hour was most probably caused by a concomi-
tant reduction in cardiac output during L-NAME infusion. At the end of the 12 hour infusion 
period mean arterial blood pressure was only slightly raised as compared to baseline level 
whereas systemic vascular resistance remained elevated. However, some reservations must be 
made when interpreting the results of the present study. We did not include a control group 
(most appropriately receiving D-NAME) for comparison and spontaneous changes in the 
variables studied may have occurred over time. Furthermore, at this moment it is unclear 
whether the optimum hemodynamic effect was obtained with the currently used dosage of L-
NAME. Possibly a higher or lower dose of L-NAME could have prevented the fall in blood 
pressure during prolonged infusion, although higher doses resulted in puhnonary hypertension 
in prior experinlents. Also, we do not know to what extent nitric oxide synthesis was inhibited 
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by L-NAME since no measurements were made of nitrite/nitrate levels, the stable end products 
of nitric oxide metabolism.20 New techniques for direct determination of nitric oxide ill vivo, 
may help to further explore this idea. 21 
Animal studies in dogs and rabbits have shown that L-NAME is converted by serum 
esterases to L-NA, an active inhibitor of nitric oxide synthase, through esterification of the 
carboxyl group. 15.22 At the time of our study no data were available about pharmacokinetics 
of L-NAME in humans. Using high performance liquid chromatography, we could detect high 
plasma levels of L-NA at the end of L-NAME infusion, whereas plasma levels of L-NAME 
were much lower, only 15 % of the L-NA plasma concentration. These results suggest 
conversion of L-NAME to L-NA in humans, similar to what was found in animals. 15•22 
Furthermore, 24 hours following the end of L-NAME infusion, plasma levels of L-NA were 
still about 40 % of maximum whereas L-NAME itself was undetectable suggesting a long half-
life of L-NA in humans. At this moment we do not know to what proportion L-NAME was 
responsible for inhibition of nitric oxide synthesis as compared to the active metabolite L-NA 
in the patients studied. Also, it is unknown how L-NA is further metabolized and cleared from 
the human body. To answer these questions further pharmacokinetic studies are warranted. 
Cardiac output was depressed during L-NAME infusion as has been reported with other 
inltibitors of NO synthesis in both animals and humans.'·10 So far the precise mechanism 
underlying this reduction in cardiac output remains unclear.'" The reduction in cardiac output 
could partially have resulted from a reflex change due to the increased systelnic vascular resis-
tance and afterload, or a reduction in catecholamine dosage. A direct toxic effect of L-NAME 
on cardiac myocytes is improbable." Although myocardial depression secondary to coronary 
vasoconstriction and myocardial ischemia have been suggested as mechanisms for toxic cardiac 
effects in animal studies using inhibitors of NO synthesis," this pathogenesis is unlikely in the 
present study since no changes on the electrocardiogram were observed during L-NAME 
infusion. The reduction in cardiac output and parallel reduction in oxygen delivery may be 
harmful since tissue perfusion is reduced. Several animal studies have shown harmful effects 
of nitric oxide synthase inhibitors on organ function and outcome in experimental sepsis 
possibly as a result of tissue underperfusion related to the unselectivity of these inhibitors for 
the constitutive nitric oxide synthase (c-NOS)."·" L-NAME and L-NA show some preference 
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Urine production in seven patients with severe septic shock during continuous infusion of 1 
mg/kgfb of ~-nitro-L-arginine methyl ester (L-NAME) for twelve hours. Time of L-NAME 
infusion is from t=O to t=12 hours. Values are displayed as mean±SEM, for all values 
p>O.05 for comparison with the baseline value. Four other patients were not included in the 
statistical analysis since they had renal failure requiring continuous hemodialysis. 
towards c-NOS versus the inducible isoform.' However, much of the detrimental effects 
reported in these studies, depend on the dose of the nitric oxide synthase inhibitor 
administered, the moment of inhibition and the experimental model used. 12.27 Induction of the 
inducible nitric oxide synthase (i-NOS) takes a lag-phase of several hours." When 
administration of nitric oxide synthase inhibitors is done in the early phase of sepsis, i-NOS 
may not have been expressed and only the constitutive isoform is blocked, resulting in 
detrimental vasoconstriction. 29 Furthermore, in a situation of hypodynamic shock with reduced 
cardiac output and reduced organ perfusion, additional vasoconstriction by inhibition of nitric 
oxide synthesis could be detrimental. TIns possibility made us include only patients with 
hyperdynantic sepsis with increased cardiac output, where there is an overperfusion of tissues 
to begin with. In our study no evidence of comprontised tissue oxygenation was found during 
L-NAME adntinistration since oxygen consumption was unaffected and arterial lactate and pH 
were unchanged. This finding ntight suggest that L-NAME preferentially causes vasoconstric-
tion in metabolic inactive tissues. Also no significant adverse effects were seen on renal and 
liver function. Although not significant, urine output showed a tendency to increase during L-
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NAME infusion. The effect of L-NAME on intestinal perfusion remains to be determined and 
measurement of gastric intramucosal pH, a proposed marker for splanchnic perfusion and an 
index of patient tissue oxygenation, could be useful in further studies.3D 
The role of nitric oxide is not limited to that of a vasodilator. Nitric oxide has 
antithrombotic properties that result from inhibition of platelet adhesion and aggregation which 
can be influenced by inhibitors of nitric oxide synthesis.3I •32 Furthermore nitric oxide may 
inhibit leukocyte adhesion to the endothelium.32•33 In the present study platelet numbers and 
leukocyte count were not significantly changed following 12 hours of L-NAME infusion 
suggesting that enhanced platelet aggregation andlor leukocyte adhesion by L-NAME played 
only a minor role. The small changes in platelet numbers and leukocyte count that were seen, 
probably represent the natural course of the disease and not a direct effect of L-NAME. 
A regulatory role of nitric oxide on puimonary vascular tone has been described and 
inhaled nitric oxide can be used to reduce puimonary hypertension and improve oxygenation 
in patients with Adult Respiratory Distress Syndrome (ARDS)."·3S That nitric oxide vasodUates 
the puimonary vasculature is underscored by the fmding that L-NAME increased puimonary 
artery pressure and pulmonary vascular resistance. Pulmonary vasoconstriction is an 
undesirable effect that may lead to pulmonary hypertension with right ventricular failure and 
reduced left ventricular preload and may also lead to problems in puimonary gas exchange. 
In prior dose-fmding experiments higher doses of L-NAME resulted in puimonary 
hypertension for which L-NAME infusion had to be stopped. However, in our study group no 
signs of pulmonary hypertension were seen and right atrial pressure and pulmonary artery 
wedge pressure were unchanged. These results suggest that the detrimental effects of L-NAME 
on the puimonary vasculature are dose-related and only found when high doses of L-NAME 
are used. In fact arterial oxygenation was improved during of L-NAME infusion despite the 
profound pulmonary vasoconstriction and reduction in cardiac output. This fmding may 
suggest that L-NAME temporarily redistributed intrapulmonary blood to well oxygenated 
alveoli. Similar effects of L-NAME on arterial oxygenation were described by Sprague et al.36 
using a model of unilateral alveolar hypoxia in anaesthetized rabbits. To prevent puimonary 
vasoconstriction seen with the systemic administration of inhibitors of nitric oxide synthesis, 
selective pulmonary vasodilatation through the combined use of nitric oxide inhalation, may 
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be an elegant solution.37 
In conclusion prolonged inhibition of nitric oxide synthesis may help to maintain 
vascular tone and blood pressure in patients with severe sepsis and give us valuable time to 
start therapy directed at the cause of sepsis. However, at this time it is too early to introduce 
inhibitors of nitric oxide synthesis into routine clinical use. Despite tlle fact that blood pressure 
and vascular resistance were increased during the twelve hours of L-NAME infusion, the 
overall clinical condition was not improved and mortality rate remained high in these severely 
ill patients. This fInding could suggest that there are only limited effects of L-NAME on 
outcome, and more randomised clinical studies will be required to further investigate this 
question. 
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Abstract 
In this pmspective clinical study we tested the effects of continuous infusion of NG_ 
nitm-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide (NO) synthesis on 
cardiovascular performance and pulmonary gas exchange in eleven patients with hyperdynamic 
septic shock. Standard hemodynamic measurements were made and blood samples taken 
before, during and after 12 hours of continuous infusion of 1 mg/kg/h of L-NAME. 
Continuous infusion of L-NAME increased mean arterial pressure (MAP) fmm 65 ± 3 
(SEM) to 93±4 mmHg and systemic vascular resistance (SVR) from 962±121 to 1563±173 
dyne·s·cm-slm'. Parallel to this cardiac index (CI) decreased from 4.8±OA to 3.9±OA 
Llminlm' and myocardial stroke volume (SV) was reduced from 43±3 to 34±3 m1fm'. Left 
ventricular stroke work was increased in the first hour of L-NAME infusion fmm 31 ±3 to 
43±4 gm'mlm' (allp<O.OI compared to baseline). Heart rate, cardiac fIlling pressures and 
right ventricular stroke work did not change significantly (p> 0.05). L-NAME increased the 
ratio of arterial pO, to the fraction of inspired oxygen (paO,IFiO,) from 167 ±23 to 212±27 
rmnHg (p<0.05). Venous admixture (QvAlQr) was reduced from 19A±2.6 to 14.2±2.1 % 
(p<0.05) and oxygen extraction ratio increased fmm 21.1 ±2.4 to 25.3 ±2.7 % (p <0.05). 
Oxygen delivery (DO,) was reduced following L-NAME, whereas oxygen uptake and arterial 
lactate and pH were unchanged. 
Pmlonged inhibition of NO synthesis with L-NAME can restore MAP and SVR in 
patients with severe septic shock. Myocardial SV and CI decrease, pmbably as a result of 
increased afterload since heart rate and stroke work were not reduced. L-NAME can improve 
pulmonary gas exchange with a concomitant reduction in QvAlQr. L-NAME did not promote 
anaerobe metabolism despite a reduction in DO,. 
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Introduction 
Sepsis and septic shock are characterised by massive systemic vasodilatation with low 
vascular resistance, increased cardiac output despite myocardial depression, decreased 
sensitivity to catecholamines and high mortality rate.'·2 Recent evidence suggests that patholo-
gic overproduction of the nitric oxide (NO) radical, a potent vasodilator fomlerly known as 
endothelium derived relaxing factor (EDRF), is at least in part responsible for the 
cardiovascular dysfunction seen in sepsis and endotoxemia.3•4 
Under normal conditions small amounts of NO are formed from L-arginine by the 
constitutive NO synthase present in the vascular endothelium. This results in a constant 
vasodilatory tone maintaining adequate tissue perfusion. Upon stimulation by endotoxins (LPS) 
and cytokines such as TNF and IL-l, an inducible calcium independent isoform of NO syntha-
se is formed in various cell types. This inducible enzyme differs from the constitutive isoform 
in that it releases massive amounts of NO over long periods of time resulting in profound 
vasodilatation, hypotension and resistance to catecholamines,' Furthermore, the early 
hypotension and hyporeactivity to constrictors seen after exposure to endotoxins may result 
from increased activity of the constitutive enzyme.5 High levels of nitrite and nitrate, the stable 
end product of NO metabolism, are found in patients with severe sepsis and these levels may 
correlate with vasodilation.6 Recently NO has been incriminated in cascade leading to the 
myocardial depression during sepsis, as suggested by ill vitro studies.'" 
Both the constitutive and inducible isoform of NO synthase are competitively inhibited 
by NG-substituted analogues of L-arginine, such as NG-monomethyl-arginine (L-NMMA), N°-
nitro-L-arginine (L-NA) and NG-nitro-L-arginine methyl ester (L-NAME).9·IOInfusion of these 
analogues of L-arginine can reverse endotoxin or cytokine induced hypotension and can restore 
reactivity to catecholamines in animals. u-13 In patients with septic shock, short-term administ-
ration of these inhibitors of NO synthesis have been shown to increase blood pressure and 
systemic vascular resistance.'~16 Furthermore, methylene blue, an inhibitor of soluble guanyla-
te cyclase which is the effector enzyme of NO, has been shown to temporarily raise blood 
pressure in septic patients. 17 Therefore, inhibitors of NO synthesis have been suggested to be 
of value in the treatment of hypotension during human septic shock. However, limited data are 
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present about the effects of continued inhibition of NO synthesis on cardiovascular 
performance in human sepsis and the effect on pulmonary function remains to be determined." 
Since inhalation of NO can improve oxygenation in patients with ARDS one could hypothesize 
that systemic inhibition of NO synthesis could compromise pulmonary gas exchange through 
pulmonary vasoconstriction. 19 
The present study was to designed to asses the effects of prolonged inhibition of NO 
synthesis on cardiovascular performance and puhnonary gas exchange during continuous infu-
sion of NG-nitro-L-arginine methyl ester (L-NAME) for 12 hours in patients with severe septic 
shock. To study the effect of L-NAME on NO production measurements were made of serum 
nitrite and nitrate levels. 
Materials and Methods 
Subjects. The hospital's Medical and Ethics Committee approved the study. First 
degree relatives were informed of the nature of the study and gave informed consent. Eleven 
adult critically ill patients of the intensive care unit of our hospital were included in the study. 
All patients met the criteria of sepsis as described by Bone et al.'o These criteria 
include evidence of infection, tachycardia (> 90 beats/min in the absence of p-adrenergic 
receptor blockade), tachypnea (respiratory rate >20 breaths/min or the requirement of mech-
anical ventilation), fever or hypothermia (temperature >38.3°C or <35.6°C), plus at least 
one of the following signs of inadequate organ perfusion: Pao,/Fio, <280 (without other 
puhnonary or cardiovascular disease as the cause), increased blood lactate levels (>2 
mmollL), and oliguria «0.5 mL/kg/h) for at least I hr. All patients were in shock (systolic 
BP < 90 mmHg or a decrease > 40 mmHg from baseline unresponsive to fluid challenge) on 
admission requiring therapy with pressor agents. At the time of the study all patients were 
receiving dopamine > 15 j£g/kg/min and/or noradrenaline > 0.1 j£g/kg/min. All patients had 
respiratory failure and required mechanical ventilation. Patients received antibiotic therapy 
based on culture results. Four patients required continuous hemodialysis because of renal 
failure. Only patients with cardiac index> 3.0 Llminlm' were included since earlier reports 
have shown reductions of cardiac output during inhibition of NO synthesis. ,,,'6 We hypothe-
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sized that a further reduction in cardiac output would be undesirable and even dangerous in 
a state where cardiac output is reduced. Exclusion criteria for the study were severe coronary 
artery stenosis (angina pectoris grade III according to NYHA classification), pregnancy and 
cardiac index <3.0 Llminlm2 • 
Study Protocol. All patients underwent continuous electrocardiographic monitoring and 
had indwelling radial artery and pulmonary artery catheter (Criticath, Ohmeda, Singapore). 
Mean systemic arterial blood pressure (MAP), central venous pressure (CVP) and mean 
pulmonary artery pressure (pAP) were continuously measured. Triplicate measurements of 
cardiac output (CO) were made according to the thermodilution method, and the mean value 
reported. Data were recorded on a computerised data system (Mennen Medical Systems, 
USA). Cardiac output and pulmonary artery occlusion pressure (p AOP) were measured three 
and six hours before L-NAME infusion (f= -6 and -3 h), at baseline (T= 0), during L-
NAME infusion (T= 0.5, I, 3, 6, and 12 h) and three and six hours following L-NAME 
infusion (T= 15 and 18 h). L-NAME was obtained from Sigma Chemicals (St. Louis, MO, 
USA). The hospital pharmacy prepared a sterile and pyrogen-free solution of L-NAME 10 
mg/mL, ready for infusion. Within six hours after inclusion, baseline measurements were 
made and L-NAME 1 mg/kg/h infusion was started and continued for 12 hours. If mean 
arterial blood pressure increased above 100 nnnHg, the administration of vasopressors was 
gradually reduced and the dosage noted. Concomitant therapy was at the discretion of the 
clinician managing the patient. Continuous infusion of L-NAME was chosen since the effect 
of a bolus injection of 0.15 mg/kg L-NAME lasted only 5-10 minutes (unpublished observati-
ons). Before and after administration of L-NAME, blood was withdrawn for routine measure-
ment of serum electrolytes, and creatinine, liver function tests, lactate, hemoglobin, platelets 
and leucocytes. Arterial and central venous blood was withdrawn at T= 0, 1,3,6, 12 and 15 
h and blood gases, pH and hemoglobin content were analyzed (ABL505, Radiometer, 
Copenhagen) for determination of pulmonary gas exchange parameters, oxygen delivery and 
oxygen consumption. Since central venous blood gas measurements were incomplete in three 
patients, mean values of gas exchange parameters and related calculations are reported for only 
eight patients. In all patients blood was withdrawn at T= 0, I, 3, 6, 12, IS, 18 and 24 h for 
determination of nitrite and nitrate levels, the stable end products of NO metabolism, and 
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analyzed using an automated procedure based on the Griess reaction. 21 Serum of eight 
postoperative intensive care patients served as control for nitrite and nitrate levels. 
Calculatiolls alld statistical alia lysis. Calculations were performed according to 
standard formulas. Recorded variables were compared with baseline values using Student's 
paired t-test with Bonferroni correction. Nitrite/nitrate levels were compared with control 
using Student's unpaired t-test. Ap-value <0.05 was considered statistically significant. Data 
are expressed as mean ± SEM. 
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Table 1. Patient characteristics 
Age, yr 
Sex, MIF 
APACHE II score* 
Sepsis Severity Score* 
Source of sepsis 
Bacteria 
Local culture 
Blood culture 
Mechanical ventilation 
PEEP (CIll H,O) 
Mortality (at day 28) 
51.7±3.9 
lOll 
20.7± 1.0 
20.8±0.9 
peritonitis (n=5) 
pneumonia (n=2) 
pancreatitis (n=2) 
mediastinitis (0=1) 
peritonitis + pneumonia (n= 1) 
Enterococcus jaecalis (n=6) 
Staphylococclls epidermidis (n=3) 
Klebsiella plleullloniae (0= 1) 
StreptococCllS pnellllloniae (0= 1) 
Escherichia coli (n = 1) 
Clostridilllll difficile (n= 1) 
Bacteroides species (n=l) 
Enterococcus jaecalis (0= 1) 
Pseudomonas aerugillosa (0= 1) 
Staphylococcus aureus (n= 1) 
Proteus vulgaris (0= 1) 
Klebsiella pJleulIlolliae (n= 1) 
11 
5.7±2.0 
6/11 
Values are displayed as mean±SEM of eleven patients. *APACHE II = Acute Physiology 
and Chronic Health Evaluation, Knaus et al. [22]. :j: Sepsis Severity Score as described by 
Elebute and Stoner [23], PEEP = positive end-expiratory pressure. 
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Results 
Patient characteristics are shown in Table I. The majority of patients had an intra-abdo-
minal infection as the cause for sepsis. Cultures of the infective focus revealed both gram 
negative and gram positive bacteria with positive blood cultures in 45% of patients. Mortality 
at 28 days was 55 % and one patient died at day 34 when treatment was discontinued because 
of inoperable surgical problems. No obvious link was noted between deaths and infusion of 
L-NAME. 
Figure 1. 
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Effects of continuous infusion of 1 mglkg/h of N{J-nitro-L-arginine methyl ester (L-NAME) on 
cardiac performance in eleven patients with severe septic shock. SV = stroke volume, SW = 
stroke work, LVSW = left ventricular stroke work, RVSW = right ventricular stroke work. 
Time ofL-NAME infusion is from t=O to t=12 hours. Values are displayed as mean±SEM, 
*p<O.05 for comparison with the baseline value. 
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Continuous infusion of L-NAME resulted in an increase in blood pressure (MAP), sys-
temic vascular resistance (SYR), pulmonary artery pressure (PAP) and pulmonary vascular 
resistance (pYR) which was direct in onset (Table 2; p<O.OI). Parallel to these changes 
cardiac index (Cl) and myocardial stroke volume (SV) were reduced (Table 2 and Figure 1; 
p<O.OI). Left ventricular stroke work (LYSW) was increased only in the fIrst hour of L-
NAME infusion whereas right ventricular stroke work (RYSW) was not significantly changed 
(Figure 1). Heart rate and cardiac filling pressures did not change significantly (Table 2). L-
NAME infusion resulted in improved arterial oxygenation (Figure 2 and Table 3) with a 
maximum increase in tile ratio of arterial PO, to the fraction of inspired 0, (paO/FiO,) from 
167±23 to 212±27 l1ll1lHg after 3 h of L-NAME infusion (p<0.05). Venous admixture 
(QVAlQT) was reduced from 19.4±2.6 to a minimum of 14.2±2.1 % (p<0.05) after 6 h of 
L-NAME infusion (Figure 2) and oxygen extraction ratio (O,ER) increased from 21.1 ±2.4 
to 25.3±2.7 % (p<0.05). No significant changes were seen in partial pressure of arterial 
carbon dioxide (paCO,) and alveolar-arterial oxygen pressure difference (p(A-a)O,) (Table 3). 
The PEEP level was not significantly changed during L-NAME infusion (5.7 ±2.0 versus 4.7-
±2.0 cm H,O at the end of L-NAME infusion, p > 0.05). Other ventilatory parameters such 
as mean airway pressure, peak inspiratory pressure and minute volume were unchanged (not 
shown). Oxygen consumption (YO,) was unchanged despite a reduction in oxygen delivery 
(DO,) (Table 3). Vasopressor support was significantly reduced during L-NAME administrati-
on (dopamine from 1920±170 to 1630±200 I'g/min and noradrenaline from 8.3±2.1 to 
7.5±2.3l'g/min at the end ofL-NAME infusion, bothp<0.05). During continuous infusion 
of L-NAME the hemodynamic effects persisted, although the effects on MAP were most 
pronounced in the early stages of L-NAME administration. CI and SY remained depressed 
throughout the whole 12 hour infusion period. At baseline, nitrite/nitrate levels ranged from 
13 to 86 (median 37) I'mol/L in the study group which was increased compared to control 
(range 5 to 17 (median 11) I'moUL, p<0.05). Serum nitrate and nitrite showed no significant 
changes during L-NAME infusion (Figure 3). Urine output increased from 92±27 to a 
maximum of 157 ±59 mL/h during L-NAME infusion which was not statistically significant 
(n=7; p=0.09). Arterial lactate (from 3.7±1.2 to 3.0±0.7 mmol/L) and arterial pH (from 
7.36±0.02 to 7.36±0.02) were not significantly changed after the 12 h of L-NAME infilsion. 
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Table 2. Effect of L-NAME infusion on hemodynamic variables in patients with severe sepsis 
continuous L-NAME infusion 
baseline 0.5 h Ih 3h 6h 12h 15 h 18h 24h 
CI. Uminlm' 4.8±0.4 4.4±0.4* 4.3±0.4* 3.9±0.4* 4.0±0.4* 4.1±O.4* 4.2±0.4* 4.2±0.3* 4.4±0.4 
MAP,mmHg 6S±3 93±4* 87±4* 80±4* 7S±3* 7l±3* 66±3 66±3 68±3 
SVR, dyne's'cm" 1m' 962±121 IS63±173* IS31±183* 1483±172* 1410±173* 1206±137* 1088±127 1092±124 1096±131 
PAP,mmHg 31±2 3S±2* 36±2* 36±2* 33±2 31±2 30±2 30±2 30±2 
PVR. dyne·s·cm's 1m2 329±31 432±SI* 463±SI* 47S±S3* 469±S7* 418±49 380±38 376±43 374±41 
HR, beatslmin 112±4 1l0±4 108±4 112±4 1l0±4 1l0±4 107±S 108±S 108±S 
CVD,mmHg 12.9±1.0 14.1 ± 1.1 13.S±1.2 14.1±1.3 11.8± 1.0 11.7±1.3 11.7±0.9 11.9±0.7 11.6±1.3 
PAOP,mmHg 12.7±0.9 14.l±O.9 13.9±O.9 14.4± 1.2 12.7±0.9 12.3±1.l 12.2±0.8 12.6±O.8 12.9±1.0 
L-NAME infusion = 1 mg/kg/h of NG-nitro-L-arginine methyl ester. CI = cardiac index, MAP = mean arterial pressure, SVR = systemic vascular resistance, PAP = 
pulmonary artery pressure, PVR = pulmonary vascular resistance, HR = heart rate, eVD = central venous pressure, PAOP = pulmonary artery occlusion pressure. 
Values are displayed as mean±SEM of eleven patients, *p < 0.05 for comparison with the baseline value. 
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Table 3. Effect of L-NAME infusion on pulmonary and metabolic variables in patients with severe sepsis. 
continuous L-NAME infusion 
baseline Ih 3h 6h 12h 15 h 18 h 
FlO" % 57±6 57±6 56±6 51±5 50±5 51±5 50±5 
PaO"mmHg 81.0±5.4 99.4±1O.6* 107.6±13.5* 93.1±7.9* 84.8±7.5 81.5±4.6 77.6±4.8 
PaCO"mmHg 34.9±1.3 35.5±1.3 36.2±1.4 35.5±1.1 35.4±1.4 34.7±1.5 36.1±!.5 
P(A-a)O" mmHg 292±48 273±48 258±42* 234±40* 236±39* 246±46 242±46 
PVO" mmHg' 41.3±1.8 41.8±1.7 4O.7±2.0 39.3±1.9 40.3±1.6 40.0±1.4 39.6±1.6 
QvAlQr, %' 19.4±2.6 17.1±2.9* 14.9±2.6* 14.2±2.1* 14.3±2.3* 14.1±2.2* 13.9±2.2* 
O,ER, %' 21.1±2.4 23.3±2.7 24.7±2.6* 25.3±2.7* 24.1±2.1 24.4±2.5 23.5±2.1 
DO" mL/minlm" 713±68 658±64* 600±51* 621±55* 644±60 673±57 653±49 
VO" mL/minlm" 158± 12 153±13 151±1O 162±12 156±16 167±19 159±19 
Pa02 = partial pressure of arterial oxygen, PaCCh = partial pressure of arterial carbon dioxide, P(A-a)Oz = alveolar-arterial oxygen difference, PVO;! = 
partial pressure of venous oxygen, QVA/QT = venous admixture, OzER = oxygen extraction ratio, 002 = oxygen delivery, VOl = oxygen consumption. 
FlOz = fraction of inspired oxygen. Values are displayed as mean±SEM of eleven (:j:or eight) patients, *p < 0.05 for comparison with the baseline value. 
L-NAME and cardiopulmonary fUlIction 
Also serum electrolytes, urea and creatinine, liver function tests, platelets and teucocytes were 
not significantly changed at the end of L-NAME infusion (results not shown). During 
administration of L-NAME no changes were seen in the electrocardiogram. No side effects 
were seen during administration of L-NAME. 
Discussion 
The mortality rate from septic shock remains high despite progress in antibiotic and 
Figure 2. 
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Effect of continuous infusion of 1 mg/kg/h of NG-nitro-L-arginine methyl ester (L-NAME) on 
pulmonary gas exchange in patients with severe septic shock. PaO/Fi02 = ratio of arterial pOl 
to the fraction of inspired oxygen (0=11), QvAiQr = venous admixture (0=8). Time of L-
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for comparison with the baseline value. 
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vasopressor therapy and therefore new treatment modalities are warranted. I Increased producti-
on of nitric oxide (NO) by the inducible NO synthase has been implicated as a major 
contributor to the cardiovascular dysfunction of endotoxin and cytokine induced shock in 
animals. II•13 The present study shows that NO is at least in part responsible for the hemody-
namic derangements in patients WWI severe sepsis. Prolonged inhibition of NO synthesis with 
NG-nitro-L-arginine methyl ester (L-NAME) can improve cardiovascular status and pulmonary 
gas exchange in these severely ill patients and may provide a new treatment modality in the 
management of septic shock. 
Although no conclusions can be made regarding mortality in this non-randomised study 
with only eleven patients, the mortality rate was high (over 60%) which could raise questions 
regarding safety of L-NAME. However, no obvious deterioration of condition was noted 
during L-NAME infusion and mortality was not different from predicted death rate as 
computed by the APACHE II and Sepsis Severity scores."·23 Some animal studies have shown 
detrimental effects and increased mortality following L-NAME and other analogues of L-
arginine during septic shock. 24.25 The detrimental effects of these NO synthase inhibitors have 
been contributed to their non-specifity towards the constitutive isoform of NO synthase and 
selective inbibition of the inducible enzyme has been suggested to be more effective. 25•26 Recent 
reports however, suggest that the constitutive form of NO synthase disappears in endotoxemia 
and other forms of sepsis." If this is true, then the use of a non-specific inhibitor of NO 
synthase would be as effective as an inhibitor specific to the inducible isoform. In addition, 
the inhibition of the inducible isotype could hinder inunune defense and bactericidal 
mechanisms which are important in sepsis." Furthermore the detrimental effects described in 
many of these studies may be explained by administration of the inhibitor in the early phase 
of sepsis. In tltis situation the inducible NO synthase will not be yet fully expressed since this 
takes a lag-phase of several hours' and only the constitutive NOS will be blocked, resulting 
in severe and detrimental vasoconstriction. In addition the detrimental effects are dose-
dependent and mostly seen in studies using extremely high doses of the NO synthase 
inhibitor. 29 
In our study patients received L-NAME 1 mg/kg/h for 12 hours resulting in a total 
dose of 12 mg/kg of L-NAME which is relatively low compared to the doses of NO inhibitors 
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used in most animal studies 1Z•13 and comparable to the doses used in studies in humans. 14-16.30 
Animal studies have shown that L-NAME is probably a pro-drug that is converted to the active 
L-NA. which is much more stable and has a high plasma half-life." However, little is known 
about pharmacokinetics and metabolism of L-NAME in humans. To minimize the potential 
chance of developing toxicity from high serum levels of L-NAME or L-NA we did not 
continue L-NAME infusion for a longer period than 12 hours and we did not restart L-NAME 
when patients redeveloped hypotension. At this time we do not know whether the optimum 
therapeutic dose of L-NAME was used and possibly the 12 hour administration period of L-
NAME was too short for clinical improvement. Further pharmacodynamic studies will be 
necessary to find the optimum dose and schedule for L-NAME administration. 
Our findings show that L-NAME can raise blood pressure in severe septic shock 
through preventing excess vasodilatation. Similar results have been found in previous studies 
using analogues of L-arginine in human sepsis, '4-'6 although most reports only describe initial 
effects. The hemodynamic effects of L-NAME were direct in onset and persisted during the 
12 hours of infusion. However, the effect on blood pressure was most pronounced in the first 
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hour of infusion and tended back towards baseline after one hour of L-NAME infusion. Since 
SVR remained elevated, the decline in blood pressure was probably caused by a concomitant 
decrease in CI and SV although some form of tolerance or counter-regulation may have played 
a role. 
The reduction in CI has been reported with other inhibitors of NO synthesis in both 
animals and humansY-16 So far the precise mechanism underlying this reduction in cardiac 
output remains unclear. In our study it could partially have resulted from a reflex change due 
to the increased systemic vascular resistance and afterload, or a reduction in vasopressor 
support. Since LVSW was improved during L-NAME infusion and heart rate and RVSW were 
not significantly changed, direct cardiac depression by L-NAME seems unlikely. Myocardial 
depression secondary to myocardial ischemia" could have played a role although no changes 
on the electrocardiogram were observed during L-NAME infusion. The reduction in CI and 
concomitantly DO" may be harmful since tissue perfusion may be reduced. Therefore we only 
included patients with hyperdynamic sepsis as characterized by increased CI. The observations 
that VO, was unaffected and arterial lactate and pH were unchanged suggest that L-NAME did 
not promote anaerobe metabolism and that L-NAME preferentially caused vasoconstriction in 
metabolic inactive tissues. However, these observations only include indirect parameters that 
do not necessarily reflect what happens at capillary or cellular level. Thus, despite these 
rmdings, local areas of tissue underperfusion could have existed during L-NAME infusion. 
Nitric oxide contributes to puhnonary vascular tone and inhaled nitric oxide can be 
used to reduce pulmonary hypertension and improve oxygenation in patients with Adult 
Respiratory Distress Syndrome (ARDS).19.33 That NO vasodilates the pulmonary vasculature 
is underscored by the finding that L-NAME increased PAP and PVR. Pulmonary vasocon-
striction is an undesirable effect that may lead to pUlmonary hypertension and related 
deleterious effects on circulation, particularly on right sided cardiac function. Indeed in prior 
pilot experiments we found that ltigher doses of L-NAME resulted in severe puhnonary hyper-
tension. The pulmonary vasoconstriction seen with L-NAME and other inhibitors of NO 
synthase,12-15 may limit their clirtical application especially in patients with high PAP. Since 
NO inhalation may improve oxygenation in patients with ARDS we hypothesized that 
inltibition of NO synthesis might lead to problems in puhnonary gas exchange. However, we 
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found that arterial oxygenation was improved during L-NAME infusion despite pulmonary 
vasoconstriction. Parallel to this there was a reduction in QvAlQr which implicates a decrease 
of tile pu~nonary right-to-left shunt. This may suggest that L-NAME caused a redistribution 
of intrapulmonary blood to well ventilated alveoli, improving ventilation-perfusion mismatch. 
Similar effects of L-NAME on arterial oxygenation were described by Sprague et al." using 
a model of unilateral alveolar hypoxia in anaesthetized rabbits. Furthermore in a study by 
Radermacher et al." it was found that the increase in cardiac output by systemic administration 
of Ilitrovasodilators worsened ventilation-perfusion mismatching and gas exchange in patients 
with ARDS. The combined use of NO inhalation with systemic inhibition of NO synthesis may 
prove effective therapy in the future. 36 
Septic patients had increased levels of nitrite and nitrate in the selUm as compared to 
control. Although this could reflect increased systemic NO production,6 some reservations 
must be made since NO is but one of the ways that nitrite and nitrates are formed. L-NAME 
infusion did not result in reduced selUm levels of nitrite and nitrate, despite profound 
vasoconstriction. At tllis time we cannot explain tltis rmding but it could suggest that L-NAME 
is not an effective inhibitor of NO synthesis and other mechanisms, independent of systemic 
inhibition of NO synthesis, may playa role in the increase in MAP and SVR by L-NAME." 
Furthermore selUm levels of nitrite and nitrate may not directly reflect the local amount of NO 
released or inhibited since active excretion through kidneys and gastro-intestinal tract takes 
place." 
In conclusion prolonged inhibition of NO synthesis with L-NAME may improve cardio-
vascular status with improvement of puimonary gas exchange in severe septic shock. Mortality 
rate was high which could suggest only limited effects of L-NAME on outcome. Furtllermore, 
the increase in PAP and the reduction in cardiac output are potentially harmful effects tllat may 
hinder the clinical utility of L-NAME and other NO synthase inhibitors. More randomised 
clinical studies will be required to further investigate whether inhibition of NO synthesis is 
beneficial in human septic shock. 
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Abstract 
It has been suggested that inhibitors of nitric oxide synthesis are of value in the 
treatment of hypotension during sepsis. In this pilot study we examined the effects of inhibition 
of nitric oxide synthesis by continuous infusion ofNG-nitro-L-arginine methyl ester (L-NAME) 
1. 5 rug/kg/h in a patient with severe septic shock. 
L-NAME produced a rise in mean arterial blood pressure and systemic vascular 
resistance; catecholamine infusion could be reduced. Parallel to these rmdings there was a 50% 
reduction in cardiac output and a five-fold rise in pulmonary vascular resistance which resulted 
in severe pulmonary hypertension after three hours of L-NAME infusion for which infusion 
had to be stopped. Following stop of L-NAME infusion putmonary artery pressure and blood 
pressure returned to baseline values, although putmonary and systemic vascular resistance 
remained elevated for several hours. 
We conclude that nitric oxide appears to playa role in the cardiovascular derangements 
during human sepsis. Inhibition of nitric oxide synthesis with L-NAME can increase blood 
pressure and systemic vascular resistance. However, reduced cardiac output and pulmonary 
hypertension are possible side effects of continuous NO synthase inhibition. These side effects 
necessitate careful monitoring and may hinder the clinical application of NO synthase 
inhibitors. 
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Introduction 
Human septic shock is characterised by massive systemic vasodilatation with low 
vascular resistance, increased cardiac output, hypotension and high mortality rate.' Increased 
synthesis of the potent vasodilator nitric oxide (NO) has been incriminated in the hypotension 
and vasodilatation that occurs during sepsis and endotoxemia.' Under normal conditions small 
amounts of NO are formed from L-arginine by the constitutive NO synthase (eNOS) present 
in the vascular endothelium.' TIlls endothelium derived NO (EDNO) plays a role in the regula-
tion of blood pressure and tissue perfusion by maintaining vasodilatory tone. Upon stimulation 
by endotoxins and cytokines such as tumor necrosis factor and interleukine- I, an inducible 
form of NO synthase (iNOS) is formed in macrophages and vascular smooth muscle cells.' 
This inducible enzyme differs from the constitutive isoform in that it releases massive amounts 
of NO resulting in profound vasodilatation with hypotension; dysfunction of vascular 
autoregulation, resistance to catecholamines and tissue damage.2,4 
Analogues of L-arginine, such as N°-mono-methyl-arginine (L-NMMA), NG-nitro-L-
arginine (L-NA) and NG-nitro-L-arginine methyl ester (L-NAME), competitively inhibit the 
production of NO from L-arginine by both isoforms of nitric oxide synthase.5 Animal studies 
have shown that these inhibitors of NO synthesis can prevent or reverse endotoxin or cytokine 
induced hypotension.6 In human sepsis these inhibitors of NO synthesis can increase blood 
pressure and systemic vascular resistance. 7.' Therefore inhibitors of NO synthesis have been 
suggested to be of value in the treatment of hypotension during human septic shock. 
The present study tested the effects of continuous infusion of the NO synthase inhibitor 
L-NAME in a patient with severe septic shock. 
Methods 
The study was approved by the hospital's Medical and Ethics Committee. Direct family 
members were informed of the nature of the study and gave informed consent. The criteria 
used to define sepsis were described by Bone et ai.' These criteria include evidence of 
infection, tachycardia (>90 beats/min in the absence of p-adrenergic receptor blockade), 
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tachypnea (respiratory rate > 20 breaths/min or the requirement of mechanical ventilation), 
fever or hypothermia (temperature > 38.3°C or <35.6°C), plus at least one of the following 
signs of inadequate organ perfusion: PaO,lFiO, < 280 (without other puhnonary or 
cardiovascular disease as the cause), increased blood lactate levels (>2 nunoIlL), and oliguria 
« 0.5 mL/kg/h) for at least I h. The patient had a puhnonary artery catheter and cardiac 
output was measured by the thermodilution method. Hemodynalnic calculations were 
performed according to standard formulas and variables were indexed for body surface area 
(BSA). During L-NAME infusion, a 12-lead ECG was made at 30 min intervals. Blood was 
collected at intervals in heparin-coated tubes and immediately centrifuged; plasma was stored 
at -80'C. For phalmacokinetic analysis, plasma L-NAME and L-NA (the degradation product 
of L-NAME) were determined using high performance liquid chromatography (HPLC) as 
described by Kreycy et aJ. 10 For indirect determination of global NO release, the sum of 
plasma nitrite/nitrate was determined by an automated procedure based on the Griess 
reaction. II Normal values for plasma nitrite/nitrate were determined in ten healthy volunteers. 
L-NAME was purchased from Sigma Chemical (St. Louis, MO, USA). The hospital pharmacy 
prepared a sterile and pyrogen-free solution of 10 mg/mL L-NAME, ready for infusion. 
Results 
A 68-year old male (body weight 73 kg, body surface area 1.9 m') was admitted to the 
intensive care unit after esophagectomy for esophageal carcinoma with gastric tube 
reconstruction. On the second day following the operation, the patient developed sepsis of 
unknown origin with fever, shock (MAP = 56 unnHg, CI = 4.1 Llminlm' and SVRI = 935 
dyne·s·cm-5/m2) and respiratory failure (Fi02 100%, PEEP 10 cm H20). Anastomotic leakage 
of the gastrostomy was suspected, but no signs of tllis were found during endoscopy. Despite 
antibiotics, and vasopressor support with dopamine at 15 Jtg/kg/min and noradrenaline 0.4 
Jtg/kg/min the circulatory status of the patient worsened. Then, continuous infusion of L-
NAME was started in a dose of 1.5 mg/kg/h. Continuous infusion was chosen because recent 
reports suggest its superiority to high-dose bolus administration and we found that the effect 
of a low-dose bolus injection of 0.15 mg/kg L-NAME lasted only 5-10 minutes (our 
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Effect of continuous infusion of 1.5 mg/kg/h of NO~nitfO-L~arginine methyl ester (L~NAME) 
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to 1=3 hours. L~NAME infusion was stopped because of severe pulmonary hypertension. Note 
the reduction in cardiac index during L~NAME infusion. MAP = mean arterial pressure; 
MPAP = mean pulmonary artery pressure; SVRI = systemic vascular resistance index; PVRI 
= pulmonary vascular resistance index; CI = cardiac index. 
unpublished observations). L-NAME infusion resulted in a direct increase (within 5 min) in 
blood pressure, systemic vascular resistance, pulmonary artery pressure and pulmonary 
vascular resistance (Figure 1). Parallel to these changes cardiac index decreased and heart rate 
was reduced from 115 to 100 beats/min. Central venous pressure and pulmonary artery 
occlusion pressure were only slightly changed (from 8 to 10 mmHg and 10 to 13 mmHg, 
respectively). Vasopressors could be reduced during L-NAME administration, dopamine from 
15 to 7 ltg/kg/min and noradrenaline from 0.4 to 0.02 ltg/kg/min. After three hours of L-
NAME infusion, pulmonary artery pressure had risen to a mean value of 50 mmHg (systolic 
65 mmHg, diastolic 45 mmHg) with a five-fold rise in pulmonary vascular resistance index 
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to 1408 dyne·s·cm·5Im2 and almost 50% reduction in cardiac index. Since these values were 
considered unacceptably high, L-NAME infusion was stopped. This resulted in a reduction in 
pulmonary and systemic blood pressure to pre-infusion values within one hour (Figure I). 
However, pulmonary and systemic vascular resistance remained elevated and cardiac output 
depressed for twelve hours. Arterial oxygenation was not impaired during L-NAME infusion 
(P,02= 63 mmHg before and 83 mmHg during L-NAME infusion). Urine output was 
increased from 48 mL/h to 67 mLlh during L-NAME infusion. Arterial lactate was 1.6 
nunollL before L-NAME and 1.2 nuuol/L at the end of L-NAME infusion. During administ-
ration of L-NAME no signs of myocardial ischemia were seen on the electrocardiogram. 
Plasma nitritelnitrate concentration was 31 I'mollL before L-NAME infusion which is 
increased as compared to normal (12±5 JlmoIlL). Plasma nitritelnitrate concentration slowly 
declined in the hours after L-NAME infusion (Figure 2). Pharmacokinetic analysis revealed 
a plasma level of 1.4l'g/mL L-NAME and 4.81'g/mL L-NA at the end of the 3-h infusion 
period. 
Since the patient remained hypotensive and vasopressor dependent, one day later the 
patient was reoperated; failure of the intra-thoracic anastomosis was found and the anastomosis 
was disconnected. In the next three days the hemodynamic parameters of the patient improved 
and catecholamines were stopped. Six weeks later the patient left the hospital in good health. 
Discussion 
This study shows that pulmonary hypertension and reduced cardiac output can be major 
side effects of continuous NO synthase inhibition. Pulmonary vasoconstriction is undesirable 
because it may compromise pulmonary gas exchange and because it increases the workload on 
the right ventricle. In cases where strain already exists on the right ventricle (e.g. sepsis or 
PEEP ventilation) or in cases where right sided cardiac reserve is minimal, such increase in 
workload may lead to right ventricular failure, reduced cardiac output and compromised tissue 
perfusion. 
Recently inhibitors of NO synthase have been presented as new therapeutic tools in the 
management of hypotension and vasodilatation in sepsis.'" In the present study it was 
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demonstrated that blood pressure and systemic vascular resistance increased during infusion 
of the NO synthase inhibitor L-NAME, and the dosage of catecholamines was reduced. The 
vasoconstrictive response to L-NAME most likely was the result of blocking the NO system 
as supported by the finding that the supranormal plasma levels of nitrite and nitrate, the stable 
endproducts of NO metabolism, slowly declined following L-NAME infusion. However, NO 
is but one of the ways which nitrite and nitrate are formed and nitrite/nitrate levels may not 
directly reflect the local amount of NO released. 
In addition to the systemic effects ofL-NAME, severe pulmonary vasoconstriction was 
observed with L-NAME. Analogous to these rmdings, in patients with Adult Respiratory 
Distress Syndrome (ARDS), inhalation of NO is reported to be beneficial by causing local 
vasodilation in bronchial and pulmonary circulation which results in reduced pulmonary 
vascular resistance and improved oxygenation. 12.13 This suggests that the pulmonary circulation 
is sensitive to the vasodilating effects of both endogenous and exogenous NO. Pulmonary 
vasoconstriction is not, therefore, unexpected with systemic inhibition of NO synthesis. In the 
endotoxemic pig, the pulmonary circulation is even more sensitive to the inhibition of NO 
synthase than the systemic circulation probably through the enhanced release of cyclo-
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oxygenase products." In the present study, which used a continuous infusion of a Wgh dose 
of L-NAME, pulmonary vascular resistance increased five-fold, whereas systemic vascular 
resistance "only" doubled. Whether this difference in response refiects differences in 
sensitivity to L-NAME, the release of cyclo-oxygenase products, the tumor associated changes 
in vascular responsiveness, or the distribution of the different iso-enzymes of NO synthase or 
whether this difference can be explained by the pharmacokinetic distribution of the drug, 
cannot be deduced from our results. In the present study pulmonary hypertension was 
reversible after stopping L-NAME infusion. In prior experiments with a lower dose of L-
NAME, puhnonary vasoconstriction was less pronounced and did not result in puhnonary 
hypertension.' Thus, pulmonary hypertension is a dose-related effect of L-NAME that can 
probably be attributed to overdosing of the drug, although the currently measured plasma 
levels of the drug were not Wgh.6•7 The presence of L-NA in the plasma during L-NAME 
infusion suggests conversion of L-NAME to L-NA in humans, as was reported in animals. lO 
The reduction in cardiac output during inWbition of NO synthesis has been described 
by others." So far the precise mechanism underlying this reduction in cardiac output remains 
unclear. In the present study reduced cardiac output may have directly resulted from the 
extreme increase in pulmonary vascular resistance compromising venous return and left 
ventricular preload andlor a reflex reduction in heart rate by the increase in vascular resistance 
and blood pressure. Also the reduction in catecholamine dosage may have played a role. In 
addition L-NAME may have influenced myocardial perfusion, IS although no evidence of 
myocardial ischemia was noted on the EeG. The reduction in cardiac output may be 
deleterious since tissue perfusion is reduced although arterial lactate was not increased in the 
present study. Several studies have shown harmful effects of nitric oxide synthase inhibitors 
on organ function and outcome in experimental sepsis and have related these detrimental 
effects to the inhibition of the constitutive NO synthase." Most analogues of L-arginine inhibit 
both iso-types of NO synthase. L-NA and its precursor L-NAME even show preference 
towards the constitutive enzyme.17 Therefore too much inhibition of the constitutive NO 
synthase by L-NAME may have played an additional role in the pulmonary hypertension and 
reduction in cardiac output in the present study. Whether selective inhibitors of the inducible 
enzyme are effective in human septic shock remains to be determined. 
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We conclude that pulmonary hypertension and reduced cardiac output are unwanted 
side effects of continuous NO synthase inhibition with L-NAME. In clinical situations, such 
as severe septic shock refractory to conventional therapy, blocking the NO system must be 
done with caution and at least under careful cardiovascular monitoring. 
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on plasma levels of IL-6, IL-8, TNF-a and nitrite/nitrate 
in human septic shock 
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Abstract 
In this prospective clinical study we tested the effects of N°-nitro-L-arginine methyl 
ester (L-NAME), an inhibitor of nitric oxide (NO) synthesis, on plasma levels of IL-6, IL-S, 
TNF-o: and nitrite/nitrate (NO,'INO,') in eleven consecutive patients with severe septic shock. 
Standard hemodynamic measurements were made and blood samples taken at intervals hefore, 
during and after a 12 h infusion period of L-NAME 1 mg/kg/h for deterntination of plasma 
IL-6, IL-S, TNF-o: and NO,'INO,' concentration. 
Septic patients had increased plasma levels of IL-6, IL-8, TNF-o: and NO,-INO,' 
(p < 0.05). Plasma levels ofIL-6, IL-S and NOilNOi were negatively correlated with systentic 
vascular resistance (r=-0.62, r=-0.65 and r=-0.7S respectively, allp<0.05). Continuous 
infusion of L-NAME increased mean arterial pressure and systemic vascular resistance with 
a concomitant reduction in cardiac output (allp<O.OI). No significant changes were seen in 
levels of plasma IL-6, IL-S and NO,-INO,' during the 24 h observation period. Plasma levels 
of TNF-a were significantly reduced during L-NAME infusion as compared to baseline 
(p<O.05). 
We conclude that nitric oxide plays a role in the cardiovascular derangements of human 
septic shock. Inhibition of nitric oxide synthesis with L-NAME does not promote excessive 
cytokine release in patients with severe sepsis. 
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Introduction 
Human septic shock is often characterised by massive systemic vasodilatation with low 
vascular resistance, increased cardiac output and high mortality rate.'·2 The overproduction of 
nitric oxide (NO), a potent vasodilator formerly known as endothelium derived relaxing factor 
(EDRF), has recently been held responsible for the hemodynamic and metabolic consequences 
of sepsis and endotoxemia.'·' High levels of nitrite and nitrate, the stable end product of NO 
metabolism, are found in patients with severe sepsis and these levels may correlate with 
vasodilation. 5,6 
Under normal conditions small amounts of NO are formed from L-arginine by the 
constitutive NO synthase present in the vascular endothelium resulting in a constant 
vasodilatory tone maintaining adequate tissue perfusion. Upon stimulation by endotoxin (LPS) 
and cytokines, an inducible calcium independent isoform of NO synthase is formed in various 
cell types. This inducible enzyme differs from the constitutive isoform in that it releases 
massive amounts of NO over long periods of tinle resulting in profound vasodilatation, 
hypotension and resistance to catecholamines.' 
Analogues of L-arginine competitively inhibit NO synthesis and can reverse endotoxin 
or cytokine induced hypotension and restore reactivity to catecholamines in animals. 7.9 In 
patients with septic shock, administration of these inhibitors of NO synthesis have been shown 
to increase blood pressure and systemic vascular resistance for prolonged periods of time. 1()'12 
Therefore inhibitors of NO synthesis have been suggested to be of value in the treatment of 
hypotension during human septic shock. However, several animal studies have shown 
excessive production of pro-inflanlll\atory cytokines during inhibition of NO synthesis with 
detrimeutal effects. ".14 These pro-inf1aDll1latory cytokines such as interleukin-6 (IL-6), IL-8 
and tumor necrosis factor alpha (TNF-a) are involved in the pathogenesis of the sepsis 
syndrome and high levels of these cytokines may correlate with poor outcome. IS·18 
Furthermore, several ill vitro studies have shown that nitric oxide itself may have both pro-
and anti-inf1anunatory effects and plays a role in modulation of the immune response. I9.2I At 
present no data are available about the effects of inhibition of NO synthesis on cytokine 
production in human sepsis. 
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The present study was designed to asses the effects of prolonged inhibition of NO 
synthesis with L-NAME on plasma levels of 11.-6, IL-8 and TNF-u in patients with severe 
septic shock. To study the effect of L-NAME on NO production, measurements were made 
of plasma nitrite/nitrate (NOiINO,') levels. 
Materials and Methods 
Subjects. The study was conducted according to the principles established in Helsinki 
and approved by the hospital's Medical and Ethics Committee. First degree relatives were 
informed of the nature of the study and gave informed consent. Eleven patients with septic 
shock in the surgical intensive care unit of our hospital were included in the study. 
All patients met the criteria of sepsis as described by Bone et at. 22 All patients were in 
shock (systolic BP <90 mmHg or a decrease >40 mmHg from baseline unresponsive to fluid 
challenge) on admission requiring therapy with pressor agents. At the time of the study all 
patients were receiving dopamine> 15 ltg/kg/min and/or noradrenaline >0.1 ltg/kg/min. All 
patients had respiratory failure and required mechanical ventilation. Patients received antibiotic 
therapy based on culture results. Four patients (two survivors and two non-survivors) required 
continuous hemodialysis because of renal failure. Seven patients were operated before the 
onset of septic shock with a time interval between surgery and the onset of sepsis ranging from 
4 to 56 days ,(median 10 days). Only patients with a cardiac index > 3.0 l/min/m' were 
included since earlier reports have shown reductions of cardiac output during inhibition of NO 
synthesis. I()'l2 We hypothesized that a further reduction in cardiac output would be undesirable 
and even dangerous in a state where cardiac output is reduced. Exclusion criteria for the study 
were severe coronary artery stenosis (angina pectoris grade III according to NYHA classi-
fication), pregnancy and a cardiac index <3.01/minlm'. 
Study Protocol. All patients underwent continuous electrocardiographic monitoring and 
had indwelling radial artery and puhnonary artery catheters (Criticath, Ohmeda, Singapore) 
for hemodynamic measurements and data were recorded on a computerised data system 
(Mennen Medical Systems, USA). Survival was noted at 28 days. 
L-NAME was obtained from Sigma Chemicals (St. Louis, MO, USA). The hospital 
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phannacy prepared a sterile and pyrogen-free solution of L-NAME 10 mg/ml, ready for 
infusion. Following baseline measurements L-NAME 1 mg/kg/h was infused for 12 h. To 
minimize the potential chance of developing toxicity from high serum levels of L-NAME, 
infusion was not continued for longer periods. If mean arterial blood pressure increased above 
100 nunHg, the administration of vasopressors was gradually reduced and the dosage noted. 
Time between onset of septic shock and initiation of L-NAME infusion ranged from 24 h to 
21 days (median 6 days). Concomitant therapy was at the discretion of the clinician managing 
the patient. 
Blood samples. For determination of plasma IL-6, IL-8, TNF-u and nitrite/nitrate 
blood samples (10 ml) were obtained in heparin coated blood collection tubes (Vacutainer, 
France) 3 h before L-NAME infusion (T=-3), at baseline (T=O), during L-NAME infusion 
(T= I, 3, 6 and 12) and 3, 6 and 12 h after L-NAME infusion had stopped (T= IS, 18 and 
24). Control values were established in 10 healthy volunteers among the laboratory personnel. 
Table 1. Patient characteristics in survivors and non-survivors before L-NAME infusion. 
Survivors Non-survivors Normal range 
Gender (M/F) 5/0 511 
APACHE II score* 19.2± 1.2 22.0±1.4 0·6 
Source of sepsis peritonitis (n=4) pneumonia (n=2) 
pancreatitis (n= 1) peritonitis (n= I) 
pancreatitis (n= I) 
mediastinitis (n= I) 
peritonitis + 
pneumonia (n= 1) 
MAP,mmHg 68±4 62±4 70-110 
SVR, dyne·s·cm·5Im' 1082±225 859±114 1900-2400 
CI, lIminlm' 5.J±0.5 4.6±0.6 2.5-3.6 
Leucocytes, xlO'/l 19.3±3.0 14.8± 1.7 4.0-10.0 
Platelets, xlO'/l 169±33 116±30 140-320 
Lactate, mmol/l 1.6±0.2 5.4± 1.9 0.5-1.6 
*APACHE Acute physiological and chronic health evaluation [25], MAP = mean arterial pressure. SVR 
= systemic vascular resistance, CI = cardiac index. Values are displayed as mean±SEM. 
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Blood samples were immediately centrifuged (1500 g, 10 min, 4 'C), plasma was collected and 
stored at -80 'C until tested. In addition blood was withdrawn for routine biochemical and 
hematological measurements and for blond gas analysis (ABL505, Radiometer, Copenhagen). 
Cytokille assays. Levels of IL-6, IL-8 and TNF-u were measured using enzyme-linked 
immunosorbent assays (ELiSAs) as described earlier." Each ELISA was specific for the 
relevant cytokine and cytokine levels were expressed in pg/ml. 
For IL-6 determinati6n, flat-bottomed microtitre plates were coated overnight with 
purified monoclonal antibody (MAb) against IL-6 (Central Laboratory of the Netherlands Red 
Cross Blond Transfusion Service, CLB, Amsterdam, The Netherlands). After washing, serial 
dilutions of IL-6-containing samples were added. Bound IL-6 was detected by biotinylated 
affinity-purified polyclonal sheep anti-IL-6. The lower detection level of this assay was 1 
pg/ml and normal healthy control subjects were below 10 pg/ml. 
For IL-8 determination, a coat of IL-8 MAb (CLB) was applied overnight at a 
concentration of 1 I'g/ml, and bound IL-8 was detected by biotinylated affInity-purified 
polyclonal sheep anti-IL-8, also at 1l'g/ml. The lower detection limit of this ELISA was about 
5 pg per ml of serum. Values of IL-8 for bealthy control subjects determined with this ELISA 
were below 20 pg/ml. 
For TNF-u determination, flat-bottomed 96-well plates were coated with MAb (18b) 
anti-hu-TNF-u (Hofftnan-La Roche, Basle, Switzerland). Biotinylated sbeep anti-TNF-u was 
used as a second step. The detection limit of the assay was 10 pg/ml and normal healthy 
control subjects were below the detection limit. 
Determination of nitrite/nitrate concentration. Total nitrite plus nitrate concentration 
was assayed as previously described by Phizackerley et al. 24 Briefly, selUm was deproteinized 
with alkali and zinc sulphate and centrifugated for 3 min at 24000 g. To reduce nitrate to 
nitrite, volumes of 100 1'1 of supernatant or standards were incubated at room temperature for 
30 min in the presence of Klebsiella plleumoniae under anaerobic conditions. Following 
centrifugation (3 min, 24000 g) 100 1'1 of total nitrite in the supernatant was subjected to the 
Griess reaction an assayed spectrophotometrically. Data are reported as nitrite plus nitrate 
values in I'molll of plasma. 
Calculations alld statistical analysis. Hemodynamic calculations were performed 
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according to standard formulas. Data are expressed as mean ± SEM. Statistical analyses was 
performed using analysis of variance (ANOY A) for repeated measurements followed by post 
hoc Dunnett's test for comparison with the baseline value. Student's t-test was used to compare 
differences between groups. Pearson correlation and linear regression were used for analysis 
of correlations between variables. Ap·value <0.05 was considered statistically significant. 
Statistical analysis was performed on a computer using the Statistical Package for the Social 
Sciences (SPSS) software for Windows. 
Results 
The causes for sepsis are displayed in Table 1. Cultures of the infective focus revealed 
both gram negative and gram positive bacteria with positive blood cultures in 45% ofpatients. 
Mortality at 28 days was 55% whereas expected mortality rate as calculated by APACHE II 
scores" was between 52 and 64 % (95 % confidence interval). Two patients died 2 days 
following L·NAME infusion, the others at 3, 5, 8 and 22 days respectively, because of a 
combination of persistent septic shock and multiple organ failure. No obvious link was noted 
between deaths and L·NAME infusion. 
As displayed in Table 1 patients had increased APACHE II scores, hypotension, low 
systemic vascular resistance and increased levels of arterial lactate. Furthermore patients had 
increased plasma levels of IL-6, IL-8, TNF·" and N02-IN03- as compared to normal (all 
Table 2. 
IL-6, pg/mt 
IGS, pg/ml 
TNP-a, pg/ml 
NOx, ll1110lll 
Cytokine and nitrite/nitrate concentrations in survivors and non-survivors before 
infusion of L-NAME. 
Survivors Non-survivors Control 
(n=5) (n=6) (n= 10) 
357±213' 1412±679' 4±3 
3S4±25S' 1090±653' 1O±5 
324±21O' 674±31S' Undetectable 
44±12' 34+7' 12±5 
IL = interJeukin, TNF-C( = tumor necrosis factor alpha, NO~ = nilrite plus nilrale. Values are displayed 
as mean±SEM. *p<O.05 compared 10 control. 
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Scatterplot showing relation of IL--6, IL-8 and nitrite/nitrate (NO,) with systemic vascular 
resistance (SVR). Measurements were made at baseline in each of eleven patients. Levels of 
IL--6, IL--8 and nitrite/nitrate correlated negatively with systemic vascular resistance (p<O.05). 
P <0.05, Table 2). All patients had detectable levels of IL-6 and IL-8 whereas two patients, 
both survivors, had undetectable levels of TNF-a during the course of the study. Non-
survivors (n=6) tended to have higher plasma levels of lactate, IL-6, IL-8 and TNF-a as 
compared to survivors although the differences were not statistically significant (p=0.11, 
p=0.16, p=0.18 andp=0.33 respectively, Table I and 2). Plasma levels ofIL-6, IL-8 and 
NO,-/NOi were negatively correlated with systemic vascular resistance (p=0.041, p=0.038 
and p=0.012 respectively; Figure I). Furthermore a positive correlation existed between 
plasma levels of IL-6 and IL-8 (r=0.67, p=0.027), arterial lactate and IL-8 (r=0.66, 
p=0.026) and IL-8 and NO,-INO,' (r=0.71, p=0.015). Plasma NO,-/NO,- concentration was 
43 ±8 I'molll in hemodialysed patients versus 35 ± 10 /tmoUI in patients without hemodialysis 
(p=0.315). Cytokine levels in hemodialysed patients were not significantly different from 
patients without hemodialysis (data not shown). 
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L-NAME infusion resulted in profound hemodynamic changes as shown in Figure 2. 
Blood pressure and vascular resistance increased with a reduction in cardiac output and oxygen 
delivery (p < 0.01). Heart rate and oxygen consumption were not significantly changed. There 
was a concomitant reduction in vasopressor requirement. 
L-NAME infusion did not result in significant changes in the plasma levels of IL-6 and 
IL-8 in both survivors and non-survivors (Figure 3). For the whole group plasma IL-6 levels 
were 1112±443 pg/ml at baseline vs. 1268±459 pg/m1 after 12 h of L-NAME infusion and 
IL-81evels 911 ±421 vs. 772±373 pg/m1, respectively (bothp>0.05, n= 11). However, there 
was a significant reduction in TNF-Ct levels during L-NAME infusion for the whole group 
(515±207 pg/m1 at baseline vs. 20±9 pg/m1 after 12 h of L-NAME infusion, n= 11; 
p=0.042) (Figure 3). After 12 h of L-NAME infusion only one of eleven patients had a 
plasma TNF-Ct concentration above the detection limit of 10 pg/m1 versus seven patients at 
baseline. No significant changes were seen in plasma levels of NO,'/NO,- as a result of L-
NAME infusion (p>0.05) (Figure 3). Leucocytes (17.0±2.3 x10'11 before and 19.1±2.6 
x10'11 after 12 h; p=0.56) and platelets (l39±25 x10'1l before and 129±23 x10'1l after 12 
h; p=0.52) were not significantly changed by L-NAME. 
Discussion 
Cytokines playa central role in the pathophysiology of sepsis. "." Recently, the NO 
radical has been incriminated in the cardiovascular derangements of sepsis'" and inhibitors of 
NO synthesis have been proposed as a new therapeutic tools in the management of hypotension 
in sepsis and cytokine induced shock.7-I' To our knowledge, no data are available on the effect 
of inhibition of nitric oxide synthesis on cytokine release in human sepsis. This is the first 
report that describes nitrite/nitrate and cytokine levels during inhibition of NO synthesis in 
septic shock patients. 
Septic patients had increased levels of nitrite and nitrate as compared to control and 
levels of nitrite/nitrate correlated negatively with systemic vascular resistance. These findings 
are consistent with previous studies and probably reflect increased systemic NO production 
during severe sepsis.'" Unexpectedly, serum levels of nitrite and nitrate were not significantly 
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Effect of L-NAME infusion on hemodynamic and metabolic variables in severe sepsis. MAP 
= mean arterial pressure; SVR = systemic vascular resistance; PAP = pulmonary artery 
pressure; PVR = pulmonary vascular resistance; CI = cardiac index; HR = heart rate; D02 
= oxygen delivery; V02 = oxygen consumption. Values are displayed as mean±SEM. 
*p<O.05 as compared to baseline. 
reduced during L-NAME infusion. Unchanged nitrite/nitrate levels may indicate that NO 
synthase activity was only partially blocked despite the significant hemodynamic effects. At 
present we do not know if the distribution of NO synthase inhibition with L-NAME was 
uniform throughout the body or among the different isoenzymes. Possibly the profound 
vasocol15trictive effects with L-NAME were the result of inllibition of the constitutive NO 
synthase.26 However, some reservation must be made to draw conclusions from nitrite/nitrate 
levels since NO degradation is but one of the ways that nitrite and nitrate are formed." 
Possibly plasma levels of nitrite and nitrate do not reflect the local amount of NO released or 
inbibited and local concentratiol15 of nitric oxide may have been reduced without producing 
a demol15trable reduction in the plasma. Perhaps measurement of plasma nitrite/nitrate 
concentration in combination with other parameters such as urinary excretion of nitrate,27 NO 
concentrations in exhaled air," or direct NO measurement in the blood," could help to further 
explore this in future studies. 
The present study shows that TNF-u plasma concentration was reduced as compared 
to baseline during inllibition of NO synthesis with L-NAME. TNF-u is released early in the 
course of sepsis and appears to be a key mediator in the acute phase response in septic 
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shock. 17.30 Increased levels of TNF-u correlate with poor outcome in human septic shock. 15·18 
However, there is also clinical and experimental evidence that TNF-u may be useful in some 
circumstances. For instance, TNF-u has been shown to contribute to antibacterial resistance 
against infections.'1 Numerous studies have shown that TNF-u stimulates NO release through 
the induction of the inducible NO synthase.'·7 However, not much is known about the influence 
of NO on TNF-u release. Previous animal studies that examined the effect of NO synthase 
inhibition on TNF-u levels in septic animals, have yielded contradictory results. Increased 
serum TNF-u levels have been reported after L-NAME pre-treatment in septic mice and after 
administration of NG-nitro-L-arginine (L-NAl, another inhibitor of NO synthesis, in 
endotoxernic rats. 13.14 These results may indicate a negative feedback mechanism exhibited by 
NO on TNF-u synthesis." In contrast to these findings, in another study in endotoxernic rats, 
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a reduction in TNF-a levels was reported during inhibition of NO synthesis with the NO 
synthase inhibitor NG-monomethyl-L-arginine (L-NMMA)." Aminoguanidine, a more specific 
inhibitor of the inducible NO synthase, did not modify serum TNF-a in this animal model of 
endotoxernia. Therefore it was suggested that NO synthesised by the constitutive isoform of 
the NO synthase positively modulates TNF-a synthesis. These findings are further supported 
by ill vitro data suggesting that TNF-a synthesis may be up regulated by cGMP," the 
conversion product of soluble gyanylate-cyclase that is the target enzyme of NO.' Since in the 
present study with L-NAME, which is an inhibitor of both the constitutive and inducible 
isoform of NO synthase, TNF-a levels were reduced as compared to baseline, one could 
suggest that NO positively modulates TNF-a release in human sepsis. However, these are 
speculations since spontaneous changes in TNF-a levels may have occurred despite the 
relatively short time intervaI,'6-18 and the present study did not include a control group for 
comparison. Therefore, it cannot be excluded that the reduction in TNF-a levels may have 
represented the natural course of the disease. 
Levels of IL-6 and JL-8 were not changed during the 12 h period of L-NAME infusion. 
As compared to TNF-a, both IL-6 and IL-8 are secreted later in the inflammatory response 
and for longer periods of time. 17 IL-6 is a potent stimulator of liver synthesis of acute-phase 
proteins," whereas IL-8 is the most important inducer of neutrophil chemotaxis and 
activation." IL-6 and IL-8 levels were increased in this group of patients with severe 
sepsis.I'.I' Furthermore a positive correlation was found between IL-6 and IL-8 levels. Only 
few studies are present about the effect of NO on IL-6 and IL-8 release and these have shown 
contradicting results. NO can inllibit LPS-induced IL-6 production in cultured enterocytes.20 
In addition, ill vivo inhibition of NO synthesis with L-NA can increase IL-6 levels and 
mortality in endotoxemic rats. I' In contrast, in a recent ill vitro study in human whole blood, 
L-NAME inltibited IL-6 and IL-8 release following stimulation with lipopolysaccharides.'1 L-
NAME inhibition of IL-8 release was also observed at the mRNA level. Furthermore in the 
same study, direct exposure of whole blood to an exogenous NO donor resulted in increased 
production of IL-8, whereas no effect on IL-6 release was noted. Although the results from 
previous studies may indicate a complex interaction between NO and cytokine release, in the 
present study no significant changes in plasma IL-6 and IL-8 concentrations were seen. 
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However, some reservations must be made regarding interpretation of these fmdings. Cytokine 
levels in the plasma do not necessarily reflect the local synthesis of cytokines by cells. Many 
cells have surface receptors for these cytokines with high binding properties and cytokines are 
trapped by target cells and soluble receptors. 17 Thus, many of the cytokines released at the 
local level may have remained undetected in the plasma. Furthermore, cytokine concentrations 
were only measured during a 24 h observation period and changes in cytokine levels may have 
occurred later. Also, our study did not include a placebo group and spontaneolls changes in 
cytokine levels may have occurred over time. IS 
The exact role of NO in modulating cytokine production in human sepsis has yet to be 
fully explored. In contrast to what has been reported in animal studies, no evidence of 
excessive pro·inflammatory cytokine production was found during 12 h of L-NAME infusion 
in septic shock patients. More randomized clinical studies will be necessary to determine as 
to whether inhibition of NO synthesis modulates cytokine release in human septic shock. 
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Abstract 
The systemic hypotension during human sepsis has been ascribed to increased 
production of nitric oxide (NO). Therefore inhibitors of NO synthesis have been used in the 
treatment of hypotension in septic patients. In addition, NO production may inhibit the 
synthesis and vasoconstrictor effects of endothelin-l (ET-l). In this study we tested whether 
ET-l contributed to the vasopressor action of the NO synthase inhibitor NG-nitro-L-arginine 
methyl ester (L-NAME) in patients with severe septic shock. 
As compared to healthy volunteers, septic patients had increased plasma levels of 
nitrite/nitrate (37 ±5 (SEM) versus 12±5 I'moIlL, p<O.OI), the stable end products of NO 
metabolism, and ET-I (45±7 versus 3±2 pg/mL,p<O.OOI). Plasma ET-l concentration was 
not related to plasma nitrite/nitrate concentration and/or blood pressure. Continuous infusion 
of L-NAME (1 mg/kg/h IV) for 12 hours increased mean arterial pressure by 43±5% and 
systemic vascular resistance by 64±1O% (bothp<O.OI). The increase in blood pressure and 
systemic vascular resistance correlated positively with the level of ET -1 (both p < 0.005), but 
not with plasma nitrite/nitrate level. L-NAME infusion did not result in significant changes 
in the plasma concentrations of ET-l or nitrite/nitrate. 
We conclude that NO and ET-l may both playa role in the cardiovascular 
derangements of human sepsis. Although L-NAME does not increase ET -1 concentration in 
patients with septic shock, the vasopressor response induced by L-NAME depends on the 
plasma level of ET-l. These findings may suggest that inhibitors of NO synthesis unmask a 
tonic pressor response of endothelin-l in human septic shock. 
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Introduction 
Recent evidence suggests a complex ioteraction of endothelium derived factors, 
including endothelin-l (ET-l) and nitric oxide (NO), io the control of vascular smooth muscle 
tone io health and disease.' ET -1 is a 21-aminoacid peptide with potent vasoconstrictor actions 
io animals and man.'·' NO is a short-lived radical, derived from the amino acid L-argioioe by 
the enzyme NO synthase, with direct vasodilatory action. 4•5 III vitro experiments show that 
contiouous NO production inhibits the synthesis' and/or the vasoconstrictor action of ET -J.1 
Furthermore, endothelin receptor antagonists fail to affect blood pressure in normal animals.8 
This apparent absence of vascular effects of ET-l has been attributed to continuous NO 
production. This is further supported by Ole fmdiog that iohibition of NO synthesis in rats can 
unmask a tonic pressor response of endothelin and results io iocreased plasma levels of ET-
1.'.10 So far the precise interaction ofET-l and NO in humans remaios to be determioedY·12 
Human sepsis is characterized by massive vasodilatation with low systemic vascular 
resistance, high cardiac output and severe hypotension. " Increased production of NO by an 
inducible isotype of NO synthase, has been held responsible for the cardiovascular 
derangements during sepsis.'·" High levels of nitrite and nitrate, the stable end products of NO 
metabolism, are found in patients with severe sepsis and these levels may correlate with 
vasodilation." Analogues of L-arginine competitively iohibit the production of NO from L-
arginine'6 and can reverse hypotension in endotoxin and cytokine induced shock in animals, 5,17 
More recently these iohibitors of nitric oxide synthesis have been used to iocrease blood 
pressure in human sepsis. ,s.", At present it is unknown whether inhibition of NO synthesis 
modulates endothelio release in septic shock. Sioce high levels of ET-l have been found in 
septic patients,"·22 we hypothesized that part of the vasoconstrictive response after iohibition 
of NO synthesis may result from increased production of ET-1. 
The purpose of the present study was to examine whether ET-l plays a role in the 
increase io blood pressure after inhibition of NO synthesis io patients with severe sepsis. 
Plasma concentrations of ET-l and nitrite/nitrate, as an iodirect measure of NO production, 
were measured during contiouous iofusion of the L-arginine analogue N°-nitro-L-argioioe 
methyl ester (L-NAME) in patients with severe septic shock. 
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Methods 
Subjects The hospital's Medical and Ethics Committee approved the study. First 
degree relatives were informed of the nature of the study and gave informed consent. Eleven 
adult critically ill patients of the intensive care unit of our hospital were included in tlle study. 
All patients met the criteria of sepsis as described by Bone et a!. 23 The source for sepsis was 
peritonitis (n=5), pneumonia (n=2), pancreatitis (n=2), mediastinitis (n=l) and peritonitis 
with pneumonia (n=I). Patients were in shock (systolic BP <90 mmHg or a decrease >40 
mmHg from baseline unresponsive to fluid challenge) on admission requiring therapy with 
pressor agents. At the time of the study all patients were receiving dopamine > 15 I'g/kg/min 
and/or noradrenaline> O.ll'g/kg/min. All patients required mechanical ventilation because 
of respiratory failure. Four patients required continuous hemodialysis because of renal failure. 
Only patients with cardiac index> 3.0 Liminlm' were included since earlier reports have 
shown reductions of cardiac output during inhibition of NO synthesis. Exclusion criteria for 
the study were severe coronary artery stenosis (angina pectoris grade III according to NYHA 
classification), pregnancy and cardiac index <3.0 Liminlm'. 
Study Protocol All patients underwent continuous electrocardiographic monitoring and 
had indwelling radial artery and pulmonary artery catheters (Criticath, Ohmeda, Singapore). 
Measurements of systemic arterial blood pressure, central venous pressure, puhnonary artery 
pressure and cardiac output (thermodilution method) were made at baseline and at 0.5, 1,3 
and 6 h intervals, for a total period of 24 hours. Systemic and pulmonary vascular resistance 
were calculated according to standard formula. Following baseline measurements L-NAME 
1 mg/kg/h infusion was started and continued for 12 hours. To minimize the potential chance 
of developing toxicity from high serum levels of L-NAME, infusion was not continued for 
longer periods. Maximum changes in blood pressure and systemic vascular resistance were 
noted after 30 minutes of L-NAME20 and hemodynamic variables at tltis time point were used 
to compare with the baseline value. Concomitant therapy was at the discretion of the clinician 
managing the patient. 
Blood sGmples. For later determination of plasma ET-l, nitrite/nitrate and cortisol, 
arterial blood samples (10 mil were obtained in heparin coated blood collection tubes 
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(Vacutainer, France) at baseline (T=O), during L-NAME infusion (T= 0.5, 1,3,6 and 12) 
and 3, 6 and 12 h after L-NAME infusion had stopped (T= 15, 18 and 24). Control values 
were established in 10 healthy volunteers among the laboratory personnel. Blood samples were 
immediately centrifuged (1500 g, 10 min, 4 'C), plasma was collected and stored at -80' C 
until tested. Creatinine concentration was determined by a standard method. 
Detenllinatioll of Endothelin-I. Endothelin-l was determined, after Sep-Pak extraction, 
with a commercially available radioimmunoassay kit (Nichols Institute, Wijchen, The 
Netherlands), as previously described by Smits et al.24 Normal values in our laboratory were 
1-5 pg/mL. The limit of detection was I pg/mL. 
Detennination of nitrite/nitrate cOllcelllratioll. Total nitrite plus nitrate concentration 
was assayed as described by Phizackerley et al." To reduce nitrate to nitrite, supernatant or 
standards were incubated at room temperature in the presence of Klebsiella plleullloniae under 
anaerobic conditions. Total nitrite in the supernatant was subjected to the Griess reaction and 
Table 1. Patient characteristics, plasma endothelin, nitrite/nitrate and 
cortisol concentration in severe septic shock. 
Age. yr 
Sex, M/F 
MAP, nunHg 
SVR. dyne's'cm-s/m2 
CI, Llminlm' 
Creatinine, {(moUL 
ET-l, pg/mL 
NO" pmol/L 
Cortisol, nmoUL 
Mortality (at day 28) 
Septic patients 
52±4 
1011 
65±3 
962±121 
4.8±OA 
283±56 
45±7*** 
37±5** 
753±87* 
6/11 
Control 
[70-110] 
[1900-2400] 
[2.5-3.6] 
[60-110] 
3±2 
12±5 
521±62 
Values are displayed as mean±SEM. MAP = mean arterial pressure, SVR = systemic 
vascular resistance, CI = cardiac index, ET -1 = endothelin-l, NOx = nitrite plus nitrate. 
***p<O.OOl, **p<O.Ol and *p<O.05 as compared to healthy volunteers. Normal range 
indicated between brackets. 
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assayed spectrophotometrically. Data are reported as the sum of nitrite plus nitrate. Nonnal 
values in our laboratory were 5-15 I'moUL. The limit of detection was 0.1 I'mollL. 
Determillatioll of cortisol. Cortisol concentrations were detennined with a commercially 
available radioimmunoassay kit (DPC, Los Angeles, CA, USA) as described previously." 
Normal values were 400-800 nmolfL (15-30 I'gfdL). The limit of detection was 28 nmoUL. 
Drugs L-NAME was obtained from Sigma Chemicals (St. Louis, MO, USA). The 
hospital pharmacy prepared a sterile and pyrogen-free solution of L-NAME 10 mgfmL, ready 
for N infusion. 
Data analysis All results are expressed as mean ± SEM. Changes over time were 
compared with baseline values by repeated measures ANOV A. Differences between groups 
were compared by Student's t-test. Pearson correlation and scatter plots were used for analysis 
of correlation between variables. A p-value < 0.05 was considered statistically significant. 
Results 
Patient characteristics are shown iu Table I. All patients had hypotension, low systemic 
vascular resistance, high cardiac output and increased serum creatinine due to septic shock 
(Table I). As compared to healthy volunteers, plasma levels of ET-I, nitratefnitrate and 
Figure 1. 
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cortisol were significantly increased in septic patients (allp<0.05, Table 1). 
No correlation was found between plasma ET-l concentration and plasma nitrite/nitrate 
, 
concentration (r=0.07, p>0.80), blood pressure (1'=-0.34, p=0.30), systemic vascular 
resistance (1'=-0.41, p=O.22) or creatinine concentration (r=-O.13, p=0.69). ET-l 
concentration was 46±5 pg/mL in survivors and 43±12 pg/mL in non-survivors (p>0.05). 
Plasma nitrite/nitrate concentration was negatively correlated with systemic vascular resistance 
(r=-O. 78, p=O.OI2) (Figure 1), but not with creatinine concentration (1'=-0.03, p=0.93). 
Continuous infusion of L-NAME (1 mg/kg/h IV) resulted in a maximum increase of 
mean arterial pressure by 43±5% and systemic vascular resistance by 64±1O% (Figure 2). 
There was a concomitant reduction in cardiac output by 20±4%. The increase in blood 
pressure (1'=0.84, p=O.OOI) and systemic vascular resistance (r=0.81, p=0.OO2) during L-
NAME infusion correlated positively with the baseline plasma concentration of ET -1 (Figure 
3). The increase in blood pressure with L-NAME did not correlate with plasma nitrite/nitrate 
level (r=0.12, p=0.89). L-NAME infusion for a period of 12 hours did not result in changes 
in the plasma concentration levels of ET -I (from 45 ± 7 at baseline to 43 ±6 pg/mL after 12 
h of L-NAME, p>0.05) and/or cortisol (from 753±86 at baseline to 682±73 mnollL after 
12 h of L-NAME, p>0.05; Figure 4). Plasma nitrite/nitrate also did not change during L-
NAME (from 37 ±5 at baseline to 36±5 "mollL after 12 h of L-NAME, P > 0.05). 
Figure 2. 
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Effect of continuous infusion of NO-nitro-L-arginine methyl ester (L-NAME. 1 mg/kg/h IV) on 
hemodynamic variables in patients with severe septic shock. MAP = mean arterial pressure; 
SVR = systemic vascular resistance; MPAP = mean pulmonary artery pressure; PVR = 
pulmonary vascular resistance; CO = cardiac output; HR = heart rate. Values are maximum 
changes as compared to baseline and displayed as mean±SEM. 
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Figure 3. 
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in blood pressure (lipper graph) and systemic vascular resistance (lower graph) during 
continuous infusion of NO-nitro-L-arginine methyl ester (L-NAME, 1 mg/kg/h. IV) in patients 
with severe septic shock. 
Inhibitors of NO synthase have recently been presented as new therapeutic tools in the 
management of hypotension in human septic shock."-20 The present study demonstrates that 
the increase in blood pressure and the magnitude of the vasopressor respol15e induced by the 
NO synthase inhibitor L-NAME is related to the plasma level of ET-I suggesting that 
inhibitors of NO synthesis unmask a tonic pressor respol15e of ET -1 in human septic shock. 
In addition this study shows that prolonged inhibition of NO synthesis WiOl L-NAME does not 
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further increase the already elevated plasma ET-l concentration. 
In the present study elevated plasma levels of ET -1 were found in patients with severe 
sepsis, as has been reported by others.21 •22 The mechanism involved in the increase of ET-l 
concentration during sepsis is largely unknown. High ET -1 levels could have resulted from 
increased synthesis and/or diminished clearance of ET -1. Levels of circulating cytokines such 
as tumour necrosis factor (TNI') and interleukins are increased in septic shock and may 
stimulate ET-l production in endothelial cells and macrophages. 21.28 Furthermore, intravascular 
leakage of ET -1 from damaged endothelial cells may have occurred." Since most septic 
patients had impaired renal function, diminished renal clearance could have played a role. 29•30 
However, no correlation was found between plasma ET-l and creatinine in the present study. 
This supports the idea for the occurrence of increased generation of endothelin in human 
sepsis, although other vascular beds, including liver and skeletal muscles, may also contribute 
to the clearance ofET-i. The finding that high ET-llevels coincided with high nitrite/rtitrate 
levels as an indirect measure of increased NO production, are not in line with previous data 
that indicate an inhibitory action of NO on ET-l releaseY This suggests that the normal 
interaction between NO and ET-l is disturbed during sepsis. Abnormalities in the balance 
between vasoconstricting and vasodilating factors have been reported during sepsis."·31 
However, at present the exact interaction between ET-l and NO in septic shock remains to be 
determined. We hypothesize that the high circulating ET-l concentration helps to maintain 
vascular tone during sepsis and opposes the vascular smooth muscle relaxation induced by 
increased NO production. Indeed, the high circulating ET-llevels in patients with sepsis, in 
the present study 45 pg/mL (~18 pmoIlL), are sufficient to induce relevant 
vasoconstriction."'" The fact that the increase in blood pressure with L-NAME correlated with 
the level of ET-I further supports the idea of a continuous vasopressor tone by ET-I during 
human sepsis and that this vasopressor tone is unmasked by an inhibitor of NO synthesis. Our 
findings are consistent with prior reports in normal rats where the increase in blood pressure 
with L-NAME was reduced with the specific endothelin receptor antagonist bosentan.'·10 In 
healthy humans" and humans with chronic heart failure," endotllelin receptor antagonists can 
reduce blood pressure. In the present study we did not test the effects of an endothelin receptor 
antagonist. We speculate that endothelin receptor antagonism during human septic shock, 
155 
Chapter 8 
where plasma levels of ET-I are high, would be detrimental since it may result in severe 
hypotension. Whether endothelin receptor antagonists can prevent the increase in blood 
pressure of NO synthase inhibitors in humans, remains to be determined. 
In the present study no increase was found in the plasma levels of ET -I during 12 
hours of inhibition of NO synthesis with L-NAME. These findings may suggest that ET-I 
release itself is not modulated by L-NAME in septic patients. In normal rats acute inhibition 
of NO synthesis results in modest increases in ET-I levels, but these ET-I levels were 
measured only 15 and 35 min after L-NAME infusion.'·10 In contrast to these findings chronic 
inhibition of NO synthesis with L-NAME (three weeks) in normal rats does not increase ET-I 
Figure 4. 
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levels and/or gene expression. 36 Only a few reports are available on the NO-endothelin 
interaction in humans. Although nitrovasodilators can reduce ET-I production by human 
endothelial cells in culture," intravenous infusion of nitroglycerin, a NO donating drug, does 
not change plasma ET-I levels in healthy subjects. 11 In a recent study in healthy men, the NO 
synthase inhibitor L-NMMA temporarily (only after 20 min) increased ET-llevels from 7.6 
to 9.6 pmolfL. 12 In our study we did not find a temporary increase in already elevated ET-l 
concentration. One possible explanation is that the continuous high release of ET -1 during 
sepsis resulted in a depletion of storage vesicles with ET-l (or its precursor)." The results 
from the present study and previous reports suggest that increased production of ET -1 does 
not playa major role in the rise in blood pressure during prolonged inhibition of NO synthesis. 
However, some reservations must be made regarding interpretation of plasma ET-1 
levels. Plasma levels of ET-l may not correctly reflect production rate, and the local 
concentration of the peptide at the vascular smooth muscle bil'lding sites is probably more 
essential. For instance, big endothelin, that needs conversion to endothelin by tissue 
endot!lelin-converting enzyme to gain activity, is able to cause vasoconstriction without notable 
increases in plasma endothelin." Since main ET-l release seems to occur abluminally, local 
concentrations of ET-l are probably higher than in the plasma.40 Therefore, in the present 
study increased local production of ET -1 may have occurred with L-NAME without detectable 
changes in plasma concentration. Similar reservations must be made regarding nitrite/nitrate 
levels. NO is but one of the ways that nitrite and nitrate are formed and L-NAME infusion did 
not result in reduced serum levels of nitrite and nitrate, despite increased vasoconstriction. 
Possibly plasma levels of nitrite and nitrate do not directly reflect the local amount of NO 
released and active excretion of nitrite/nitrate through kidneys and gastro-intestinal tract may 
have influenced the plasma levels currently measured." 
Cortisol has a vital role in the maintenance of vascular tone and endothelial function." 
Furthermore cortisol potentiates the vasoconstrictor actions of catecholamines.43 Thus, 
increases in plasma cortisol may indirectly increase vasopressor tone. ArUmal studies have 
shown that inhibition of NO synthesis with L-NAME stimulates adrenal steroidogenesis."'" 
We hypothesized that increased cortisol production might be an additional mechanism by 
which L-NAME increases blood pressure. However, we found no evidence of changes in 
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cortisol levels during inhibition of NO synthesis in septic patients. We conclude that changes 
in cortisol levels do not contribute to the increase in blood pressure with L-NAME. 
In conclusion, inhibitors of NO synthesis may unmask a tonic pressor response of ET-l 
in humans with septic shock. Prolonged inhibition of NO synthesis does not influence the 
plasma levels of ET-l. These results suggest that ET-l maintains blood pressure in human 
sepsis and plasma ET-l concentration may determine the vasopressor response of NO synthase 
inhibitors in septic shock. These findings may provide furOler evidence of interaction between 
NO and ET -1 in pathological conditions of the cardiovascular system where an imbalance 
between endothelial-derived vasodilator and vasoconstrictor substances disturbs the normal 
regulation of vascular tone. 
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Abstract 
The present study tested pharmacokinetics of NG-nitro-L-arginine methylester (L-
NAME), an inhibitor of nitric oxide (NO) synthesis, in patients with septic shock. Blood was 
sampled at intervals before, during and after a 12 h infusion period of L-NAME I mg/kg/h 
in nine septic shock patients for determination of plasma concentrations by Wgh performance 
liquid chromatography. In three patients renal clearance of the drug was determined. 
Incubation of L-NAME with plasma ill vitro revealed hydrolysis to NG-nitro-L-arginine 
(L-NA), an active inhibitor of NO synthesis. L-NA, however, did not undergo further 
degradation. Continuous intravenous infusion of I mg/kg/h of L-NAME for 12 h in patients 
with septic shock increased blood pressure and resulted in increasing plasma levels of L-NA 
(Cm~ 6.2± 1.0 (SD) I'g/ml at 12 h) whereas L-NAME concentrations reached a plateau witWn 
1.5 h (C=, 1.0±0.2I'g/ml). After the infusion was stopped L-NAME disappeared from the 
plasma rapidly (half-life 19.2±2.4 min) whereas L-NA concentration only declined slowly 
(half-life 22.9±3.0 h). The calculated volume of distribution for L-NAME was 449± 119 
ml!kg body weight and 1957 ±270 ml/kg for L-NA. The renal clearance of L-NA was 
3.5±0.6% of total body clearance for L-NA. L-NAME could not be detected in urine. 
We conclude that inhibition of nitric oxide synthesis with L-NAME in septic patients 
may result (at least in part) from hydrolysis to L-NA. The Wgh plasma half-life and volume 
of distribution for L-NA suggests extensive distribution to extravascular tissues. Since renal 
excretion is minimal, elimination of the metabolite L-NA follows other pathways. TIllS 
pharmacokinetic information may be useful in future studies using L-NAME or L-NA in 
humans. 
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IntI'oduction 
Human septic shock is often characterised by massive systemic vasodilatation with low 
vascular resistance and hypotension unresponsive to treatment with vasopressors.l Nitric oxide 
(NO), a potent endogenous vasodilator formerly known as endothelium derived relaxing factor 
(EDRF), has recently been held responsible for the hemodynamic and metabolic consequences 
of sepsis and endotoxemia.2.3 
Nitric oxide is a small molecule formed from the precursor amino acid L-arginine by 
two forms of the enzyme NO synthase, and stimulates the enzyme soluble guanylate-cyclase 
(GC) in the vascular smooth muscle cell which converts GTP to cGMP resulting in 
vasodilatation.2 NO normally plays a key role in the regulation of vascular tone. During sepsis 
and endotoxemia overproduction of the nitric oxide radical results in massive vasodilatation. 
High concentrations of nitrite and nitrate, the stable end product of NO metabolism, are found 
in patients with sepsis and these levels may correlate with vasodilation. 4 
Analogues of L-arginine competitively inhibit NO production by NO synthase.3 NG_ 
nitro-L-arginine methyl ester (L-NAME), is an analogue of L-arginine, that induces 
enantiomerically a specific reversible inhibition of NO synthase ill vitro and ill vivo.'·6 L-
NAME has been used to reverse endotoxin and cytokine induced hypotension and restore 
reactivity to catecholamines in animals. 7.' Recently, L-NAME has been used to reverse 
hypotension in patients with septic shock. '.10 Pharmacokinetic studies in rats have shown the 
conversion of L-NAME to NG-nitro-L-arginine (L-NA), an active inhibitor of NO synthesis, II 
tllat has a long plasma half life of approximately 20 hours. 12.13 However, no pharmacokinetic 
information exists on the clearance, biodistribution or excretion of L-NAME in humans, and 
the rationale for dosage regimens in septic patients has been largely empirical.'·10 
The present study assessed the pharmacokinetics of L-NAME ill vitro and during 
continuous intravenous (IV) infusion for 12 hours in patients with severe septic shock. Such 
information about may be useful in further studies using L-NAME or L-NA to inhibit NO 
synthesis in humans. 
Materials and Methods 
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Hydrolysis of L-NAME to L-NA iii vitro; in buffer (a), plasma (b) and whole blood (c) of 
septic patients. L-NAME (10 IIg/ml) was incubated at 37 (lC for the indicated time period, 
followed by determination of L-NAME (0) and L-NA (e) by h.p.Lc. as described in the 
Methods section. Samples were assayed in duplo. Data are mean ± SD of four experiments 
with plasma and blood from four different septic patients. 
Subjects. The study was conducted according to the principles established in Helsinki 
and approved by the hospital Medical and Ethics Committee. First degree relatives were 
informed of the nature of the study and gave informed consent. In total eleven patients were 
given L-NAME, and in nine patients plasma samples were collected for pharmacokinetic 
analysis. 
Patients met the criteria of sepsis as described by Bone et al." and were receiving 
dopamine> 15 jig/kg/min and/or noradrenaline> 0.1 jig/kg/min. All patients had respiratory 
failure and required mechanical venti1ation. Three patients of nine required continuous 
hemodialysis because of renal failure. Only patients with a cardiac index> 3.0 J/minlm' were 
included since earlier reports have shown reductions of cardiac output during inhibition of NO 
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synthesis."!' Exclusion criteria for the study were severe coronary artery stenosis (angina 
pectoris grade III according to NYHA classification), pregnancy and a cardiac index <3.0 
IIminfm'. 
Study Protocol. All patients underwent continuous electrocardiographic monitoring and 
had indwelling radial and pulmonary artery catheters (Criticath, Ohmeda, Singapore) for 
hemodynamic measurements and data were recorded on a computerised data system (Mennen 
Medical Systems, USA). 
L-NAME hydrochloride was obtained from Sigma Chemicals (St. Louis, MO, USA). 
The hospital pharmacy prepared a sterile and pyrogen-free solution of L-NAME 10 mg/ml 
(content L-NA <2% by h.p.l.c. analysis), for infusion. Following baseline measurements L-
NAME 1 mg/kg/h was infused for 12 h. The rationale for the continuous infusion resulted 
from pilot experiments where the effect of a bolus i'1jection of 0.15 mg/kg L-NAME lasted 
only 5-10 minutes. In prior dose-fmding experiments, L-NAME at a rate of 1.5 mg/kg/h 
resulted in unacceptably high pulmonary artery pressure for which the infusion had to be 
stopped.!' Therefore the present study used a lower dose of L-NAME 1 mg/kg/h which 
avoided in pulmonary hypertension. To minimize the potential chance of developing toxicity 
from high serum levels of L-NAME, infusion was not continued for longer periods. Concomi-
tant therapy was at the discretion of the clinician managing the patient. 
Blood samples. For pharmacokinetic analysis, blood samples (10 mI) were obtained in 
heparin coated blood collection tubes (Vacutainer, France) at baseline (T=O), during L-NAME 
infusion (T= 0.5, 1,3,6 and 12 h) and I, 3, 6 and 12, 36 and 72 h after L-NAME infusion 
had stopped (T= 13, IS, 18,24, 48, and 72 h). Blood samples were inlli1ediately centrifuged 
(1500 g, 10 min, 4 'C), and the plasma stored at -80' C until tested. In three patients with 
creatinine clearances above 90 ml/min urine samples were collected at T = 12 h for 
determination of the renal clearances of L-NAME and L-NA. In four untreated septic patients 
blood (10 m!) was withdrawn for il/ vitro analysis of L-NAME hydrolysis. 
In vitro hydrolysis oj L-NAME. Aqueous solutions of L-NAME and L-NA (Sigma 
Chemicals, st. Louis, MO, USA) (10 mg/ml) were prepared and added to phosphate buffer 
(pH 7.4), plasma and whole blood of septic patients (n=4), to give a fmal concentration of 10 
Itg/ml. Samples were shaken in a waterbath at 37 'C over the whole observation period, and 
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at the each time point (after 5, 30, 60, 120, 180, 240 min and 12 h) aliquots were removed 
for h.p.I.c. analysis. 
Allalysis of L-NAME alld L-NA. The h.p.I.c method used for quantitative analysis of 
L-NAME and L-NA has been described previously by Kreycy et aI." Blood samples of 200 
1'1 were pipetted into a vial containing 40 1'1 perchloric acid (4.4 M). Plasma, buffer and urine 
samples of 100 1'1 were transferred into vials containing 10 1'1 perchloric acid (4.4 M). 
Samples were vortex mixed for 1 min and centrifuged at 16000 g for 10 min. Aliquots of the 
supernatant were diluted and analyzed in duplo by high performance liquid chromatography. 
The apparatus used included a gradient pump and a multi wavelength detector set at 268 om 
(Kratos Analytical Instruments, Ramsey, New Yersey, USA). For chromatographic separation 
we used a Nucleosil 5 I'm 5 SA 250·4 mm column (Machery Nagel, DUren, Germany). The 
mobile phase consisted of 100 mM NaH,PO, + 10% methanol (Merck, Darmstadt, Germany), 
pH 2.3. The flow rate was 1.5 mllmin. Calibration of the method with authentic L-NAME and 
L-NA, freshly dissolved in 100 mM NaH,PO, (PH 2.3), yielded linear responses of peak areas 
versus concentration in the range of 0.1 to 50 I'gimL. The detection limit for L-NAME and 
L-NA was 0.05 I'gimL. 
Pharll/acokilletic calculatiolls alld statistics. Data are expressed as mean ± SD. The 
half-life of L-NAME hydrolysis ill vitro was calculated from linear regression analysis of log 
concentration versus time plots. In patients receiving L-NAME non-compartmental methods 
were used to detennine phannacokinetic parameters from the concentration to time data, using 
comnlercially available software (Mediware, Heereveen, The Netherlands). Pharmacokinetic 
parameters included area under the plasma concentrations vs. time curve (AUC), systemic 
clearance (Cl,), apparent volume of distribution (Vd), plasma half-life (tIh), mean residence 
time (MRT) and renal clearance (Cl,). Hemodynamic changes were compared with baseline 
values using Student's paired (-test with Bonferroni correction. Pearson correlation was used 
for analysis of correlations between plasma concentrations and hemodynamic effects. 
Results 
The ill vitro data on hydrolysis of L-NAME are displayed in Figure 1. Following 
166 
Figure 2. 
Pharmacokinetics of L-NAME 
8 l·NAME 
-0- L·NA 
::::::-
E 6 
-
-e- L·NAME Ol 
:tf 
::>. 
~ 
c 
0 
''::; 4 :"" '" ~ 
-
I 
C 
<D 
0 
c 2 0 
0 
0 
0 12 24 36 48 60 72 
Time (h) 
Hydrolysis of L-NAME to L-NA during continuous infusion of L-NAME (1 mg/kglh IV) in 
patients with severe septic shock. Time of L-NAME infusion is from t=O to 1=12 h. Blood 
samples were taken at indicated time points, followed by determination of L-NAME (e) and 
L-NA (0) by h.p.l.c. as described in the Methods section. Samples were assayed in duplo. 
Data are mean±SD of plasma samples from nine different septic patients. 
addition of L·NAME to buffer (pH 7.4) there was an apparently non·enzymatic hydrolysis to 
L·NA with a half·life of 383±24 min (Figure la). After 12 hours the concentration of L· 
NAME and L·NA were 2.7 ±O.3 and 6.6±O.6f1g/nU, respectively. Plasma incubation almost 
doubled the rate ofL·NAME hydrolysis (t'h=2l8±7 min) (Figure Ib). After incubation for 
12 h in plasma, the concentrations ofL·NAME and L·NA were I.O±O.2 and 8.1 ±O.7 flg/ml, 
respectively. In whole blood, L·NAME was metabolized to L·NA at half·life of 33 ±6 min, 
and after 3 hours of incubation hydrolysis was essentially complete (Figure Ic). L·NA was 
stable after incubation for 12 hours in buffer, plasma and whole blood (results not shown). 
As shown in Figure 2, continuous intravenous infusion of I mg/kg/h of L-NAME for 
12 h resulted in increasing plasma levels ofL·NA (C~ 6.2±1.0 flg/nU) whereas L·NAME 
concentration reached a plateau within 1.5 h (C_, I.O±O.2f1g/ml). After infusion was stopped 
L·NAME disappeared from the plasma with a half·life of 19.2±2.4 min whereas L·NA 
concentration only declined slowly (half·life 22.9±3.0 h). Pharmacokinetic parameters are 
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displayed in Table 1. L-NA had a high apparent volume of distribution and a relatively low 
total body clearance. The L-NA concentration in urine determined in three patients was 12±5 
I'g/ml, whereas L-NAME was undetectable in urine. The renal clearance of L-NA was 
2.0±0.3 mI/h/kg and was 3.5±0.6% of total body clearance of L-NA. 
Continuous infusion of L-NAME (1 mg/kg/h) increased mean arterial pressure and 
systemic vascular resistance (Figure 3). Although sustained hemodynamic effects were seen, 
L-NAME was most effective during the early stages of administration and the effect on blood 
pressure and vascular resistance tended to diminish during continued infusion. The increases 
in blood pressure and/or systemic vascular resistance were not significantly correlated with 
plasma concentrations of L-NAME (r=0.54 and r=0.60, respectively; both p>0.05) or 
plasma levels of L-NA (r=-0.018 and r=-0.15, respectively; bothp>0.05). 
Discussion 
L-NAME and L-NA are inhibitors of NO synthesis that can be used therapeutically to 
reverse hypotension in patients with severe septic shock.9.10 However, most studies in humans 
have related their dosage regimens on an empirical basis since little pharmacokinetic 
information on the clearance, biodistribution, and excretion is available. 
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Table 1. 
Parameter 
C_, (pg/ml) 
Phannacokinetic parameters of L-NAMB and the metabolite L-NA in 
patients with septic shock. 
L-NAME L-NA 
1.0±0.2 6.2±1.0 
AUC ... (pg/ml'h) 12.8±2.5 208±27 
CL, (mllhlkg) 961±161 59.8±7.0 
Vd (ml/kg) 449±97 1957± 120 
t" (h) 0.32±0.03 22.9±3.0 
MRT (h) 0.46±0.04 32.9±4.2 
L-NAME (1 mg/kglh IV) was infused for 12 hours in nine patients with severe septic shock. 
L-NAME = NO.nitro·L-arginine methyl ester, L-NA = N°·nitro·L-arginine, CIf' . .u = maximum 
plasma concentration, AVC = area under curve, CL, = systemic clearance, Vd = volume of 
distribution, t'h = plasma half·life, MRT = mean residence time. Values are mean±SD. 
Figure 3. 
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Effect in time of continuous infusion of L-NAME (1 mg/kg/h IV) on mean arterial blood 
pressure (MAP, solid bars) and systemic vascular resistance (SVR, hatched bars) in patients 
with severe septic shock. Data are displayed as % increase compared to baseline (T=O). Data 
are mean±SD of nine septic patients. *p<O.05 as compared to baseline. 
The present study shows that in humans with sepsis L-NAME is rapidly hydrolysed to 
L-NA both ill vitro and ill vivo. Since hydrolysis was almost doubled in plasma as compared 
to buffer, plasma esterases may contribute to the apparently non-enzymatic hydrolysis in buffer 
as has been reported by others."·16 Metabolism of L-NAME was faster in whole blood which 
could suggest that L-NAME is mainly metabolised by blood cell esterases. Since the in vivo 
half-life of L-NAME in septic shock patients was even shorter (t" = 19 min), other cells, e.g. 
vascular endothelial cells or hepatic cells, may have contributed to intracellular conversion of 
the drug by esterases. In the anaesthetized rabbit the calculated half-life of L-NAME following 
bolus injection was only 7.5 min suggesting that species differences exist in esterase activity. 17 
The conversion of L-NAME to L-NA may be accompanied by the formation of 
neurotoxic methanol. 18.19 In the present study methanol was not measured and although no 
obvious signs of neurotoxicity were noticed in the present study, conversion to methanol may 
have occurred. If so, it may hinder the clinical application of L-NAME as an inhibitor of NO 
synthesis and the direct use of L-NA may be superior to the use of L-NAME.20 However, 
maximum conversion of L-NAME (total dose 900 mg in 12 h, body weight 75 kg) would have 
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generated approximately 0.15 g of methanol, which is 30% of total daily endogenous methanol 
production in humans,21 and unlikely to cause any toxic manifestations. 
High concentrations of L-NA were found at the end of the L-NAME infusion and these 
only declined slowly after the L-NAME infusion was stopped. The high apparent volume of 
distribution (almost 2 l/kg) for L-NA together with relatively low plasma clearance are 
reflected by an extremely high plasma half-life of around 22 h. Similar rmdings were observed 
in pharmacokinetic studies in rats given L-NA. In a study by Tabrizi et al. 13 after a single 
intravenous bolus of L-NA 10 mg/kg, plasma volume of distribution was 2.5 l/kg which is 
comparable to that found in man in the present study. These findings indicate extensive 
extravascular distribution. In the same animal study L-NA was not detected in urine. In 
contrast, we found concentrations of L-NA up to 18 I'g/ml in urine of patients. This accounted 
for less than 5 % of the total clearance of L-NA, and renal excretion is clearly not a major 
pathway of L-NA excretion. L-NA may be cleared primarily by' biliary excretion," or further 
conversion to unknown metabolites. 
The long half-life of L-NAME has important clinical implications. Recent animal 
studies on NO synthase inhibitors suggest that continuous infusions may be superior to high 
dose bolus administration.ll In the present study a continuous infusion was used; to minimize 
the risk of toxicity it was not continued for more than 12 hours. Although a steady state 
concentration of L-NAME was reached during infusion, the long plasma half-life for L-NA 
will cause a continuous increase so that a steady state plasma concentration will not be reached 
before at least 60 hours of infusion. Therefore, with prolonged infusions of L-NAME or L-NA 
caution is warranted,9,10 since L-NA will accumulate. 
Prior ill vitro studies suggest that L-NAME is an inactive pro-drug and that L-NA is 
the only active component. 16.24 Unexpectedly, in the present study no correlation was found 
between plasma concentrations of the active drug L-NA and increases in blood pressure and/or 
systemic vascular resistance. In additionJ blood pressure and systemic vascular resistance 
tended to diminish during continued L-NAME infusion, despite increasing plasma 
concentrations of L-NA. At present we cannot explain these findings. Plasma concentrations 
of L-NAME and L-NA may not accurately reflect the local concentrations in effector cells, 
i.e. endothelial cells and vascular smooth muscle cells. Indeed, several in vitro studies have 
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suggested that L-NAME easily enters the intracellular compartment whereas L-NA does not." 
Once inside the cell, L-NAME may be converted by esterases to L-NA which is then 
"trapped" in the cell. By this mechanism L-NA may accumulate intracellularly and only slowly 
redistribute to the plasma." These speculations should be further investigated with 
measurement of the intracellular concentration of the drug. 
In summary, we have characterized some of the fundamental pharmacokinetic 
characteristics of L-NAME and L-NA in patients Witll severe septic shock. These results may 
help to develop rational designs for further studies. 
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General discussion 
Septic shock is the most common cause of death in todays intensive care.'·2 Despite 
progress in antibiotic therapy, new therapeutic interventions and better intensive care support, 
mortality from septic shock has remained high over the years. Therefore new treatment 
modalities are warranted. Endotoxin and cytokine stimulated overproduction of nitric oxide 
(NO) from L-arginine has been suggested to play a central role in the cardiovascular 
derangements of septic shock. Since NO has emerged as a fmal common mediator leading to 
vasodilatation in shock, pharmacologic manipulation of NO production may be used as a novel 
therapeutic approach in the treatment of hypotension in septic shock. However, the exact role 
of NO during sepsis is yet unclear and the consequences of inhibition of NO synthesis remain 
to be detennined. The objectives of our studies were: 
I. To investigate the pathophysiological role of NO in vasodilatation in an animal model of 
hyperdynamic sepsis. 
2. To investigate the pathophysiological role of NO in patients with hyperdynamic sepsis. 
3. To investigate the hemodynalnic, metabolic and immunologic effects of L-NAME, an 
inhibitor of NO synthesis, in patients with septic shock. 
A hyperdynamic model of endotoxemla in the rat was developed that used 
intraperitoneal injection of lipopolysaccharides (LPS). After 12 hours this model resulted in 
raised temperature, reduced blood pressure, increased levels of plasma lactate, and increased 
plasma concentration of nitrate and nitrite (NO,), the stable end products of NO metabolism. 
These changes resemble much of the changes as found in patients with sepsis.'" Furthermore 
this model has the advantage that allows induction of i-NOS which has been shown to take a 
lag-phase of at least 4 to 8 hours needed for de /lOVO synthesis of protein.' Several others have 
used models of LPS and cytokine-induced shock where the time between induction of shock 
and initiation of experiments is too short for the inducible NO synthase to form. In 
endotoxemlc dogs two hours following IV injection ofLPS or TNF, inhibition of NO synthesis 
resulted in correction of hypotension.6.7 However, shock in this animal model was probably 
not caused by increased production of NO by i-NOS but rather by other mechanisms. Direct 
cardiac depression or increased production of NO by the constitutive enzyme may have played 
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a role. 8 Although LPS injection in humans may result in many of the characteristics of sepsis, 
LPS injection is only a simplified model of the clinical syndrome of sepsis and septic shock.9 
Chronic animal models of sepsis such as prolonged infusion of live bacteria 01' slow release 
from an implanted, infected clot may better sinlUlate the sequence of events associated with 
clinical sepsis.tO.l! 
During isolated perfusion of the rat heart we observed increased coronary flow rates 
with dysfunction of coronary autoregulation. Similar inappropriate coronary flow rates can be 
seen in patients with sepsis and these changes resemble the changes in the peripheral 
vasculature." The vasodilatation and dysfunction of vascular autoregulation, were normalised 
with an inhibitor of NO synthesis and methylene blue. These fIndings conftrm the central role 
for NO in cardiovascular derangements during septic shock and the therapeutic potential of 
inhibitors of NO synthesis. However, endotoxemia promoted myocardial ischemia in 
vulnerable areas of the heart following inhibition of the NO pathway or direct vasoconstriction 
(Chapter 2). This local myocardial ischemia may have resulted from pathological heterogenous 
microcirculatory flow distribution as has been found by others during experimental sepsis. B •14 
Possibly increased nitric oxide production prevents these vulnerable areas from becoming 
hypoxic. This could suggest that part of increased NO release during sepsis may be benefIcial 
and inhibition of NO synthesis could be detrimental. Indeed, many animal studies have shown 
controversial data on the use of pharmacological inhibitors of NO synthesis. Inhibition of NO 
synthesis can raise mortality 15 and increase damage to the liver, 16 gastrointestinal tract17 and 
kidney" in animal models of shock. However, most of tllese studies use models of sepsis and 
endotoxemia that cause a hypodynamic circulation with reduced cardiac output. In tllis 
situation there is already an underperfusion of the organs in contrast to hyperdynamic septic 
shock. Additional vasoconstriction by inhibition of NO synthesis can, in this situation, lead 
to a further reduction in cardiac output and organ perfusion. Therefore inhibition of NO 
synthesis might be less effective in hypodynamic shock. 
The presented ill vitro studies were designed to investigate the role of NO in the 
pathophysiology of sepsis. Although the rmdings from ill vitro and ill vivo animal studies 
cannot be directly extrapolated to the clinical situation, their data can used in the design of 
clinical studies to test the therapeutic effIcacy of NO synthase inhibition in human sepsis. 
175 
Chapter 10 
Prolonged inhibition of NO synthesis with L-NAME I mg/kg/h in hyperdynamic septic 
patients resulted in increased blood pressure and systemic vascular resistance with a 
concomitant reduction in cardiac output (Chapter 4 and 5). Reductions in cardiac output have 
been reported by others during inhibition of NO synthesis in sepsis.!'·2o Therefore, in the 
presented study we only included patients with hyperdynamic shock and increased cardiac 
output. So far the precise mechanism underlying this reduction in cardiac output remains un-
clear. In our study the reduction in cardiac output did not result from direct cardiac depression 
since cardiac work was not compromised and was probably related to a reflex change due to 
U,e increased systemic vascular resistance and afterload. The reduction in cardiac output may 
also have contributed to the reduction in blood pressure during continued L-NAME infusion. 
In a recent study by Kiehl et al. 2! in leucocytopenic septic patients, L-NAME in a lower 
dosage of 0.3 mg/kg/h did not result in significant changes in cardiac output and the increase 
in blood pressure was maintained for at least 24 h. Possibly the dosage we used in the present 
study was to high for optimum hemodynamic effects and a lower dose, with lesser effects on 
cardiac output, could be more effective. This could be further investigated in additional dose-
response studies. To prevent the reduction in cardiac output and augment the anti-hypotensive 
effects of L-NAME and other inhibitors, co-infusion of the inotropic agent dobutamine may 
be a possible solution." 
Despite the reduction in cardiac output in our study, no detrimental effects on organ 
function indices were seen. Furthermore arterial lactate and oxygen consumption were not 
changed (Chapter 4 and 5). These findings may indicate that a reduction in cardiac output is 
not necessarily detrimental in hyperdynamic sepsis and suggest that L-NAME preferentially 
caused vasoconstriction in metabolic inactive tissues. However, these observations only include 
indirect parameters that do not directly rellect what happens at capillary or cellular level. 
However, in clinical practice these indirect macrovascular parameters are mostly the only 
parameters available. Microvascular parameters such as tissue p02, microvascular flow 
patterns and tissue redox state are not routine clinical measurements and not often measured 
in patient related studies because of the invasive nature of most techniques, the need for special 
equipment and the time consuming nature of the measurements. In future studies it would be 
interesting to investigate U,e effect of L-NAME and other inhibitors of nitric oxide synthesis, 
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on microvascular parameters of different organs in human sepsis or appropriate animal models 
of hyperdynamic sepsis. Microvascular parameters could be studied with oxygen electrodes 
to measure tissue p02' intravital microscopy to measure microvascular flow patterns and 
optical spectroscopy to measure tissue redox state." 
NO has a role as a physiologic mediator in the lung." NO synthase is present in lung 
epithelium and other puhnonary cells and has been suggested to be a mediator of nerve-
dependent bronchodilatation.25 Furthermore hypoxic pulmonary vasoconstriction may result 
from reduced NO release." Inhalation of NO can be used to improve oxygenation in patients 
with ARDS and reduce puhnonary artery pressure in patients with puhnonary hypertension." 
In two patients a high continuous dose ofl,NAME resulted in severe puhnonary hypertension 
for which infusion had to be stopped (Chapter 6). Puhnonary hypertension is dangerous since 
it may cause right sided heart failure and circulatory collapse. Although lower doses of L-
NAME increased pulmonary vascular resistance, no signs of puhnonary hypertension were 
seen in these patients (Chapter 5). We conclude that puhnonary hypertension is a dose-related 
side effect of L-NAME infusion. Inspired NO gas acts locally without systemic effects and co-
administration of inspired NO may be used to prevent the puhnonary hypertension during 
inhibition of NO synthesis." Since NO inhalation may improve oxygenation in respiratory 
insufficiency we hypothesized that inhibition of NOS may compromise puhnonary gas 
exchange. Unexpectedly, we found that pulmonary gas exchange was improved during 
inhibition of NO synthesis probably through a reduction in puhnonary right-to-left shunt with 
L-NAME and an improvement of ventilation-perfusion mismatch. 
Most inhibitors of NO synthase such as L-NA, L-NAME and L-NMMA are non-
selective toward the different isotypes of NO synthase and inhibit bOUl the constitutive and the 
inducible isoform. III vitro L-NAME even shows some preference towards the constitutive 
enzyme.29 Some have been related negative side effects of NO synthase inhibition to inhibition 
of the constitutive isoform of NO synthase and selective inhibition of the inducible enzyme 
could be more effective. In theory the inhibition of only the i-NOS may attenuate the excessive 
vasodilation, correct hypotension and prevent the toxic effects of increased NO synthesis 
without interfering in physiologic NO mediated processes, whereas inhibition of the 
constitutive enzyme may lead to the disturbance of physiologic processes regulated by NO and 
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may lead to tissue hypoperfusion and ischemia. However, titis hypothesis has never been tested 
in hyperdynamic models of sepsis. Recently identified, non-arginine based NOS inhibitors, 
such as aminoguanidine30 and S-methyl isothiourea and related compounds" may show selec-
tivity for the inducible enzyme. Aminoguanidine can inhibit delayed circulatory failure in 
endotoxic shock in the anaesthetized rat. 32 S-methyl-isothiourea sulphate, a novel potent 
inhibitor of i-NOS, can improve survival in a rodent model of septic shock." Recent reports 
however, suggest that the constitutive fonn of nitric oxide synthase disappears in endotoxemia 
and other fonns of sepsis."'" If this is true, the use of an unselective inhibitor of NOS would 
be as effective as an inhibitor specific to the inducible isoform. In addition, inhibition of 
inducible NOS could be hannful to inunune defense and bactericidal mechanisms which could 
be extra important in case of sepsis." The theoretical benefit of selective inhibitors of the 
inducible NO synthase has not been established in human sepsis and this needs to be clarified 
in further studies. Furthermore these selective inhibitors may prove to be of help in other 
disease states where the inducible NO synthase plays a role (Chapter 1). 
Not much attention has been given to the immunologic consequences of NO synthase 
inhibition during septic shock. Activated macrophages release NO for the killing of bacteria 
and fungi,35 although it is not yet clear or the same mechanism is present in humans.36 Nitric 
oxide may inhibit leucocyte adherence, regulate gene expression of certain cytokines such as 
TNF-u and IL-6, and inilibit or facilitate T-cel proliferation."·38 Induction of i-NOS may be 
associated with graft rejection. 39 Excessive production of pro-inflammatory cytokines have 
been found during inhibition of NO synthesis in septic animals.,"·4l These results may indicate 
a negative feedback mechanism exhibited by NO on cytokine production. In contrast to these 
findings, we found no evidence of excessive cytokine production during prolonged inilibition 
of NO synthesis in human sepsis (Chapter 7). Although TNF-u levels were reduced as 
compared to baseline this may have represented the natural course of the disease since no 
untreated control group was included for comparison. 
Septic patients had increased plasma levels of nitrite and nitrate, as an indirect measure 
of increased NO production,' and these levels correlated with vasodilatation (Chapter 7). 
However, reservation must be made since NO is but one of the ways that nitrite and nitrate 
are formed and unexpectedly L-NAME infusion did not result in significant changes in 
178 
General disclission 
nitrite/nitrate levels. Probably plasma nitrite/nitrate levels do not accurately reflect the local 
production of NO. Tllis has to be verified in further studies. 
Besides nitric oxide, other vasoactive mediators are released during human septic 
shock' In the present study endothelin-I (ET -I), a potent endothelial derived vasoconstrictor 
substance, was increased in septic patients and ET-Ilevels determined the extent of the anti-
hypotensive response to L-NAME in these patients (Chapter 8). These findings may indicate 
that L-NAME unmasks a tonic pressor response to ET-I in septic shock and that measurement 
of ET -I levels before treatment may help to select these patients that benefit most from 
inhibition of NO synthesis in septic shock. 
In the present study mortality rate was almost 60% in these patients with severe sepsis. 
This mortality rate was in line with predicted death rate as computed by APACHE II scores. 
Although hemodynanlics were improved by L-NAME, this did not result in mortality lower 
or higher than the predicted death rate. We could speculate that L-NAME did not influence 
mortality in the present study. However these are only speculations since it is impossible to 
deternline the impact on survival in an 11 patient study and this study was not designed to do 
so. Furthermore we did not include an untreated control group for comparison wllich is a 
major linlitation of the studies. To determine the effect of L-NAME on mortality, a 
randomised placebo controlled (multicenter) study with much larger numbers of patients would 
be necessary. For L-NMMA such a study is currently undertaken. L-NMMA has the 
theoretical advantage that acts more on the inducible enzyme than L-NAME, although this may 
have immunologic disadvantages as discussed earlier. Preliminary data in 312 patients show 
that L-NMMA (546C88, Glaxo Wellcome) 0-20 mg/kg/h resulted in a significant increase in 
the proportion of patients with resolution of shock at 72 h (24 % in the L-NMMA group 
compared to 39% in the placebo group)." Since this surrogate end point correlated with 
survival, it was suggested that L-NMMA may improve survival. However overall survival at 
28 days was not significantly different between groups (83 survivors in the L-NMMA group 
compared 80 in the placebo group). The final results of the phase III clinical trial must be 
awaited to see whether inllibition of NO synthesis with L-NMMA can improve survival in 
patients with septic shock. 
Increased synthesis of nitric oxide is only one of many factors contributing to the 
179 
Chapter 10 
derangements in the pathophysiological processes of septic shock (Chapter 1). Inhibition of 
nitric oxide synthesis is probably not the 'magic bullet' for single treatment of sepsis. In our 
opinion, inhibition of nitric oxide synthesis alone will most likely not be sufficient in stopping 
the cascade of events leading to overactivation of the innnune system in this complicated 
disease process. In the last years, more than a dozen other magic bullet candidates have failed 
to improve outcome of sepsis in randomized placebo-controlled clinical trialsY However, a 
modest effect on outcome by a single agent may provide a piece of the puzzle and increase the 
depth of our understanding of this disease process. Besides adequate removal of the infective 
focus, ultimately a combination of approaches that attack vasodilatation, cardiac depression, 
cytokine imbalance, multiple organ damage and metabolic disturbances may be needed to treat 
septic shock. Further investigations should be performed to gather the pieces and eventually 
solve the puzzle. 
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Stunmary 
Chapter 1 is the general introduction of this thesis. The characteristics and 
pathophysiology of septic shock and the central role that nitric oxide (NO) may play are 
described. Sepsis is the systemic response to infection and characterised by the release of 
several inflammatory mediators leading to massive vasodilatation, shock and organ failure. 
Nitric oxide (NO), formerly known as Endothelium Derived Relaxing Factor (EDRF), a 
powerful endogenous vasodilator, is released in high quantities during sepsis. NO may be 
responsible for much of the vasodilatation and hypotension seen during sepsis and NO may 
be involved in myocardial depression during septic shock. The release or action of NO can be 
inhibited by pharmacologic agents that intervene with the L-arginine/NO/c-GMP pathway and 
these pharmaCOlogic agents may be used to investigate the role of nitric oxide in the 
pathophysiology of sepsis and other diseases. Furthermore, these pharmacologic agents may 
offer new therapeutic potential in the treatment of hypotension in septic shock patients. At the 
end of Chapter 1 the aims of the study are presented. We investigated the pathophysiological 
role of NO and the effect of NO synthase inhibitors in experin,ental and clinical sepsis. 
Chapter 2 shows the role of nitric oxide during hyperdynamic endotoxemia in the rat 
as a model for sepsis. Similar to human sepsis, this experimental model resulted in raised 
temperature, decreased mean arterial blood pressure, increased heart rate, hyperlactatemia and 
increased serum levels of nitrite + nitrate, as a sign of increased systemic release of NO. 
Isolated perfusion of the hearts showed increases in coronary flow and oxygen consumption 
following endotoxemia that resulted from increased NO production. NG-Nitro-L-Arginine (L-
NA), an inhibitor of NO synthesis, and methylene blue (MB), an inhibitor of soluble guanylate 
cyclase, could prevent coronary vasodilatation, although this resulted in local myocardial 
ischemia in endotoxin-treated hearts. These data suggest that vasodilatation in endotoxemia 
results from increased NO production which can be prevented by inhibitors of NO synthesis. 
However, vasoconstriction may result in myocardial ischemia in vulnerable areas of the 
endotoxic heart which warrants caution when using NO synthase inhibitors in clinical sepsis. 
Chapter 3 describes coronary autoregulation in the mentioned model of hyperdynamic 
endotoxemia in the rat. Autoregulation was studied in the isolated rat heart by analyzing flow-
183 
Summary 
pressure relations and reactive hyperemia after occlusion of coronary flow. Endotoxemia 
resulted in dysfunction of coronary autoregulation and altered reactive hyperemia. The 
dysfunction in vascular autoregulation was corrected with L-NA and MB, but not with 
vasopressin. These rmdings suggest that endotoxemia results in dysfunction of vascular 
autoregulation by increased production of nitric oxide which can be corrected by inhibition of 
NO synthesis but not by direct vasoconstriction. 
Chapter 4 shows the results of a prospe~tive clinical study that evaluated the effects 
of prolonged inhibition of NO synthesis with the NO synthase inhibitor L-NAME in patients 
with severe septic shock. The 'L-NAME trial' was conducted in the intensive care units of the 
department of Surgery and the department of Internal Medicine of the University Hospital 
Rotterdam Dijkzigt. Patients were included in the period between January 1995 and February 
1996. In this chapter the effects on hemodynamic, biochemical and metabolic parameters are 
presented during continuous L-NAME infusion in eleven patients with septic shock. L-NAME 
increased blood pressure and systemic vascular resistance with a concomitant reduction in 
cardiac output and oxygen supply. Despite the reduction in cardiac output, no negative effects 
on organ function indices were found. Although sustained hemodynamic effects were seen, L-
NAME was most effective during the early stages of administration and the effect on blood 
pressure and vascular resistance tended to diminish during continued infusion. 
Chapter 5 presents the effects of continuous L-NAME infusion on cardiac performance 
and puhnonary gas exchange. Despite the reduction in cardiac index no reduction was seen in 
left and right ventricular stroke work indices which makes direct cardiac depression unlikely. 
The increase in afterload is probably the main reason for the reduction in cardiac output. 
Analogous to the effects on the peripheral vasculature, L-NAME resulted in pulmonary 
vasoconstriction as indicated by increased puhnonary vascular resistance. However, this did 
not result in puhnonary hypertension and unexpectedly puhnonary gas exchange was improved 
during L-NAME infusion. The reason for this was a reduction in puhnonary right-to-left shunt 
and improvement of ventilation-perfusion mismatch. Nitric oxide appears to playa role in the 
cardiovascular derangements during human sepsis and inhibitors of NO synthesis may provide 
new therapeutic tools for the treatment of unresponsive hypotension in septic shock. 
Chapter 6 describes the dose related side effects of L-NAME in a postoperative patient 
184 
Summary 
with severe septic shock. High dose continuous infusion of L-NAME resulted in severe 
pulmonary hypertension and an extreme reduction in cardiac output. For these reasons L-
NAME was stopped after three hours of infusion. We conclude that puhnonary hypertension 
and reduced cardiac output are major dose related side effects of NO synthase inhibition. In 
clinical situations, such as severe septic shock refractory to conventional therapy, blocking the 
NO system must be done with caution and at least under careful cardiovascular monitoring. 
Chapter 7 analyzes some of the inununologic consequences of NO synthase inhibition 
in human sepsis. Septic patients had increased levels of IL-6, IL-8 and TNF-u. During 
continuous L-NAME infusion no signs of detrimental increases in plasma cytokine levels were 
found. Plasma IL-6 and IL-8 levels were not significantly changed, whereas plasma TNF-u 
concentration was reduced as compared to baseline. However I these observations may have 
been confounded by spontaneous changes over time. Plasma nitrite + nitrate (NO,) levels, as 
an indirect measure of NO production, were increased in septic patients and these levels 
correlated with vascular resistance. However, NO, levels were not significantly reduced during 
L-NAME infusion which may indicate that NO, does not directly reflect local NO production. 
Chapter 8 shows that part ofthe vasoconstriction with L-NAME in human septic shock 
results from increased plasma levels of endothelin-l (ET-l). Septic patients had increased 
plasma levels of ET-l. No significant changes in plasma ET-l concentration were observed 
during L-NAME infusion. However, the increase in blood pressure and systemic vascular 
resistance was significantly correlated with the plasma level of ET -1, but not with plasma 
nitrite+nitrate concentration. These fmdings may suggest that inhibitors of NO synthesis 
unmask a tonic pressor response of endothelin-l in human septic shock. 
Chapter 9 evaluates pharrnacokinetic information on tile clearance, biodistribution, and 
excretion ofL-NAME in septic patients. Analysis of samples was done using high performance 
liquid chromatography (HPLC). L-NAME was converted to L-NA both ill vitro and ill vivo. 
A high plasma half-life and volume of distribution was found for L-NA ill vivo suggesting 
extensive distribution to extravascular tissues. Since renal excretion was minimal, elimination 
of the metabolite L-NA follows other pathways. We conclude that inhibition of NO synthesis 
with L-NAME results at least in part from hydrolysis to L-NA. This pharmacokinetic 
information may be useful in future studies using L-NAME or L-NA. 
185 
Samem'attillg 
Samenvatting 
Hoofdstuk 1 is de algemene inleiding van dit proefschrift. In dit hoofdstuk worden de 
kenmerken en pathofysiologie van septische shock beschreven en de centrale rol die 
stikstofoxide hierin speelt. Sepsis is de reactie van het lichaam op infectie en wordt 
gekenmerkt door het vrijkomen van verschillende ontstekingsmediatoren die leiden tot massale 
vaatverwijding, shock en orgaan falen. Stikstofoxide (NO), eerder bekend als Endothelium 
Derived Relaxing Factor, is een krachtige endogene vaatverwijder, die tijdens sepsis in grote 
hoeveelheden vrijkomt. NO is mogelijk de oorzaak voor de vaatverwijding en llypotensie 
tijdens sepsis en speelt mogelijk een rol in de verminderde pompfunktie van het hart tijdens 
septische shock. De produktie en het effect van NO kan geremd worden door farmaca die het 
L-arginine/NO/c-GMP pad bemvloeden en deze stoffen kunnen gebruikt worden om de rol van 
NO in het onstaan van sepsis en andere ziektebeelden te onderzoeken. Tevens zouden deze 
farmaca als geneesmiddel gebruikt kunnen worden in de behandeling van hypotensie bij 
paW:nten met septisclle shock. Aan het eind van hoofdstuk 1 worden de doelstellingen van het 
onderzoek beschreven. Wij onderzochten de pathofysiologische rol van NO en het effect van 
NO synthese remming in experimentele en klinische sepsis. 
Hoofdstuk 2 beschrijft de rol van NO tijdens hyperdynarnische endotoxemie in de rat 
als model voor sepsis. Zoals bij humane sepsis, resulteerde dit diermodel in koorts, 
verminderde arteriele bloeddruk, verhoogd serum lactaat en verhoogd serum nitraat+nitriet 
gehalte, een indirecte maat voor verhoogde systemische produktie van NO. Gelsoleerde 
perfusie van het rattenhart liet een verhoogde coronaire doorstroming en zuurstof consumptie 
zien na endotoxemie die het gevolg was van verhoogde NO produktie. NG-Nitro-L-Arginine 
(L-NA), een NO synthese remmer, en methyleen blauw (MB), een remmer van guanylate 
cyclase, voorkwarnen de coronaire vaatverwijding, hoewel hierbij lokale myocardiale ischemie 
optrad in endotoxine behandelde harten. Deze bevindingen laten zien dat vaatverwijding tijdens 
endotoxemie wordt veroorzaakt door verhoogde NO produktie hetgeen voorkomen kan worden 
met NO synthese remmers. Behter, vasoconstrictie kan leiden tot lokale myocard ischemie in 
kwetsbare gebieden in het endotoxine hart en voorzichtigheid is derhalve geboden indien NO 
synthese remmers tijdens klinische sepsis worden gebruikt. 
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Hoofdsluk 3 gaat in op de corona ire autoregulatie in het bescheeven endotoxemie 
model in de rat. Autoregulatie werd bestudeerd in het geYsoleerde rattenhart door de relatie 
tussen flow en perfusiedruk en door de reactieve hyperemie na ocelusie van flow te analyseren. 
Endotoxemie resulteerde in een verstoorde coronaire autoregulatie en veranderde reactieve 
hyperemie. De verstoorde vasculaire autoregulatie kon gecorrigeerd worden met L-NA en MB, 
maar niet met de directe constrictor vasopressine. De bevindingen laten zien dat endotoxemie 
leidt tot een verstoorde vasculaire autoregulatie als gevolg van verhoogde NO produktie welke 
gecorrigeerd kan worden door NO synthese remmers. 
Hoofdstnk 4 toont de resultaten van een klinische studie die de effecten onderzocht van 
langdurige NO synthese remming met de NO synthase remmer L-NAME in patienten met 
ernstige septische shock. De 'L-NAME trial' werd uitgevoerd op de intensive care van de 
afdelingen chirurgie en interne geneeskunde in het Academisch Ziekenhuis Rotterdam Dijkzigt 
in de periode tussen januari 1995 en februari 1996. In dit hoofdstuk worden de effecten van 
continue L-NAME toediening op hemodynalnische, biochemische en metabole parameters 
bescheeven in elf patienten met septische shock. L-NAME verhoogde bloeddruk en 
systemische vaatweerstand met een gelijktijdige reductie in cardiac output en zuurstoftoevoer. 
Ondanks deze reductie in cardiac output werden geen negatieve effecten gezien op 
orgaanfunctie gerelateerde parameters. Hoewellangdurige hemodynamische effecten gezien 
werden, was L-NAME het meest effectief in de begin periode van toediening en het effect op 
bloeddruk en vaatweerstand werd geleidelijk minder. 
Hoofdsluk 5 laat de effecten zien van continue L-NAME toediening op myocardfunctie 
en pullnonale gasuitwisseling. Ondanks de vermindering in cardiac output werd geen verrnin-
dering gezien in slagarbeid van linker en rechter ventrikel hetgeen directe cardiale depressie 
onwaarschijnlijk maakt. De toename in afterload is waarschijnlijk de belangrijkste reden voor 
de afname in cardiac output. Analoog aan het effect op de perifere vasculatuur, was er sprake 
van pulmonale vasoconstrictie met verhoging van de pulmonale vaatweerstand, echter zonder 
pulmonale hypertensie. Tevens was er een onverwachte verbetering in pullnonale gas 
uitwisseling. De reden voor de verbeterde arteriele oxygenatie was een vermindering in de 
pullnonale rechts-naar-links shunt. Wij concluderen dat NO een rol speelt in de cardio-
vasculaire stoornissen tijdens humane sepsis. Remmers van NO synthese kunnen mogelijk als 
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nieuwe therapie gebruikt worden in de behandeling van hypotensie tijdens septische shock. 
Hoofdstuk 6 beschrijft de dosis gerelateerde bijwerkingen van L-NAME in een post-
operatieve patient met septische shock. Tijdens continue infusie met een hoge dosis L-NAME 
ontstond ernstige pulmonale hypertensie met een extreme reductie van cardiac output. Om deze 
redenen werd L-NAME na 3 uur toediening gestaakt. Pulmonale hypertensie en reductie in 
cardiac output zijn twee belangrijke dosis-afhankelijke bijwerkingen van NO synthese remming 
in de klinische situatie. Het gebruik van NO synthese remmers in patienlen moet daarom met 
voorzichtigheid gebeuren en lenminste onder cardiovasculaire bewaking op een intensive care. 
Hoofdstuk 7 analyseert de mogelijk inununologische consequenties van NO synthese 
remming in humane sepsis. Septische patienten hadden verhoogde plasma concentraties van 
interleukine-6 (IL-6), [L-8 en tumor necrosis factor-a (TNF-a). Tijdens continue L-NAME 
infusie werden geen lekenen gevonden van verhoogde cytokine produktie. Plasma IL-6 en !L-8 
waarden veranderden niet significant tijdens L-NAME en plasma TNF-a concentratie was 
verminderd vergeleken de uitgangswaarde. Echler deze metingen kunnen belnvloed zijn door 
spontane veranderingen van cylokine coneentraties in de tijd. Plasma nitraat+nitriet 
concentratie, als een indirecte maat voor NO synthese. was verhoogd in patienten met sepsis 
en deze concentratie correleerde met de systemische vaatweerstand. Nitraat+ nitriet 
concentratie verminderde echter niet tijdens L-NAME infusie hetgeen kan betekenen dal 
plasma nitraal+nitriet gehalte mogelijk geen goede maat is voor lokale NO produktie. 
Hoofdstuk 8 laal zien dat een deel van de vasoconstrictie door L-NAME in humane 
septische shock wordt veroorzaakt door verhoogde plasma concentraties van endotheline-I 
(ET -I). Sepsis patienten hadden hoge ET-I spiegels in hel blood. Tijdens L-NAME toodiening 
werden geen veranderingen gezien in plasma concentratie ET -I. De toename in bloeddruk en 
systemische vaatweerstand waren duidelijk gecorreleerd met de hoogle van het plasma ET-I 
niveau, echter niet met het nitraat + nitriet gehalte. Deze bevindingen laten zien dat de 
blooddruk stijging door NO synthese remming in humane septische shock gedeeltelijk verloopt 
via een continue vaattonus door ET -1. 
Hoofdstuk 9 bestudeert de farmacokinetiek van L-NAME in septische shock. Voor 
analyse van de monsters werd gebruik gemaakt van high performance liquid chromatography 
(HPLC). L-NAME bleek omgezet te worden naar L-NA, waarschijnlijk door esterases, zowel 
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ill vitro als ill vivo. Ben hoge plasma halfwaardetijd en distributievolume werden gevonden 
voor L-NA in sepsis patienten hetgeen uitgebreide verdeling over de extravasculaire weefsels 
waarschijnlijk maakt. Aangezien renale excretie minimaal was, voigt de eliminatie van de 
metaboliet L-NA andere paden. Wij concluderen dat NO synthese remming met L-NAME 
temninste gedeeltelijk het gevolg is van hydrolyse naar L-NA. Deze farmacokinetische 
informatie kan gebulikt worden in toekomstige k1inische studies met L-NAME of L-NA. 
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List of Abbreviations 
ADP 
APACHE 
ARDS 
ArT 
AUC 
BH, 
c-GMP 
CI 
CI, 
CO 
c-NOS 
DIC 
DO, 
EDRF 
ELISA 
ET-l 
FAD 
FMN 
FiO, 
GTP 
HPLC 
ICU 
IL 
IFN 
i-NOS 
LPS 
L-NA 
L-NAME 
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adenosioe diphosphate 
acute physiology and chronic health evaluation 
acute respiratory distress syndrome 
autoregulation iodex 
area under curve 
tetrahydrobiopterin 
cyclic guanyl monophosphate 
cardiac index 
systemic clearance 
cardiac output 
constitutive nitric oxide synthase 
disseminated iotravascular coagulation 
oxygen delivery 
endothelium derived relaxing factor 
enzyme linked ioununosorbent assay 
endothelio-l 
flavin adenine dinucleotide 
flavin mononucleotide 
fraction of inspired oxygen 
guanyl triphosphate 
high performance liquid chromatography 
intensive care unit 
ioterleukine 
interferon 
ioducible nitric oxide synthase 
lipopolysaccharide 
NG-nitro-L-arginine 
NG-nitro-L-arginine methyl ester 
Abbreviations 
L-NMMA NG-monomethyl-L-arginine 
LVSW left ventricular stroke work 
MAb monoclonal antibody 
MAP mean systemic arterial pressure 
ME methylene blue 
MDF myocardial depressant factor 
MRT mean residence time 
MOF multiple organ failure 
NADH nicotinamide adenine dinucleotide 
NADPH nicotinamide adenine dinucleotide phosphate 
NNLA NO-nitro-L-arginine 
NO nitric oxide 
NP nitroprusside 
NS not significant 
O,ER oxygen extraction ratio 
PAF platelet activating factor 
PaO, partial pressure of arterial oxygen 
PaCO, partial pressure of carbon dioxide 
P(A-a)O, alveolar-arterial oxygen pressure difference 
PEEP positive end-expiratory pressure 
PVR pulmonary vascular resistance 
QvAlQr venous admixture, pulmonary shunt 
r correlation coefficient 
RVSW right ventricular stroke work 
SOD superoxide dismutase 
SVR systemic vascular resistance 
SV stroke volume 
t'h half-life 
VO, oxygen uptake 
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